

# **EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)**

S. Gravas (Chair), J.N. Cornu, M. Gacci, C. Gratzke,  
T.R.W. Herrmann, C. Mamoulakis, M. Rieken,  
M.J. Speakman, K.A.O. Tikkinen

Guidelines Associates: M. Karavitakis, I. Kyriazis, S. Malde,  
V. Sakalis, R. Umbach

TABLE OF CONTENTS	PAGE
1. INTRODUCTION	4
1.1 Aim and objectives	4
1.2 Panel composition	4
1.3 Available publications	4
1.4 Publication history	4
2. METHODS	4
2.1 Introduction	4
2.2 Review	5
2.3 Patients to whom the guidelines apply	5
3. EPIDEMIOLOGY, AETIOLOGY AND PATHOPHYSIOLOGY	5
4. DIAGNOSTIC EVALUATION	6
4.1 Medical history	6
4.2 Symptom score questionnaires	7
4.2.1 The International Prostate Symptom Score (IPSS)	7
4.2.2 The International Consultation on Incontinence Questionnaire (ICIQ-MLUTS)	7
4.2.3 Danish Prostate Symptom Score (DAN-PSS)	7
4.3 Frequency volume charts and bladder diaries	7
4.4 Physical examination and digital-rectal examination	8
4.4.1 Digital-rectal examination and prostate size evaluation	8
4.5 Urinalysis	8
4.6 Prostate-specific antigen (PSA)	9
4.6.1 PSA and the prediction of prostatic volume	9
4.6.2 PSA and the probability of PCa	9
4.6.3 PSA and the prediction of BPO-related outcomes	9
4.7 Renal function measurement	9
4.8 Post-void residual urine	10
4.9 Uroflowmetry	10
4.10 Imaging	11
4.10.1 Upper urinary tract	11
4.10.2 Prostate	11
4.10.2.1 Prostate size and shape	11
4.10.3 Voiding cysto-urethrogram	11
4.11 Urethrocystoscopy	11
4.12 Urodynamics	12
4.12.1 Diagnosing bladder outlet obstruction	12
4.12.2 Videourodynamics	12
4.13 Non-invasive tests in diagnosing bladder outlet obstruction in men with LUTS	13
4.13.1 Prostatic configuration/intravesical prostatic protrusion (IPP)	13
4.13.2 Bladder/detrusor wall thickness and ultrasound-estimated bladder weight	13
4.13.3 Non-invasive pressure-flow testing	14
4.13.4 The diagnostic performance of non-invasive tests in diagnosing bladder outlet obstruction in men with LUTS compared with pressure-flow studies	14
5. DISEASE MANAGEMENT	15
5.1 Conservative treatment	15
5.1.1 Watchful waiting (WW)	16
5.1.2 Behavioural and dietary modifications	16
5.1.3 Practical considerations	16
5.2 Pharmacological treatment	17
5.2.1 $\alpha$ 1-Adrenoceptor antagonists ( $\alpha$ 1-blockers)	17
5.2.2 5 $\alpha$ -reductase inhibitors	18
5.2.3 Muscarinic receptor antagonists	19
5.2.4 Beta-3 agonist	20
5.2.5 Phosphodiesterase 5 inhibitors	22
5.2.6 Plant extracts - phytotherapy	23

5.2.7	Combination therapies	25
5.2.7.1	$\alpha$ 1-blockers + 5 $\alpha$ -reductase inhibitors	25
5.2.7.2	$\alpha$ 1-blockers + muscarinic receptor antagonists	26
5.3	Surgical treatment	28
5.3.1	Resection of the prostate	28
5.3.1.1	Monopolar and bipolar transurethral resection of the prostate	28
5.3.1.2	Holmium laser resection of the prostate	30
5.3.1.3	Thulium:yttrium-aluminium-garnet laser (Tm:YAG) vaporessection of the prostate Mechanism of action:	30
5.3.1.4	Transurethral incision of the prostate	31
5.3.2	Enucleation of the prostate	31
5.3.2.1	Open prostatectomy	31
5.3.2.2	Bipolar transurethral enucleation of the prostate (B-TUEP)	32
5.3.2.3	Holmium laser enucleation of the prostate	33
5.3.2.4	Thulium:yttrium-aluminium-garnet laser (Tm:YAG) enucleation of the prostate Mechanism of action:	34
5.3.2.5	Diode laser enucleation of the prostate	35
5.3.2.6	Enucleation techniques under investigation	36
5.3.2.6.1	Minimal invasive simple prostatectomy	36
5.3.2.6.2	532 nm ('Greenlight') laser enucleation of the prostate	36
5.3.3	Vaporisation of the prostate	37
5.3.3.1	Bipolar transurethral vaporisation of the prostate	37
5.3.3.2	532 nm ('Greenlight') laser vaporisation of the prostate	38
5.3.3.3	Vaporisation techniques under investigation	39
5.3.3.3.1	Diode laser vaporisation of the prostate	39
5.3.4	Alternative ablative techniques	40
5.3.4.1	Aquablation – image guided robotic waterjet ablation: AquaBeam	40
5.3.4.2	Prostatic artery embolisation	41
5.3.4.3	Alternative ablative techniques under investigation	42
5.3.4.3.1	Convective water vapour energy (WAVE) ablation: The Rezum system	42
5.3.5	Alternative ablative techniques under investigation	42
5.3.5.1	Prostatic urethral lift	42
5.3.5.2	Intra-prostatic injections	43
5.3.5.3	Non-ablative techniques under investigation	44
5.3.5.3.1	(i)TIND	44
5.4	Patient selection	44
5.5	Management of Nocturia in men with lower urinary tract symptoms	47
5.5.1	Diagnostic assessment	47
5.5.2	Medical conditions and sleep disorders Shared Care Pathway	47
5.5.3	Treatment for Nocturia	49
5.5.3.1	Antidiuretic therapy	49
5.5.3.2	Medications to treat LUTD	50
5.5.3.3	Other medications	50
6.	FOLLOW-UP	51
6.1	Watchful waiting (behavioural)	51
6.2	Medical treatment	51
6.3	Surgical treatment	52
7.	REFERENCES	52
8.	CONFLICT OF INTEREST	81
9.	CITATION INFORMATION	81

# 1. INTRODUCTION

## 1.1 Aim and objectives

Lower urinary tract symptoms (LUTS) are a common complaint in adult men with a major impact on quality of life (QoL), and have a substantial economic burden. The present Guidelines offer practical evidence-based guidance on the assessment and treatment of men aged 40 years or older with various non-neurogenic benign forms of LUTS. The understanding of the LUT as a functional unit, and the multifactorial aetiology of associated symptoms, means that LUTS now constitute the main focus, rather than the former emphasis on Benign Prostatic Hyperplasia (BPH). The term BPH is now regarded as inappropriate as it is Benign Prostatic Obstruction (BPO) that is treated if the obstruction is a significant cause of a man's LUTS. It must be emphasised that clinical guidelines present the best evidence available to the experts. However, following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

## 1.2 Panel composition

The EAU Non-neurogenic Male LUTS Guidelines Panel consists of an international group of experts with urological and clinical epidemiological backgrounds. All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website Uroweb: <http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/>.

## 1.3 Available publications

A quick reference document, the Pocket Guidelines, is available in print and as an app for iOS and Android devices. These are abridged versions which may require consultation together with the full text version. All documents are accessible through the EAU website Uroweb: <http://www.uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/>.

## 1.4 Publication history

The Non-neurogenic Male LUTS Guidelines was first published in 2000. The 2021 document presents a limited update of the 2020 publication; the next full update of the Non-neurogenic Male LUTS Guidelines will be presented in 2022.

# 2. METHODS

## 2.1 Introduction

For the 2021 Management of Non-Neurogenic Male LUTS Guidelines, a detailed review and restructuring of section 5.3 Surgical Treatment has been undertaken. Section 5.3 has been restructured to reflect surgical approach rather than specific technologies and is now divided into five sections: resection; enucleation; vaporisation; alternative ablative techniques; and non-ablative techniques. The literature cut-off date for section 5.3 is April 2019. In addition, a broad and comprehensive literature search related to *Serenoa repens* in section 5.2.5 Plant extracts – phytotherapy was performed covering the timeframe between the search cut-off date of the EU monograph on *S. repens* [1] and April 2020. A detailed search strategy is available online: <http://www.uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/supplementary-material>.

For each recommendation within the guidelines there is an accompanying online strength rating form, the bases of which is a modified GRADE methodology [2, 3]. Each strength rating form addresses a number of key elements namely:

1. the overall quality of the evidence which exists for the recommendation, references used in this text are graded according to a classification system modified from the Oxford Centre for Evidence-Based Medicine Levels of Evidence [4];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact of patient values and preferences on the intervention;
6. the certainty of those patient values and preferences.

These key elements are the basis which panels use to define the strength rating of each recommendation. The strength of each recommendation is represented by the words 'strong' or 'weak' [5]. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and nature and variability of patient values and preferences.

Additional information can be found in the general Methodology section of this print, and online at the EAU website; <http://www.uroweb.org/guideline/>. A list of associations endorsing the EAU Guidelines can also be viewed online at the above address.

## **2.2 Review**

The Non-Neurogenic Male LUTS Guidelines were peer reviewed prior to publication in 2016.

## **2.3 Patients to whom the guidelines apply**

Recommendations apply to men aged 40 years or older who seek professional help for LUTS in various non-neurogenic and non-malignant conditions such as BPO, detrusor overactivity/overactive bladder (OAB), or nocturnal polyuria. Men with other associated factors relevant to LUT disease (e.g. concomitant neurological diseases, young age, prior LUT disease or surgery) usually require a more extensive work-up, which is not covered in these Guidelines, but may include several tests mentioned in the following sections. EAU Guidelines on Neuro-Urology, Urinary Incontinence, Urological Infections, Urolithiasis, or malignant diseases of the LUT have been developed by other EAU Guidelines Panels and are available online: [www.uroweb.org/guidelines/](http://www.uroweb.org/guidelines/).

# **3. EPIDEMIOLOGY, AETIOLOGY AND PATHOPHYSIOLOGY**

Lower urinary tract symptoms can be divided into storage, voiding and post-micturition symptoms [6], they are prevalent, cause bother and impair QoL [7-10]. An increasing awareness of LUTS and storage symptoms in particular, is warranted to discuss management options that could increase QoL [11]. Lower urinary tract symptoms are strongly associated with ageing [7, 8], associated costs and burden are therefore likely to increase with future demographic changes [8, 12]. Lower urinary tract symptoms are also associated with a number of modifiable risk factors, suggesting potential targets for prevention (e.g. metabolic syndrome) [13]. In addition, men with moderate-to-severe LUTS may have an increased risk of major adverse cardiac events [14].

Most elderly men have at least one LUTS [8]; however, symptoms are often mild or not very bothersome [10, 11, 15]. Lower urinary tract symptoms can progress dynamically: for some individuals LUTS persist and progress over long time periods, and for others they remit [8]. Lower urinary tract symptoms have traditionally been related to bladder outlet obstruction (BOO), most frequently when histological BPH progresses through benign prostatic enlargement (BPE) to BPO [6, 9]. However, increasing numbers of studies have shown that LUTS are often unrelated to the prostate [8, 16]. Bladder dysfunction may also cause LUTS, including detrusor overactivity/OAB, detrusor underactivity/underactive bladder, as well as other structural or functional abnormalities of the urinary tract and its surrounding tissues [16]. Prostatic inflammation also appears to play a role in BPH pathogenesis and progression [17, 18]. In addition, many non-urological conditions also contribute to urinary symptoms, especially nocturia [8].


The definitions of the most common conditions related to male LUTS are presented below:

- Acute retention of urine is defined as a painful, palpable or percussible bladder, when the patient is unable to pass any urine [6].
- Chronic retention of urine is defined as a non-painful bladder, which remains palpable or percussible after the patient has passed urine. Such patients may be incontinent [6].
- Bladder outlet obstruction is the generic term for obstruction during voiding and is characterised by increasing detrusor pressure and reduced urine flow rate. It is usually diagnosed by studying the synchronous values of flow-rate and detrusor pressure [6].
- Benign prostatic obstruction is a form of BOO and may be diagnosed when the cause of outlet obstruction is known to be BPE [6]. In the Guidelines the term BPO or BOO is used as reported by the original studies.
- Benign prostatic hyperplasia is a term used (and reserved) for the typical histological pattern, which defines the disease.

- Detrusor overactivity (DO) is a urodynamic observation characterised by involuntary detrusor contractions during the filling phase which may be spontaneous or provoked [6]. Detrusor overactivity is usually associated with overactive bladder syndrome characterised by urinary urgency, with or without urgency urinary incontinence, usually with increased daytime frequency and nocturia, if there is no proven infection or other obvious pathology [19].
- Detrusor underactivity (DU) during voiding is characterised by decreased detrusor voiding pressure leading to a reduced urine flow rate. Detrusor underactivity causes underactive bladder syndrome which is characterised by voiding symptoms similar to those caused by BPO [20].

Figure 1 illustrates the potential causes of LUTS. In any man complaining of LUTS, it is common for more than one of these factors to be present.

**Figure 1: Causes of male LUTS**



## 4. DIAGNOSTIC EVALUATION

Tests are useful for diagnosis, monitoring, assessing the risk of disease progression, treatment planning, and the prediction of treatment outcomes. The clinical assessment of patients with LUTS has two main objectives:

- to identify the differential diagnoses, since the origin of male LUTS is multifactorial, the relevant EAU Guidelines on the management of applicable conditions should be followed;
- to define the clinical profile (including the risk of disease progression) of men with LUTS in order to provide appropriate care.

### 4.1 Medical history

The importance of assessing the patient's history is well recognised [21-23]. A medical history aims to identify the potential causes and relevant comorbidities, including medical and neurological diseases. In addition,

current medication, lifestyle habits, emotional and psychological factors must be reviewed. The Panel recognises the need to discuss LUTS and the therapeutic pathway from the patient's perspective. This includes reassuring the patient that there is no definite link between LUTS and prostate cancer (PCa) [24, 25].

As part of the urological/surgical history, a self-completed validated symptom questionnaire (see section 4.2) should be obtained to objectify and quantify LUTS. Bladder diaries or frequency volume charts are particularly beneficial when assessing patients with nocturia and/or storage symptoms (see section 4.3). Sexual function should also be assessed, preferably with validated symptom questionnaires such as the International Index for Erectile Function (IIEF) [26].

Summary of evidence	LE
A medical history is an integral part of a patient's medical evaluation.	4
A medical history aims to identify the potential causes of LUTS as well as any relevant comorbidities and to review the patient's current medication and lifestyle habits.	4

Recommendation	Strength rating
Take a complete medical history from men with LUTS.	Strong

## 4.2 Symptom score questionnaires

All published guidelines for male LUTS recommend using validated symptom score questionnaires [21, 23]. Several questionnaires have been developed which are sensitive to symptom changes and can be used to monitor treatment [27-33]. Symptom scores are helpful in quantifying LUTS and in identifying which type of symptoms are predominant; however, they are not disease-, gender-, or age-specific. A systematic review (SR) evaluating the diagnostic accuracy of individual symptoms and questionnaires, compared with urodynamic studies (the reference standard), for the diagnosis of BOO in males with LUTS found that individual symptoms and questionnaires for diagnosing BOO were not significantly associated with one another [34].

### 4.2.1 The International Prostate Symptom Score (IPSS)

The IPSS is an eight-item questionnaire, consisting of seven symptom questions and one QoL question [28]. The IPSS score is categorised as 'asymptomatic' (0 points), 'mildly symptomatic' (1-7 points), 'moderately symptomatic' (8-19 points), and 'severely symptomatic' (20-35 points). Limitations include lack of assessment of incontinence, post-micturition symptoms, and bother caused by each separate symptom.

### 4.2.2 The International Consultation on Incontinence Questionnaire (ICIQ-MLUTS)

The ICIQ-MLUTS was created from the International Continence Society (ICS) Male questionnaire. It is a widely used and validated patient completed questionnaire including incontinence questions and bother for each symptom [29]. It contains thirteen items, with subscales for nocturia and OAB, and is available in seventeen languages.

### 4.2.3 Danish Prostate Symptom Score (DAN-PSS)

The DAN-PSS [32] is a symptom score used mainly in Denmark and Finland. The DAN-PSS also has questions on incontinence and measures the bother of each individual LUTS.

Summary of evidence	LE
Symptom questionnaires are sensitive to symptom changes.	3
Symptom scores can quantify LUTS and identify which types of symptoms are predominant; however, they are not disease-, gender-, or age-specific.	3

Recommendation	Strength rating
Use a validated symptom score questionnaire including bother and quality of life assessment during the assessment of male LUTS and for re-evaluation during and/or after treatment.	Strong

## 4.3 Frequency volume charts and bladder diaries

The recording of volume and time of each void by the patient is referred to as a frequency volume chart (FVC). Inclusion of additional information such as fluid intake, use of pads, activities during recording, or which grades of symptom severity and bladder sensation is termed a bladder diary [6]. Parameters that can be derived from the FVC and bladder diary include: day-time and night-time voiding frequency, total voided volume, the fraction of urine production during the night (nocturnal polyuria index), and volume of individual voids.



The mean 24-hour urine production is subject to considerable variation. Likewise, circumstantial influence and intra-individual variation cause FVC parameters to fluctuate, though there is comparatively little data [35, 36]. The FVC/bladder diary is particularly relevant in nocturia, where it underpins the categorisation of underlying mechanism(s) [37-39]. The use of FVCs may cause a 'bladder training effect' and influence the frequency of nocturnal voids [40].

The duration of the FVC/bladder diary needs to be long enough to avoid sampling errors, but short enough to avoid non-compliance [41]. A SR of the available literature recommended FVCs should continue for three or more days [42]. The ICIQ-Bladder diary (ICIQ-BD) is the only diary that has undergone full validation [43].

Summary of evidence	LE
Frequency volume charts and bladder diaries provide real-time documentation of urinary function and reduce recall bias.	3
Three and seven day FVCs provide reliable measurement of urinary symptoms in patients with LUTS.	2b

Recommendations	Strength rating
Use a bladder diary to assess male LUTS with a prominent storage component or nocturia.	Strong
Tell the patient to complete a bladder diary for at least three days.	Strong

#### 4.4 Physical examination and digital-rectal examination

Physical examination particularly focusing on the suprapubic area, the external genitalia, the perineum and lower limbs should be performed. Urethral discharge, meatal stenosis, phimosis and penile cancer must be excluded.

##### 4.4.1 Digital-rectal examination and prostate size evaluation

Digital-rectal examination (DRE) is the simplest way to assess prostate volume, but the correlation to prostate volume is poor. Quality-control procedures for DRE have been described [44]. Transrectal ultrasound (TRUS) is more accurate in determining prostate volume than DRE. Underestimation of prostate volume by DRE increases with increasing TRUS volume, particularly where the volume is > 30 mL [45]. A model of visual aids has been developed to help urologists estimate prostate volume more accurately [46]. One study concluded that DRE was sufficient to discriminate between prostate volumes > or < 50 mL [47].

Summary of evidence	LE
Physical examination is an integral part of a patient's medical evaluation.	4
Digital-rectal examination can be used to assess prostate volume; however, the correlation to actual prostate volume is poor.	3

Recommendation	Strength rating
Perform a physical examination including digital rectal examination in the assessment of male LUTS.	Strong

#### 4.5 Urinalysis

Urinalysis (dipstick or sediment) must be included in the primary evaluation of any patient presenting with LUTS to identify conditions, such as urinary tract infections (UTI), microhaematuria and diabetes mellitus. If abnormal findings are detected further tests are recommended according to other EAU Guidelines, e.g. Guidelines on urinary tract cancers and urological infections [48-51].

Urinalysis is recommended in most Guidelines in the primary management of patients with LUTS [52, 53]. There is limited evidence, but general expert consensus suggests that the benefits outweigh the costs [54]. The value of urinary dipstick/microscopy for diagnosing UTI in men with LUTS without acute frequency and dysuria has been questioned [55].

Summary of evidence	LE
Urinalysis (dipstick or sediment) may indicate a UTI, proteinuria, haematuria or glycosuria requiring further assessment.	3
The benefits of urinalysis outweigh the costs.	4



Recommendation	Strength rating
Use urinalysis (by dipstick or urinary sediment) in the assessment of male LUTS.	Strong

## 4.6 Prostate-specific antigen (PSA)

### 4.6.1 PSA and the prediction of prostatic volume

Pooled analysis of placebo-controlled trials of men with LUTS and presumed BPO showed that PSA has a good predictive value for assessing prostate volume, with areas under the curve (AUC) of 0.76-0.78 for various prostate volume thresholds (30 mL, 40 mL, and 50 mL). To achieve a specificity of 70%, whilst maintaining a sensitivity between 65-70%, approximate age-specific criteria for detecting men with prostate glands exceeding 40 mL are PSA > 1.6 ng/mL, > 2.0 ng/mL, and > 2.3 ng/mL, for men with BPH in their 50s, 60s, and 70s, respectively [56].

A strong association between PSA and prostate volume was found in a large community-based study in the Netherlands [57]. A PSA threshold value of 1.5 ng/mL could best predict a prostate volume of > 30 mL, with a positive predictive value (PPV) of 78%. The prediction of prostate volume can also be based on total and free PSA. Both PSA forms predict the TRUS prostate volume ( $\pm$  20%) in > 90% of the cases [58, 59].

### 4.6.2 PSA and the probability of PCa

The role of PSA in the diagnosis of PCa is presented by the EAU Guidelines on Prostate Cancer [60]. The potential benefits and harms of using serum PSA testing to diagnose PCa in men with LUTS should be discussed with the patient.

### 4.6.3 PSA and the prediction of BPO-related outcomes

Serum PSA is a stronger predictor of prostate growth than prostate volume [61]. In addition, the PLESS study showed that PSA also predicted the changes in symptoms, QoL/bother, and maximum flow-rate ( $Q_{max}$ ) [62]. In a longitudinal study of men managed conservatively, PSA was a highly significant predictor of clinical progression [63, 64]. In the placebo arms of large double-blind studies, baseline serum PSA predicted the risk of acute urinary retention (AUR) and BPO-related surgery [65, 66]. An equivalent link was also confirmed by the Olmsted County Study. The risk for treatment was higher in men with a baseline PSA of > 1.4 ng/mL [67]. Patients with BPO seem to have a higher PSA level and larger prostate volumes. The PPV of PSA for the detection of BPO was recently shown to be 68% [68]. Furthermore, in an epidemiological study, elevated free PSA levels could predict clinical BPH, independent of total PSA levels [69].

Summary of evidence	LE
Prostate-specific antigen has a good predictive value for assessing prostate volume and is a strong predictor of prostate growth.	1b
Baseline PSA can predict the risk of AUR and BPO-related surgery.	1b

Recommendations	Strength rating
Measure prostate-specific antigen (PSA) if a diagnosis of prostate cancer will change management.	Strong
Measure PSA if it assists in the treatment and/or decision making process.	Strong

## 4.7 Renal function measurement

Renal function may be assessed by serum creatinine or estimated glomerular filtration rate (eGFR). Hydronephrosis, renal insufficiency or urinary retention are more prevalent in patients with signs or symptoms of BPO [70]. Even though BPO may be responsible for these complications, there is no conclusive evidence on the mechanism [71].

One study reported that 11% of men with LUTS had renal insufficiency [70]. Neither symptom score nor QoL was associated with the serum creatinine level. Diabetes mellitus or hypertension were the most likely causes of the elevated creatinine concentration. Comiter *et al.* [72] reported that non-neurogenic voiding dysfunction is not a risk factor for elevated creatinine levels. Koch *et al.* [73] concluded that only those with an elevated creatinine level require investigational ultrasound (US) of the kidney.

In the Olmsted County Study community-dwelling men there was a cross-sectional association between signs and symptoms of BPO (though not prostate volume) and chronic kidney disease (CKD) [74]. In 2,741 consecutive patients who presented with LUTS, decreased  $Q_{max}$ , a history of hypertension and/or diabetes were associated with CKD [75]. Another study demonstrated a correlation between  $Q_{max}$  and eGFR in middle-aged men with moderate-to-severe LUTS [76]. Patients with renal insufficiency are at an increased risk of developing post-operative complications [77].

Summary of evidence	LE
Decreased $Q_{\max}$ and a history of hypertension and/or diabetes are associated with CKD in patients who present with LUTS.	3
Patients with renal insufficiency are at an increased risk of developing post-operative complications.	3

Recommendation	Strength rating
Assess renal function if renal impairment is suspected based on history and clinical examination, or in the presence of hydronephrosis, or when considering surgical treatment for male LUTS.	Strong

#### 4.8 Post-void residual urine

Post-void residual (PVR) urine can be assessed by transabdominal US, bladder scan or catheterisation. Post-void residual is not necessarily associated with BOO, since high PVR volumes can be a consequence of obstruction and/or poor detrusor function (DU) [78, 79]. Using a PVR threshold of 50 mL, the diagnostic accuracy of PVR measurement has a PPV of 63% and a negative predictive value (NPV) of 52% for the prediction of BOO [80]. A large PVR is not a contraindication to watchful waiting (WW) or medical therapy, although it may indicate a poor response to treatment and especially to WW. In both the MTOPS and ALTESS studies, a high baseline PVR was associated with an increased risk of symptom progression [65, 66].

Monitoring of changes in PVR over time may allow for identification of patients at risk of AUR [81]. This is of particular importance for the treatment of patients using antimuscarinic medication. In contrast, baseline PVR has little prognostic value for the risk of BPO-related invasive therapy in patients on  $\alpha$ 1-blockers or WW [82]. However, due to large test-retest variability and lack of outcome studies, no PVR threshold for treatment decision has yet been established; this is a research priority.

Summary of evidence	LE
The diagnostic accuracy of PVR measurement, using a PVR threshold of 50 mL, has a PPV of 63% and a NPV of 52% for the prediction of BOO.	3
Monitoring of changes in PVR over time may allow for identification of patients at risk of AUR.	3

Recommendation	Strength rating
Measure post-void residual in the assessment of male LUTS.	Weak

#### 4.9 Uroflowmetry

Urinary flow rate assessment is a widely used non-invasive urodynamic test. Key parameters are  $Q_{\max}$  and flow pattern. Uroflowmetry parameters should preferably be evaluated with voided volume > 150 mL. As  $Q_{\max}$  is prone to within-subject variation [83, 84], it is useful to repeat uroflowmetry measurements, especially if the voided volume is < 150 mL, or  $Q_{\max}$  or flow pattern is abnormal.

The diagnostic accuracy of uroflowmetry for detecting BOO varies considerably and is substantially influenced by threshold values. A threshold  $Q_{\max}$  of 10 mL/s has a specificity of 70%, a PPV of 70% and a sensitivity of 47% for BOO. The specificity using a threshold  $Q_{\max}$  of 15 mL/s was 38%, the PPV 67% and the sensitivity 82% [85]. If  $Q_{\max}$  is > 15 mL/s, physiological compensatory processes mean that BOO cannot be excluded. Low  $Q_{\max}$  can arise as a consequence of BOO [86], DUA or an under-filled bladder [87]. Therefore, it is limited as a diagnostic test as it is unable to discriminate between the underlying mechanisms. Specificity can be improved by repeated flow rate testing. Uroflowmetry can be used for monitoring treatment outcomes [88] and correlating symptoms with objective findings.

Summary of evidence	LE
The diagnostic accuracy of uroflowmetry for detecting BOO varies considerably and is substantially influenced by threshold values. Specificity can be improved by repeated flow rate testing.	2b

Recommendations	Strength rating
Perform uroflowmetry in the initial assessment of male LUTS.	Weak
Perform uroflowmetry prior to medical or invasive treatment.	Strong

## 4.10 Imaging

### 4.10.1 Upper urinary tract

Men with LUTS are not at increased risk for upper tract malignancy or other abnormalities when compared to the overall population [73, 89-91]. Several arguments support the use of renal US in preference to intravenous urography. Ultrasound allows for better characterisation of renal masses, the possibility of investigating the liver and retroperitoneum, and simultaneous evaluation of the bladder, PVR and prostate, together with a lower cost, radiation dose and less side effects [89]. Ultrasound can be used for the evaluation of men with large PVR, haematuria, or a history of urolithiasis.

Summary of evidence	LE
Men with LUTS are not at increased risk for upper tract malignancy or other abnormalities when compared to the overall population.	3
Ultrasound can be used for the evaluation of men with large PVR, haematuria, or a history of urolithiasis.	4

Recommendation	Strength rating
Perform ultrasound of the upper urinary tract in men with LUTS.	Weak

### 4.10.2 Prostate

Imaging of the prostate can be performed by transabdominal US, TRUS, computed tomography (CT), and magnetic resonance imaging (MRI). However, in daily practice, prostate imaging is performed by transabdominal (suprapubic) US or TRUS [89].

#### 4.10.2.1 Prostate size and shape

Assessment of prostate size is important for the selection of interventional treatment, i.e. open prostatectomy (OP), enucleation techniques, transurethral resection, transurethral incision of the prostate (TUIP), or minimally invasive therapies. It is also important prior to treatment with 5 $\alpha$ -reductase inhibitors (5-ARIs). Prostate volume predicts symptom progression and the risk of complications [91].

Transrectal US is superior to transabdominal volume measurement [92, 93]. The presence of a median lobe may guide treatment choice in patients scheduled for a minimally invasive approach since medial lobe presence can be a contraindication for some minimally invasive treatments (see section 5.3).

Summary of evidence	LE
Assessment of prostate size by TRUS or transabdominal US is important for the selection of interventional treatment and prior to treatment with 5-ARIs.	3

Recommendations	Strength rating
Perform imaging of the prostate when considering medical treatment for male LUTS, if it assists in the choice of the appropriate drug.	Weak
Perform imaging of the prostate when considering surgical treatment.	Strong

### 4.10.3 Voiding cysto-urethrogram

Voiding cysto-urethrogram (VCUG) is not recommended in the routine diagnostic work-up of men with LUTS, but it may be useful for the detection of vesico-ureteral reflux, bladder diverticula, or urethral pathologies. Retrograde urethrography may additionally be useful for the evaluation of suspected urethral strictures.

## 4.11 Urethrocystoscopy

Patients with a history of microscopic or gross haematuria, urethral stricture, or bladder cancer, who present with LUTS, should undergo urethrocystoscopy during diagnostic evaluation. The evaluation of a prostatic middle lobe with urethrocystoscopy should be performed when considering interventional treatments for which the presence of middle lobe is a contraindication.

A prospective study evaluated 122 patients with LUTS using uroflowmetry and urethrocystoscopy [94]. The pre-operative  $Q_{max}$  was normal in 25% of 60 patients who had no bladder trabeculation, 21% of 73 patients with mild trabeculation and 12% of 40 patients with marked trabeculation on cystoscopy. All 21 patients who presented with diverticula had a reduced  $Q_{max}$ .

Another study showed that there was no significant correlation between the degree of bladder trabeculation (graded from I to IV), and the pre-operative  $Q_{max}$  value in 39 symptomatic men aged 53-83 years [95]. The largest study published on this issue examined the relation of urethroscopic findings to urodynamic

studies in 492 elderly men with LUTS [96]. The authors noted a correlation between cystoscopic appearance (grade of bladder trabeculation and urethral occlusion) and urodynamic indices, DO and low compliance. It should be noted, however, that BOO was present in 15% of patients with normal cystoscopic findings, while 8% of patients had no obstruction, even in the presence of severe trabeculation [96].

Summary of evidence	LE
Patients with a history of microscopic or gross haematuria, urethral stricture, or bladder cancer, who present with LUTS, should undergo urethrocystoscopy during diagnostic evaluation.	3
None of the studies identified a strong association between the urethrocystoscopic and urodynamic findings.	3

Recommendation	Strength rating
Perform urethrocystoscopy in men with LUTS prior to minimally invasive/surgical therapies if the findings may change treatment.	Weak

## 4.12 Urodynamics

In male LUTS, the most widespread invasive urodynamic techniques employed are filling cystometry and pressure flow studies (PFS). The major goal of urodynamics is to explore the functional mechanisms of LUTS, to identify risk factors for adverse outcomes and to provide information for shared decision-making. Most terms and conditions (e.g. DO, low compliance, BOO/BPO, DUA) are defined by urodynamic investigation.

### 4.12.1 Diagnosing bladder outlet obstruction

Pressure flow studies (PFS) are used to diagnose and define the severity of BOO, which is characterised by increased detrusor pressure and decreased urinary flow rate during voiding. Bladder outlet obstruction/BPO has to be differentiated from DUA, which exhibits decreased detrusor pressure during voiding in combination with decreased urinary flow rate [6].

Urodynamic testing may also identify DO. Studies have described an association between BOO and DO [97, 98]. In men with LUTS attributed to BPO, DO was present in 61% and independently associated with BOO grade and ageing [97].

The prevalence of DUA in men with LUTS is 11-40% [99, 100]. Detrusor contractility does not appear to decline in long-term BOO and surgical relief of BOO does not improve contractility [101, 102]. There are no published RCTs in men with LUTS and possible BPO that compare the standard practice investigation (uroflowmetry and PVR measurement) with PFS with respect to the outcome of treatment; however, a study has been completed in the UK, but the final results have not yet been published [103, 104]. Once available they will be included in the next edition of the Guidelines.

A Cochrane meta-analysis was done to determine whether performing invasive urodynamic investigation reduces the number of men with continuing symptoms of voiding dysfunction. Two trials with 350 patients were included. Invasive urodynamic testing changed clinical decision making. Patients who underwent urodynamics were less likely to undergo surgery; however, no evidence was found to demonstrate whether this led to reduced symptoms of voiding dysfunction after treatment [105]. A more recent meta-analysis of retrospective studies showed that pre-operative urodynamic DOA has no diagnostic role in the prediction of surgical outcomes in patients with male BOO [106].

Due to the invasive nature of the test, a urodynamic investigation is generally only offered if conservative treatment has failed. The Guidelines Panel attempted to identify specific indications for PFS based on age, findings from other diagnostic tests and previous treatments. The Panel allocated a different degree of obligation for PFS in men > 80 years and men < 50 years, which reflects the lack of evidence. In addition, there was no consensus whether PFS should or may be performed when considering surgery in men with bothersome predominantly voiding LUTS and  $Q_{\max} > 10$  mL/s, although the Panel recognised that with a  $Q_{\max} < 10$  mL/s, BOO is likely and PFS is not necessarily needed.

Patients with neurological disease, including those with previous radical pelvic surgery, should be assessed according to the EAU Guidelines on Neuro-Urology [107].

### 4.12.2 Videourodynamics

Videourodynamics provides additional anatomical and functional information and may be recommended if the clinician considers this is needed to understand the pathophysiological mechanism of an individual patient's LUTS.

Summary of evidence	LE
Within the literature cut-off dates of the 2021 edition of the Guidelines there were no RCTs in men with LUTS and possible BPO that compare the standard practice investigation (uroflowmetry and PVR measurement) with PFS with respect to the outcome of treatment. All subsequent RCTs will be evaluated for inclusion in the next edition of the Guidelines.	3

Recommendations	Strength rating
Perform pressure-flow studies (PFS) only in individual patients for specific indications prior to invasive treatment or when further evaluation of the underlying pathophysiology of LUTS is warranted.	Weak
Perform PFS in men who have had previous unsuccessful (invasive) treatment for LUTS.	Weak
Perform PFS in men considering invasive treatment who cannot void > 150 mL.	Weak
Perform PFS when considering surgery in men with bothersome predominantly voiding LUTS and $Q_{max} > 10$ mL/s.	Weak
Perform PFS when considering invasive therapy in men with bothersome, predominantly voiding LUTS with a post void residual > 300 mL.	Weak
Perform PFS when considering invasive treatment in men with bothersome, predominantly voiding LUTS aged > 80 years.	Weak
Perform PFS when considering invasive treatment in men with bothersome, predominantly voiding LUTS aged < 50 years.	Weak

#### 4.13 Non-invasive tests in diagnosing bladder outlet obstruction in men with LUTS

##### 4.13.1 Prostatic configuration/intravesical prostatic protrusion (IPP)

Prostatic configuration can be evaluated with TRUS, using the concept of the presumed circle area ratio (PCAR) [108]. The PCAR evaluates how closely the transverse US image of the prostate approaches a circular shape. The ratio tends toward one as the prostate becomes more circular. The sensitivity of PCAR was 77% for diagnosing BPO when PCAR was > 0.8, with 75% specificity [108].

Ultrasound measurement of IPP assesses the distance between the tip of the prostate median lobe and bladder neck in the midsagittal plane, using a suprapubically positioned US scanner, with a bladder volume of 150-250 mL; grade I protrusion is 0-4.9 mm, grade II is 5-10 mm and grade III is > 10 mm.

Intravesical prostatic protrusion correlates well with BPO (presence and severity) on urodynamic testing, with a PPV of 94% and a NPV of 79% [109]. Intravesical prostatic protrusion may also correlate with prostate volume, DO, bladder compliance, detrusor pressure at maximum urinary flow, BOO index and PVR, and negatively correlates with  $Q_{max}$  [110]. Furthermore, IPP also appears to successfully predict the outcome of a trial without catheter after AUR [111, 112]. However, no information with regard to intra- or inter-observer variability and learning curve is yet available. Therefore, whilst IPP may be a feasible option to infer BPO in men with LUTS, the role of IPP as a non-invasive alternative to PFS in the assessment of male LUTS remains under evaluation.

##### 4.13.2 Bladder/detrusor wall thickness and ultrasound-estimated bladder weight

For bladder wall thickness (BWT) assessment, the distance between the mucosa and the adventitia is measured. For detrusor wall thickness (DWT) assessment, the only measurement needed is the detrusor sandwiched between the mucosa and adventitia [113].

A correlation between BWT and PFS parameters has been reported. A threshold value of 5 mm at the anterior bladder wall with a bladder filling of 150 mL was best at differentiating between patients with or without BOO [114]. Detrusor wall thickness at the anterior bladder wall with a bladder filling > 250 mL (threshold value for BOO > 2 mm) has a PPV of 94% and a specificity of 95%, achieving 89% agreement with PFS [73]. Threshold values of 2.0, 2.5, or 2.9 mm for DWT in patients with LUTS are able to identify 81%, 89%, and 100% of patients with BOO, respectively [115].

All studies found that BWT or DWT measurements have a higher diagnostic accuracy for detecting BOO than  $Q_{max}$  or  $Q_{ave}$  of free uroflowmetry, measurements of PVR, prostate volume, or symptom severity. One study could not demonstrate any difference in BWT between patients with normal urodynamics, BOO or DO. However, the study did not use a specific bladder filling volume for measuring BWT [116]. Disadvantages of the method include the lack of standardisation, and lack of evidence to indicate which measurement (BWT/DWT) is preferable [117]. Measurement of BWT/DWT is therefore not recommended for the diagnostic work-up of men with LUTS.

Ultrasound-estimated bladder weight (UEBW) may identify BOO with a diagnostic accuracy of 86% at a cut-off value of 35 g [118, 119]. Severe LUTS and a high UEBW (> 35 g) are risk factors for prostate/BPH surgery in men on  $\alpha$ -blockers [120].

#### 4.13.3 **Non-invasive pressure-flow testing**

The penile cuff method, in which flow is interrupted to estimate isovolumetric bladder pressure, shows promising data, with good test repeatability [121] and interobserver agreement [122]. A nomogram has also been derived [123] whilst a method in which flow is not interrupted is also under investigation [124].

The data generated with the external condom method [125] correlates with invasive PFS in a high proportion of patients [126]. Resistive index [127] and prostatic urethral angle [128] have also been proposed, but are still experimental.

#### 4.13.4 **The diagnostic performance of non-invasive tests in diagnosing bladder outlet obstruction in men with LUTS compared with pressure-flow studies**

The diagnostic performance of non-invasive tests in diagnosing BOO in men with LUTS compared with PFS has been investigated in a SR [129]. A total of 42 studies were included in this review. The majority were prospective cohort studies, and the diagnostic accuracy of the following non-invasive tests were assessed: penile cuff test; uroflowmetry; detrusor/bladder wall thickness; bladder weight; external condom catheter method; IPP; Doppler US; prostate volume/height; and near-infrared spectroscopy. Overall, although the majority of studies have a low risk of bias, data regarding the diagnostic accuracy of these non-invasive tests is limited by the heterogeneity of the studies in terms of the threshold values used to define BOO, the different urodynamic definitions of BOO used across different studies and the small number of studies for each test. It was found that specificity, sensitivity, PPV and NPV of the non-invasive tests were highly variable. Therefore, even though several tests have shown promising results regarding non-invasive diagnosis of BOO, invasive urodynamics remains the modality of choice.


Summary of evidence	LE
Data regarding the diagnostic accuracy of non-invasive tests is limited by the heterogeneity of the studies as well as the small number of studies for each test.	1a
Specificity, sensitivity, PPV and NPV of the non-invasive tests were highly variable.	1a

Recommendation	Strength rating
Do not offer non-invasive tests as an alternative to pressure-flow studies for diagnosing bladder outlet obstruction in men.	Strong



**Figure 2: Assessment algorithm of LUTS in men aged 40 years or older**

Readers are strongly recommended to read the full text that highlights the current position of each test in detail.



*DRE = digital-rectal examination; FVC = frequency volume chart; LUTS = lower urinary tract symptoms; PCa = prostate cancer; PSA = prostate specific antigen; PVR = post-void residual; US = ultrasound.*

## 5. DISEASE MANAGEMENT

### 5.1 Conservative treatment

#### 5.1.1 Watchful waiting (WW)

Many men with LUTS are not troubled enough by their symptoms to need drug treatment or surgical intervention. All men with LUTS should be formally assessed prior to any allocation of treatment in order to establish symptom severity and to differentiate between men with uncomplicated (the majority) and



complicated LUTS. Watchful waiting is a viable option for many men with non-bothersome LUTS as few will progress to AUR and complications (e.g. renal insufficiency or stones) [130, 131], whilst others can remain stable for years [132]. In one study, approximately 85% of men with mild LUTS were stable on WW at one year [133].

A study comparing WW and transurethral resection of the prostate (TURP) in men with moderate LUTS showed the surgical group had improved bladder function (flow rates and PVR volumes), especially in those with high levels of bother; 36% of WW patients crossed over to surgery within five years, leaving 64% doing well in the WW group [134, 135]. Increasing symptom bother and PVR volumes are the strongest predictors of WW failure. Men with mild-to-moderate uncomplicated LUTS who are not too troubled by their symptoms are suitable for WW.

### 5.1.2 **Behavioural and dietary modifications**

It is customary for this type of management to include the following components:

- education (about the patient's condition);
- reassurance (that cancer is not a cause of the urinary symptoms);
- periodic monitoring;
- lifestyle advice [132, 133, 136, 137] such as::
  - o reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient (e.g. at night or when going out in public);
  - o avoidance/moderation of intake of caffeine or alcohol, which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia;
  - o use of relaxed and double-voiding techniques;
  - o urethral milking to prevent post-micturition dribble;
  - o distraction techniques such as penile squeeze, breathing exercises, perineal pressure, and mental tricks to take the mind off the bladder and toilet, to help control OAB symptoms;
  - o bladder retraining that encourages men to hold on when they have urgency to increase their bladder capacity and the time between voids;
  - o reviewing the medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects (these recommendations apply especially to diuretics);
  - o providing necessary assistance when there is impairment of dexterity, mobility, or mental state;
  - o treatment of constipation.

There now exists evidence that self-management as part of WW reduces both symptoms and progression [136, 137]. Men randomised to three self-care management sessions in addition to standard care had better symptom improvement and QoL than men treated with standard care only, for up to a year [136].

### 5.1.3 **Practical considerations**

The components of self-care management have not been individually studied. The above components of lifestyle advice have been derived from formal consensus methodology [138]. Further research in this area is required.

Summary of evidence	LE
Watchful waiting is usually a safe alternative for men who are less bothered by urinary difficulty or who wish to delay treatment. The treatment failure rate over a period of five years was 21%; 79% of patients were clinically stable.	1b
An additional study reported 81% of patients were clinically stable on WW after a mean follow-up of seventeen months.	2
Men randomised to three self-management sessions in addition to standard care had better symptom improvement and QoL than men treated with standard care alone at up to a year. Self-care management as part of WW reduces both symptoms and progression.	1b

Recommendations	Strength rating
Offer men with mild/moderate symptoms, minimally bothered by their symptoms, watchful waiting.	Strong
Offer men with LUTS lifestyle advice and self-care information prior to, or concurrent with, treatment.	Strong

## 5.2 Pharmacological treatment

### 5.2.1 $\alpha$ 1-Adrenoceptor antagonists ( $\alpha$ 1-blockers)

*Mechanism of action:*  $\alpha$ 1-blockers aim to inhibit the effect of endogenously released noradrenaline on smooth muscle cells in the prostate and thereby reduce prostate tone and BOO [139]. However,  $\alpha$ 1-blockers have little effect on urodynamically determined bladder outlet resistance [140], and treatment-associated improvement of LUTS correlates poorly with obstruction [141]. Thus, other mechanisms of action may also be relevant.

Alpha 1-adrenoceptors located outside the prostate (e.g. urinary bladder and/or spinal cord) and  $\alpha$ 1-adrenoceptor subtypes ( $\alpha$ 1B- or  $\alpha$ 1D-adrenoceptors) may play a role as mediators of effects. Alpha 1-adrenoceptors in blood vessels, other non-prostatic smooth muscle cells, and the central nervous system may mediate adverse events.

Currently available  $\alpha$ 1-blockers are: alfuzosin hydrochloride (alfuzosin); doxazosin mesylate (doxazosin); silodosin; tamsulosin hydrochloride (tamsulosin); terazosin hydrochloride (terazosin); and naftopidil. Alpha 1-blockers exist in different formulations. Although different formulations result in different pharmacokinetic and tolerability profiles, the overall difference in clinical efficacy between the different formulations seems modest.

*Efficacy:* Indirect comparisons and limited direct comparisons between  $\alpha$ 1-blockers demonstrate that all  $\alpha$ 1-blockers have a similar efficacy in appropriate doses [142]. Clinical effects take a few weeks to develop fully, but significant efficacy over placebo can occur within hours to days [141].

Controlled studies show that  $\alpha$ 1-blockers typically reduce IPSS by approximately 30-40% and increase  $Q_{\max}$  by approximately 20-25%. However, considerable improvements also occurred in the corresponding placebo arms [63, 143]. In open-label studies, an IPSS improvement of up to 50% and  $Q_{\max}$  increase of up to 40% were documented [63, 143]. A recent SR and meta-analysis suggested that  $Q_{\max}$  variation underestimates the real effect of  $\alpha$ 1-blockers on BPO, as small improvements in  $Q_{\max}$  correspond to relevant improvements in BOO index in PFS [144].

Alpha 1-blockers can reduce both storage and voiding LUTS. Prostate size does not affect  $\alpha$ 1-blocker efficacy in studies with follow-up periods of less than one year, but  $\alpha$ 1-blockers do seem to be more efficacious in patients with smaller prostates (< 40 mL) in longer-term studies [65, 145-148]. The efficacy of  $\alpha$ 1-blockers is similar across age groups [143]. In addition,  $\alpha$ 1-blockers neither reduce prostate size nor prevent AUR in long-term studies [146-148]; however, recent evidence suggests that the use of  $\alpha$ 1-blockers (alfuzosin and tamsulosin) may improve resolution of AUR [149]. Nonetheless, IPSS reduction and  $Q_{\max}$  improvement during  $\alpha$ 1-blocker treatment appears to be maintained over at least four years.

*Tolerability and safety:* Tissue distribution, subtype selectivity, and pharmacokinetic profiles of certain formulations may contribute to the tolerability profile of specific drugs. The most frequent adverse events of  $\alpha$ 1-blockers are asthenia, dizziness and (orthostatic) hypotension. Vasodilating effects are most pronounced with doxazosin and terazosin, and are less common with alfuzosin and tamsulosin [150]. Patients with cardiovascular comorbidity and/or vaso-active co-medication may be susceptible to  $\alpha$ 1-blocker-induced vasodilatation [151]. In contrast, the frequency of hypotension with the  $\alpha$ 1A-selective blocker silodosin is comparable with placebo [152]. In a large retrospective cohort analysis of men aged > 66 years treated with  $\alpha$ 1-blockers the risks of falling (odds ratio [OR] 1.14) and of sustaining a fracture (OR 1.16) was increased, most likely as a result of induced hypotension [153].

An adverse ocular event termed intra-operative floppy iris syndrome (IFIS) was reported in 2005, affecting cataract surgery [154]. A meta-analysis on IFIS after alfuzosin, doxazosin, tamsulosin or terazosin exposure showed an increased risk for all  $\alpha$ 1-blockers [155]. However, the OR for IFIS was much higher for tamsulosin. It appears prudent not to initiate  $\alpha$ 1-blocker treatment prior to scheduled cataract surgery, and the ophthalmologist should be informed about  $\alpha$ 1-blocker use.

A SR concluded that  $\alpha$ 1-blockers do not adversely affect libido, have a small beneficial effect on erectile function, but can cause abnormal ejaculation [156]. Originally, abnormal ejaculation was thought to be retrograde, but more recent data demonstrate that it is due to a decrease or absence of seminal fluid during ejaculation, with young age being an apparent risk factor. In a recent meta-analysis ejaculatory dysfunction (EjD) was significantly more common with  $\alpha$ 1-blockers than with placebo (OR 5.88). In particular, EjD was significantly more commonly related with tamsulosin or silodosin (OR 8.57 and 32.5) than placebo, while both doxazosin and terazosin (OR 0.80 and 1.78) were associated with a low risk of EjD [157]. In the meta-regression, the occurrence of EjD was independently associated with the improvement of urinary symptoms and flow rate, suggesting that the more effective the  $\alpha$ 1-blocker is the greater the incidence of EjD.

*Practical considerations:*  $\alpha$ 1-blockers are usually considered the first-line drug treatment for male LUTS because of their rapid onset of action, good efficacy, and low rate and severity of adverse events. However,  $\alpha$ 1-blockers do not prevent occurrence of urinary retention or need for surgery. Ophthalmologists should be informed about  $\alpha$ 1-blocker use prior to cataract surgery. Elderly patients treated with non-selective  $\alpha$ 1-blockers should be informed about the risk of orthostatic hypotension. Sexually active patients treated with selective  $\alpha$ 1-blockers should be counselled about the risk of EjD.

Summary of evidence	LE
$\alpha$ 1-blockers are effective in reducing urinary symptoms (IPSS) and increasing the peak urinary flow rate ( $Q_{\max}$ ) compared with placebo.	1a
Alfuzosin, terazosin and doxazosin showed a statistically significant increased risk of developing vascular-related events compared with placebo.	1a
Alfuzosin, doxazosin, tamsulosin or terazosin exposure has been associated with an increased risk of IFIS.	1a
Ejaculatory dysfunction is significantly more common with $\alpha$ 1-blockers than with placebo, particularly with more selective $\alpha$ 1-blockers such as tamsulosin and silodosin.	1a

Recommendation	Strength rating
Offer $\alpha$ 1-blockers to men with moderate-to-severe LUTS.	Strong

### 5.2.2 $5\alpha$ -reductase inhibitors

*Mechanism of action:* Androgen effects on the prostate are mediated by dihydrotestosterone (DHT), which is converted from testosterone by the enzyme  $5\alpha$ -reductase [158], which has two isoforms:

- $5\alpha$ -reductase type 1: predominant expression and activity in the skin and liver.
- $5\alpha$ -reductase type 2: predominant expression and activity in the prostate.

Two 5-ARIs are available for clinical use: dutasteride and finasteride. Finasteride inhibits only  $5\alpha$ -reductase type 2, whereas dutasteride inhibits both  $5\alpha$ -reductase types (dual 5-ARI). The 5-ARIs induce apoptosis of prostate epithelial cells [159] leading to prostate size reduction of about 18-28% and a decrease in circulating PSA levels of about 50% after six to twelve months of treatment [160]. Mean prostate volume and PSA reduction may be even more pronounced after long-term treatment. Continuous treatment reduces the serum DHT concentration by approximately 70% with finasteride and 95% with dutasteride. However, prostate DHT concentration is reduced to a similar level (85-90%) by both 5-ARIs.

*Efficacy:* Clinical effects relative to placebo are seen after treatment of at least six months. After two to four years of treatment 5-ARIs improve IPSS by approximately 15-30%, decrease prostate volume by 18-28%, and increase  $Q_{\max}$  by 1.5-2.0 mL/s in patients with LUTS due to prostate enlargement [65, 147, 148, 161-167]. An indirect comparison and one direct comparative trial (twelve months duration) indicate that dutasteride and finasteride are equally effective in the treatment of LUTS [160, 168]. Symptom reduction depends on initial prostate size.

Finasteride may not be more efficacious than placebo in patients with prostates < 40 mL [169]. However, dutasteride seems to reduce IPSS, prostate volume, and the risk of AUR, and to increase  $Q_{\max}$  even in patients with prostate volumes of between 30 and 40 mL [170, 171]. A long-term trial with dutasteride in symptomatic men with prostate volumes > 30 mL and increased risk for disease progression showed that dutasteride reduced LUTS at least as much as the  $\alpha$ 1-blocker tamsulosin [147, 167, 172]. The greater the baseline prostate volume (or serum PSA level), the faster and more pronounced the symptomatic benefit of dutasteride as compared to tamsulosin.

$5\alpha$ -reductase inhibitors, but not  $\alpha$ 1-blockers, reduce the long-term (> 1 year) risk of AUR or need for surgery [65, 165, 173]. In the PLESS study, finasteride reduced the relative risk of AUR by 57% and need for surgery by 55% (absolute risk reduction 4% and 7%, respectively) at four years, compared with placebo [165]. In the MTOPS study, finasteride reduced the relative risk of AUR by 68% and need for surgery by 64% (absolute risk reduction 2% and 3%, respectively), also at four years [65]. A pooled analysis of three randomised trials with two-year follow-up data, reported that treatment with finasteride decreased the relative risk of AUR by 57%, and surgical intervention by 34% (absolute risk reduction 2% for both) in patients with moderately symptomatic LUTS [174]. Dutasteride has also demonstrated efficacy in reducing the risks for AUR and BPO-related surgery. Open-label trials have demonstrated relevant changes in urodynamic parameters [175, 176]. Furthermore, finasteride might reduce blood loss during transurethral prostate surgery, probably due to its effects on prostatic vascularisation [177, 178].

**Tolerability and safety:** The most common adverse events are reduced libido, erectile dysfunction (ED) and less frequently, ejaculation disorders such as retrograde ejaculation, ejaculation failure, or decreased semen volume [65, 148, 160, 179]. Gynaecomastia (with breast or nipple tenderness) develops in 1-2% of patients. Two studies have suggested that treatment with 5-ARIs is associated with a higher incidence of high-grade cancers although no causal relationship has been proven [180, 181]. There is a long-standing debate regarding potential cardiovascular side effects of 5-ARIs, in particular dutasteride [182]. Population-based studies in Taiwan and Ontario did not find an association between the use of 5-ARIs and increased cardiovascular side effects [182, 183].

**Practical considerations:** Treatment with 5-ARIs should be considered in men with moderate-to-severe LUTS and an enlarged prostate (> 40 mL) and/or elevated PSA concentration (> 1.4-1.6 ng/mL). They can reduce the risk of AUR and need for surgery. Due to the slow onset of action, they are not suitable for short-term use. Their effect on PSA needs to be considered in relation to PCa screening.

Summary of evidence	LE
After two to four years of treatment, 5-ARIs improve IPSS by approximately 15-30%, decrease prostate volume by 18-28%, and increase $Q_{max}$ by 1.5-2.0 mL/s in patients with LUTS due to prostate enlargement.	1b
5 $\alpha$ -reductase inhibitors can prevent disease progression with regard to AUR and the need for surgery. Due to 5-ARIs slow onset of action, they are suitable only for long-term treatment (years).	1a
The most relevant adverse effects of 5-ARIs are related to sexual function, and include reduced libido, ED and less frequently, ejaculation disorders such as retrograde ejaculation, ejaculation failure, or decreased semen volume.	1b

Recommendations	Strength rating
Use 5 $\alpha$ -reductase inhibitors in men who have moderate-to-severe LUTS and an increased risk of disease progression (e.g. prostate volume > 40 mL).	Strong
Counsel patients about the slow onset of action of 5 $\alpha$ -reductase inhibitors.	Strong

### 5.2.3 Muscarinic receptor antagonists

**Mechanism of action:** The detrusor is innervated by parasympathetic nerves whose main neurotransmitter is acetylcholine, which stimulates muscarinic receptors (M-cholinoreceptors) on the smooth muscle cells. Muscarinic receptors are also present on other cell types, such as bladder urothelial cells and epithelial cells of the salivary glands. Five muscarinic receptor subtypes (M1-M5) have been described, of which M2 and M3 are predominant in the detrusor. The M2 subtype is more numerous, but the M3 subtype is functionally more important in bladder contractions [184, 185]. Antimuscarinic effects might also be induced or modulated through other cell types, such as the bladder urothelium or by the central nervous system [186, 187].

The following muscarinic receptor antagonists are licensed for treating OAB/storage symptoms: darifenacin hydrobromide (darifenacin); fesoterodine fumarate (fesoterodine); oxybutynin hydrochloride (oxybutynin); propiverine hydrochloride (propiverine); solifenacin succinate (solifenacin); tolterodine tartrate (tolterodine); and trospium chloride. Transdermal preparations of oxybutynin have been formulated and evaluated in clinical trials [188, 189].

**Efficacy:** Antimuscarinics were mainly tested in females in the past, as it was believed that LUTS in men were caused by the prostate, so should be treated with prostate-specific drugs. However, there is no scientific data for this assumption [190]. A sub-analysis of an open-label trial of OAB patients showed that age, but not gender had an impact on urgency, frequency, or urgency incontinence [191]. In a pooled analysis, which included a sub-analysis of male patients, fesoterodine 8 mg was superior to tolterodine extended release (ER) 4 mg for the improvement of severe urgency episodes/24 hours and the OAB-q Symptom Bother score at week twelve, the urinary retention rate was around 2% [192].

The efficacy of antimuscarinics as single agents in men with OAB in the absence of BOO have been tested [193-198]. Most trials lasted only twelve weeks. Four *post hoc* analyses of large RCTs on the treatment of OAB in women and men without presumed BOO were performed focusing only on the men [190, 194, 199]. Tolterodine can significantly reduce urgency incontinence, daytime or 24-hour frequency and urgency-related voiding whilst improving patient perception of treatment benefit. Solifenacin significantly improved mean patient perception of bladder condition scores, mean OAB questionnaire scores, and overall perception of bladder problems. Fesoterodine improved micturition frequency, urgency episodes, and urgency urinary incontinence (UUI) episodes. In open-label trials with tolterodine, daytime frequency, nocturia, UUI, and

IPSS were significantly reduced compared with baseline values after 12-25 weeks [195, 198]. The TIMES RCT reported that tolterodine ER monotherapy significantly improved UII episodes per 24 hours compared to placebo, at week twelve. Tolterodine ER did not significantly improve urgency, IPSS total or QoL score compared with placebo. A significantly greater proportion of patients in the tolterodine ER plus tamsulosin group reported treatment benefit compared with the other three treatment groups [197].

A further analysis showed that men with PSA levels of < 1.3 ng/mL (smaller prostates) might benefit more from antimuscarinics [200]. Two other studies found a positive effect of antimuscarinics in patients with OAB and concomitant BPO [198, 201]. In a small RCT propiverine improved frequency and urgency episodes [201].

**Tolerability and safety:** Antimuscarinic drug trials generally show approximately 3-10% withdrawals, which is similar to placebo. Drug-related adverse events include dry mouth (up to 16%), constipation (up to 4%), micturition difficulties (up to 2%), nasopharyngitis (up to 3%), and dizziness (up to 5%).

Increased PVR in men without BOO is minimal and similar to placebo. Nevertheless, fesoterodine 8 mg showed higher PVRs (+20.2 mL) than placebo (-0.6 mL) or fesoterodine 4 mg (+9.6 mL) [195]. Incidence of urinary retention in men without BOO was similar to placebo for tolterodine (0-1.3% vs. 0-1.4%). With fesoterodine 8 mg, 5.3% had symptoms, which was higher than placebo or fesoterodine 4 mg (both 0.8%). These symptoms appeared during the first two weeks of treatment and mainly affected men aged 66 years or older.

Theoretically antimuscarinics might decrease bladder strength, and hence might be associated with PVR urine or urinary retention. A twelve week safety study on men with mild-to-moderate BOO showed that tolterodine increased the PVR (49 mL vs. 16 mL) but not AUR (3% in both arms) [202]. The urodynamic effects included larger bladder volumes at first detrusor contraction, higher maximum cystometric capacity, and decreased bladder contractility index,  $Q_{\max}$  was unchanged. This trial indicated that short-term treatment with antimuscarinics in men with BOO is safe [190].

**Practical considerations:** Not all antimuscarinics have been tested in elderly men, and long-term studies on the efficacy of muscarinic receptor antagonists in men of any age with LUTS are not yet available. In addition, only patients with low PVR volumes at baseline were included in the studies. These drugs should therefore be prescribed with caution, and regular re-evaluation of IPSS and PVR urine is advised. Men should be advised to discontinue medication if worsening voiding LUTS or urinary stream is noted after initiation of therapy.

Summary of evidence	LE
Antimuscarinic monotherapy can significantly improve urgency, UII, and increased daytime frequency.	2
Antimuscarinic monotherapy can be associated with increased PVR after therapy, but acute retention is a rare event in men with a PVR volume of < 150 mL at baseline.	2

Recommendations	Strength rating
Use muscarinic receptor antagonists in men with moderate-to-severe LUTS who mainly have bladder storage symptoms.	Strong
Do not use antimuscarinic overactive bladder medications in men with a post-void residual volume > 150 mL.	Weak

#### 5.2.4 **Beta-3 agonist**

**Mechanism of action:** Beta-3 adrenoceptors are the predominant beta receptors expressed in the smooth muscle cells of the detrusor and their stimulation is thought to induce detrusor relaxation. The mode of action of beta-3 agonists is not fully elucidated [203].

**Efficacy:** Mirabegron 50 mg is the first clinically available beta-3 agonist with approval for use in adults with OAB. Mirabegron has undergone extensive evaluation in RCTs conducted in Europe, Australia, North America and Japan [204-208]. Mirabegron demonstrated significant efficacy in treating the symptoms of OAB, including micturition frequency, urgency and UII and also patient perception of treatment benefit. These studies had a predominantly female study population. A meta-analysis of eight RCTs including 10,248 patients (27% male) found that mirabegron treatment resulted in reduced frequency, urgency and UII rates, as well as an improved voided volume with a statistically significant improvement of nocturia as compared with both placebo and tolterodine [209].

Mirabegron has been evaluated in male patients with OAB in the context of LUTS either associated with or not associated with BPO confirmed by urodynamics [210]. Mirabegron 25 mg daily led to increased satisfaction and improved QoL, but symptoms assessed by validated questionnaires (IPSS and OAB-SS), only



improved in non-obstructed patients. Mirabegron as an add-on therapy has been studied in OAB patients with incontinence despite antimuscarinic therapy [211], again in a predominantly female study population. An Asian study with a higher proportion of male subjects (approximately one third) reported superiority over placebo in reducing frequency of micturition, but did not report the results separately for the genders [212].

In a study of more than 1,000 patients of whom approximately 30% were male, combination therapy of mirabegron 25/50 mg and solifenacin 5/10 mg was associated with statistically significant improvements in patient outcomes and health related QoL vs. solifenacin 5 mg and placebo; however, they did not separate out the effects in men and women [213]. In another study, in which 28% patients were male, mirabegron significantly improved patient reported perception of their condition and QoL whether or not patients were incontinent [214]. A phase IV study, with a small proportion of male subjects, reported addition of mirabegron in people with persisting urgency despite solifenacin in a Japanese population [215].

In an RCT evaluating add-on therapy with mirabegron for OAB symptoms remaining after treatment with tamsulosin 0.2 mg daily in men with BPO, combination therapy was associated with greater improvements in OAB symptom score, in the urinary urgency and daytime frequency part and storage subscore of the IPSS, and in the QoL index compared to monotherapy with tamsulosin [216]. A prospective analysis of 50 elderly men showed that mirabegron add-on therapy was effective for patients whose persistent LUTS and OAB symptoms were not controlled with  $\alpha$ 1-blocker monotherapy, without causing negative effects on voiding function [217].

An RCT compared the efficacy of mirabegron 50 mg or fesoterodine 4 mg add-on therapy to silodosin in LUTS patients with persisting OAB symptoms [218]. At three months, fesoterodine add-on therapy showed a significantly greater improvement than mirabegron add-on therapy in OAB symptom score-total (-2.8 vs. -1.5,  $p = 0.004$ ), IPSS-QoL (-1.5 vs. -1.1,  $p = 0.04$ ), and OAB symptom score-urgency score (-1.5 vs. -0.9,  $p = 0.008$ ). Fesoterodine was also superior in alleviating detrusor overactivity (52.6% vs. 28.9%,  $p = 0.03$ ).

*Tolerability and safety:* The most common treatment-related adverse events in the mirabegron groups were hypertension, UTI, headache and nasopharyngitis [204-207]. Mirabegron is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure  $\geq 180$  mmHg or diastolic blood pressure  $\geq 110$  mmHg, or both). Blood pressure should be measured before starting treatment and monitored regularly during treatment. A combination of thirteen clinical studies including 13,396 patients, 25% of whom were male, showed that OAB treatments (anticholinergics or mirabegron) were not associated with an increased risk of hypertension or cardiovascular events compared to placebo [219]. The proportion of patients with dry mouth and constipation in the mirabegron groups was notably lower than reported in RCTs of other OAB agents or of the active control tolterodine [204]. Evaluation of urodynamic parameters in men with combined BOO and OAB concluded that mirabegron did not adversely affect voiding urodynamic parameters compared to placebo in terms of  $Q_{max}$ , detrusor pressure at maximum flow and bladder contractility index [220]. The overall change in PVR with mirabegron is small [220].

A small prospective study (mainly focused on males) has shown that mirabegron 25 mg is safe in patients aged 80 years or more with multiple comorbidities [221]. A pooled analysis of three trials each of twelve weeks and a one year trial showed, in patients aged  $> 65$  years, a more favourable tolerability profile for mirabegron than antimuscarinics [222]. In an eighteen week study of 3,527 patients (23% male), the incidence of adverse events were higher in the combination (solifenacin 5 mg plus mirabegron 25 mg) group (40%) than the mirabegron 25 mg alone group (32%). Events recorded as urinary retention were low ( $< 1\%$ ), but were reported slightly more frequently in the combined group when compared with the monotherapy and placebo groups. The PVR volume was slightly increased in the combined group compared with solifenacin 5 mg, and the mirabegron monotherapy and placebo groups. Combined therapy with solifenacin 5 mg plus mirabegron 25 mg and solifenacin 5 mg plus mirabegron 50 mg provided improvements in efficacy generally consistent with an additive effect [223].

In a retrospective analysis of persistence and adherence in 21,996 patients, of whom 30% were male, the median time to discontinuation was significantly longer for mirabegron (169 days) compared to tolterodine (56 days) and other antimuscarinics (30-78 days) ( $p < 0.0001$ ). There was no statistical difference between men and women [224]. Data on the safety of combination therapy at twelve months are awaited from the SYNERGY II trial.

*Practical considerations:* Long-term studies on the efficacy and safety of mirabegron in men of any age with LUTS are not yet available. Studies on the use of mirabegron in combination with other pharmacotherapeutic agents for male LUTS are pending. However, pharmacokinetic interaction upon add-on of mirabegron or tamsulosin to existing tamsulosin or mirabegron therapy does not cause clinically relevant changes in safety profiles [225]. Available studies on mirabegron in combination with antimuscarinics in OAB patients had a predominantly female study population, while further trials are still pending.

Summary of evidence	LE
Mirabegron improves the symptoms of OAB, including micturition frequency, urgency and UUI.	2
Patients prescribed mirabegron remained on treatment longer than those prescribed antimuscarinics.	3

Recommendation	Strength rating
Use beta-3 agonists in men with moderate-to-severe LUTS who mainly have bladder storage symptoms.	Weak

### 5.2.5 Phosphodiesterase 5 inhibitors

**Mechanism of action:** Phosphodiesterase 5 inhibitors (PDE5Is) increase intracellular cyclic guanosine monophosphate, thus reducing smooth muscle tone of the detrusor, prostate and urethra. Nitric oxide and PDE5Is might also alter reflex pathways in the spinal cord and neurotransmission in the urethra, prostate, or bladder [226]. Moreover, chronic treatment with PDE5Is seems to increase blood perfusion and oxygenation in the LUT [227]. Phosphodiesterase 5 inhibitors could also reduce chronic inflammation in the prostate and bladder [228]. The exact mechanism of PDE5Is on LUTS remains unclear.

Although clinical trials of several selective oral PDE5Is have been conducted in men with LUTS, only tadalafil (5 mg once daily) has been licensed for the treatment of male LUTS.

**Efficacy:** Several RCTs have demonstrated that PDE5Is reduce IPSS, storage and voiding LUTS, and improve QoL. However,  $Q_{max}$  did not significantly differ from placebo in most trials.

A recent Cochrane review included a total of sixteen randomised trials that examined the effects of PDE5Is compared to placebo and other standard of care drugs ( $\alpha$ 1-blockers and 5-ARIs) in men with LUTS [229]. Phosphodiesterase 5 inhibitors led to a small reduction (mean difference (MD) 1.89 lower, 95% CI 2.27 lower to 1.50 lower) in IPSS compared to placebo. There was no difference between PDE5Is and  $\alpha$ 1-blockers in IPSS. Most evidence was limited to short-term treatment up to twelve weeks and of moderate or low certainty. In earlier [230] and more recent [231] meta-analysis, PDE5Is were also found to improve IPSS and IIEF score, but not  $Q_{max}$ .

Tadalafil 5 mg reduces IPSS by 22-37% and improvement may be seen within a week of initiation of treatment [232]. A three point or greater total IPSS improvement was observed in 60% of tadalafil treated men within one week and in 80% within four weeks [233]. The maximum trial (open label) duration was 52 weeks [234]. A subgroup analysis of pooled data from four RCTs demonstrated a significant reduction in LUTS, regardless of baseline severity, age, previous use of  $\alpha$ -blockers or PDE5Is, total testosterone level or predicted prostate volume [235]. In a recent *post hoc* analysis of pooled data from four RCTs, tadalafil was shown to also be effective in men with cardiovascular risk factors/comorbidities, except for patients receiving more than one antihypertensive medication. The use of diuretics may contribute to patients' perception of a negated efficacy [236]. Among sexually active men > 45 years with comorbid LUTS/BPH and ED, tadalafil improved both conditions [235].

An integrated data analyses from four placebo controlled clinical studies showed that total IPSS improvement was largely attributed to direct (92.5%,  $p < 0.001$ ) vs. indirect (7.5%,  $p = 0.32$ ) treatment effects via IIEF-EF improvement [237]. Another analysis showed a small but significant increase in  $Q_{max}$  without any effect on PVR [238]. An integrated analysis of RCTs showed that tadalafil was not superior to placebo for IPSS improvement at twelve weeks in men  $\geq 75$  years (with varied effect size between studies), but was for men < 75 years [239]. An open label urodynamic study of 71 patients showed improvements in both voiding and storage symptoms, confirmed by improvements in BOO index (61.3 to 47.1;  $p < 0.001$ ), and resolution of DO in 15 (38%) of 38 patients. Flow rate improved from 7.1 to 9.1 mL/s ( $p < 0.001$ ) and mean IPSS from 18.2 to 13.4 [240].

A combination of PDE5Is and  $\alpha$ -blockers has also been evaluated. A meta-analysis of five RCTs (two studies with tadalafil 20 mg, two with sildenafil 25 mg, and one with vardenafil 20 mg), showed that combination therapy significantly improved IPSS score (-1.8), IIEF score (+3.6) and  $Q_{max}$  (+1.5 mL/s) compared with  $\alpha$ -blockers alone [230]. A Cochrane review found similar findings [229]. The effects of tadalafil 5 mg combined with finasteride 5 mg were assessed in a 26-week placebo-controlled RCT [241]. The combination of tadalafil and finasteride provided an early improvement in urinary symptoms ( $p < 0.022$  after 4, 12 and 26 weeks), with a significant improvement of storage and voiding symptoms and QoL. Combination therapy was well tolerated and improved erectile function [241]. However, only tadalafil 5 mg has been licensed in the context of LUTS management while data on combinations of PDE5Is and other LUTS medications is emerging.

**Tolerability and safety:** Reported adverse effects in RCTs comparing the effect of all PDE5Is vs. placebo in men with LUTS include flushing, gastroesophageal reflux, headache, dyspepsia, back pain and nasal congestion [230]. The discontinuation rate due to adverse effects for tadalafil was 2.0% [242] and did not differ by age, LUTS severity, testosterone levels, or prostate volume in the pooled data analyses [235].



Phosphodiesterase 5 inhibitors are contraindicated in patients using nitrates, the potassium channel opener nicorandil, or the  $\alpha$ 1-blockers doxazosin and terazosin. They are also contraindicated in patients who have unstable angina pectoris, have had a recent myocardial infarction (< three months) or stroke (< six months), myocardial insufficiency (New York Heart Association stage > 2), hypotension, poorly controlled blood pressure, significant hepatic or renal insufficiency, or if anterior ischaemic optic neuropathy with sudden loss of vision is known or was reported after previous use of PDE5Is.

*Practical considerations:* To date, only tadalafil 5 mg once daily has been officially licensed for the treatment of male LUTS with or without ED. The meta-regression suggested that younger men with low body mass index and more severe LUTS benefit the most from treatment with PDE5Is [230]. Long-term experience with tadalafil in men with LUTS is limited to one trial with a one year follow-up [234]; therefore, conclusions about its efficacy or tolerability greater than one year are not possible. There is limited information on reduction of prostate size and no data on disease progression.

Summary of evidence	LE
Phosphodiesterase 5 inhibitors improve IPSS and IIEF score, but not $Q_{max}$ .	1a
A three point or greater total IPSS improvement was observed in 59.8% of tadalafil treated men within one week and in 79.3% within four weeks.	1b

Recommendation	Strength rating
Use phosphodiesterase type 5 inhibitors in men with moderate-to-severe LUTS with or without erectile dysfunction.	Strong

#### 5.2.6 Plant extracts - phytotherapy

*Potential mechanism of action:* Herbal drug preparations are made of roots, seeds, pollen, bark, or fruits. There are single plant preparations (mono-preparations) and preparations combining two or more plants in one pill (combination preparations) [243].

Possible relevant compounds include phytosterols,  $\beta$ -sitosterol, fatty acids, and lectins [243]. *In vitro*, plant extracts can have anti-inflammatory, anti-androgenic and oestrogenic effects; decrease sexual hormone binding globulin; inhibit aromatase, lipoxigenase, growth factor-stimulated proliferation of prostatic cells,  $\alpha$ -adrenoceptors, 5  $\alpha$ -reductase, muscarinic cholinceptors, dihydropyridine receptors and vanilloid receptors; and neutralise free radicals [243-245]. The *in vivo* effects of these compounds are uncertain, and the precise mechanisms of plant extracts remain unclear.

*Efficacy:* The extracts of the same plant produced by different companies do not necessarily have the same biological or clinical effects; therefore, the effects of one brand cannot be extrapolated to others [246]. In addition, batches from the same producer may contain different concentrations of active ingredients [247]. A review of recent extraction techniques and their impact on the composition/biological activity of available *Serenoa repens* based products showed that results from different clinical trials must be compared strictly according to the same validated extraction technique and/or content of active compounds [248], as the pharmacokinetic properties of the different preparations can vary significantly.

Heterogeneity and a limited regulatory framework characterise the current status of phytotherapeutic agents. The European Medicines Agency (EMA) has developed the Committee on Herbal Medicinal Products (HMPC). European Union (EU) herbal monographs contain the HMPC's scientific opinion on safety and efficacy data about herbal substances and their preparations intended for medicinal use. The HMPC evaluates all available information, including non-clinical and clinical data, whilst also documenting long-standing use and experience in the EU. European Union monographs are divided into two sections: a) Well established use (marketing authorisation): when an active ingredient of a medicine has been used for more than ten years and its efficacy and safety have been well established (including a review of the relevant literature); and b) Traditional use (simplified registration): for herbal medicinal products which do not fulfil the requirements for a marketing authorisation, but there is sufficient safety data and plausible efficacy on the basis of long-standing use and experience. Table 1 lists the available EU monographs for herbal medicinal products.

**Table 2: European Union monographs for herbal medicinal products**

Herbal substance	HMPC evaluation	Therapeutic Indication by HMPC	Date of monograph
<i>Serenoa repens</i> , fructus (saw palmetto, fruit) Extraction solvent: hexane [1]	Well established use	Symptomatic treatment of BPH	14/01/2016
<i>Serenoa repens</i> , fructus (saw palmetto, fruit) Extraction solvent: ethanol [1]	Traditional use	LUTS related to BPH*	14/01/2016
<i>Cucurbita pepo</i> L, semen (pumpkin seed) Preparation as defined in the monograph [249]	Traditional use	LUTS related to BPH or related to an OAB*	25/03/2013
<i>Prunus africana</i> (Hook f.) Kalkm., cortex (pygeum africanum bark) Preparation as defined in the monograph [250]	Traditional use	LUTS related to BPH*	01/09/2017
<i>Urtica dioica</i> L., <i>Urtica urens</i> L., their hybrids or their mixtures, radix Preparation as defined in the monograph [251]	Traditional use	LUTS related to BPH*	05/11/2012
<i>Epilobium angustifolium</i> L. and/or <i>Epilobium parviflorum</i> Schreb., herba (Willow herb) Preparation as defined in the monograph [252]	Traditional use	LUTS related to BPH*	13/01/2016

\*After serious conditions have been excluded by a medical doctor.

**Panel interpretation:** Only hexane extracted *Serenoa repens* (HESr) has been recommended for well-established use by the HMPC. Based on this a detailed scoping search covering the timeframe between the search cut-off date of the EU monograph and April 2020 was conducted for HESr.

A large meta-analysis of 30 RCTs with 5,222 men and follow-up ranging from 4 to 60 weeks, demonstrated no benefit of treatment with *S. repens* in comparison to placebo for the relief of LUTS [253]. It was concluded that *S. repens* was not superior to placebo, finasteride, or tamsulosin with regard to IPSS improvement,  $Q_{max}$ , or prostate size reduction; however, the similar improvement in IPSS or  $Q_{max}$  compared with finasteride or tamsulosin could be interpreted as treatment equivalence. Importantly, in the meta-analysis all different brands of *S. repens* were included regardless or not of the presence of HESr as the main ingredient in the extract.

Another SR focused on data from twelve RCTs on the efficacy and safety of HESr [254]. It was concluded that HESr was superior to placebo in terms of improvement of nocturia and  $Q_{max}$  in patients with enlarged prostates. Improvement in LUTS was similar to tamsulosin and short-term use of finasteride. An updated SR analysed fifteen RCTs and also included twelve observational studies. It confirmed the results of the previous SR on the efficacy of HESr [255]. Compared with placebo, HESr was associated with 0.64 (95% CI 0.98 to 0.31) fewer voids/night and an additional mean increase in  $Q_{max}$  of 2.75 mL/s (95% CI 0.57 to 4.93), both were significant. When compared with  $\alpha$ -blockers, HESr showed similar improvements in IPSS (WMD 0.57, 95% CI 0.27 to 1.42) and a comparable increase in  $Q_{max}$  when compared to tamsulosin (WMD 0.02, 95% CI 0.71 to 0.66). Efficacy assessed using IPSS was similar after six months of treatment between HESr and 5-ARIs. Analysis of all available published data for HESr showed a mean significant improvement in IPSS from baseline of 5.73 points (95% CI 6.91 to 4.54) [255].

A network meta-analysis tried to compare the clinical efficacy of *S. repens* (HESr and non-HESr) against placebo and  $\alpha$ 1-blockers in men with LUTS. Interestingly, only two RCTs on HESr were included in the analysis. It was found that *S. repens* achieved no clinically meaningful improvement against placebo or  $\alpha$ 1-blockers in short-term follow-up. However, *S. repens* showed a clinical benefit after a prolonged period of treatment, and HESr demonstrated a greater improvement than non-HESr in terms of IPSS [256].

With respect to safety and tolerability, data from the SRs showed that HESr had a favourable safety profile with gastrointestinal disorders being the most frequent adverse effects (mean incidence 3.8%) while HESr had very limited impact on sexual function.

A cross-sectional study compared the combination of HESr with silodosin to silodosin monotherapy in patients treated for at least twelve months (mean duration 13.5 months) [257]. It was reported that 69.9% of the combination therapy patients achieved the predefined clinically meaningful improvement (improvement more than three points in baseline IPSS) compared to 30.1% of patients treated only with silodosin. In addition, a greater than 25% improvement in IPSS was found in 68.8% and 31.2% of the patients in the combination and the monotherapy groups, respectively. These data suggest that combination of a  $\alpha$ 1-blocker with HESr may result in greater clinically meaningful improvements in LUTS compared to  $\alpha$ 1-blocker monotherapy [257].

*Practical considerations:* Available RCTs do not use the same endpoints (e.g. IPSS). More studies on the use of HESr in combination with other pharmacotherapeutic agents for male LUTS are pending. There is a need to define the subpopulation of patients who will benefit most from therapy with HESr.

Summary of evidence	LE
HESr improves $Q_{\max}$ and results in fewer voids/night [0.64 (95% CI 0.98 to 0.31)] compared to placebo.	2
HESr has a very limited negative impact on sexual function.	2

Recommendations	Strength rating
Offer hexane extracted <i>Serenoa repens</i> to men with LUTS who want to avoid any potential adverse events especially related to sexual function.	Weak
Inform the patient that the magnitude of efficacy may be modest.	Strong

### 5.2.7 Combination therapies

#### 5.2.7.1 $\alpha$ 1-blockers + 5 $\alpha$ -reductase inhibitors

*Mechanism of action:* Combination therapy consists of an  $\alpha$ 1-blocker (Section 5.2.1) together with a 5-ARI (Section 5.2.2). The  $\alpha$ 1-blocker exhibits clinical effects within hours or days, whereas the 5-ARI needs several months to develop full clinical efficacy. Finasteride has been tested in clinical trials with alfuzosin, terazosin, doxazosin or terazosin, and dutasteride with tamsulosin.

*Efficacy:* Several studies have investigated the efficacy of combination therapy against an  $\alpha$ 1-blocker, 5-ARI or placebo alone. Initial studies with follow-up periods of six to twelve months demonstrated that the  $\alpha$ 1-blocker was superior to finasteride in symptom reduction, whereas combination therapy of both agents was not superior to  $\alpha$ 1-blocker monotherapy [162, 163, 258]. In studies with a placebo arm, the  $\alpha$ 1-blocker was consistently more effective than placebo, but finasteride was not. Data at one year in the MTOPS study showed similar results [65].

Long-term data (four years) from the MTOPS and CombAT studies showed that combination treatment is superior to monotherapy for symptoms and  $Q_{\max}$ , and superior to  $\alpha$ 1-blocker alone in reducing the risk of AUR or need for surgery [65, 147, 148].

The CombAT study demonstrated that combination treatment is superior to either monotherapy regarding symptoms and flow rate starting from month nine, and superior to  $\alpha$ 1-blocker for AUR and the need for surgery after eight months [148]. Thus, the differences in MTOPS may reflect different inclusion and exclusion criteria and baseline patient characteristics.

Discontinuation of the  $\alpha$ 1-blocker after six to nine months of combination therapy was investigated by an RCT and an open-label multicentre trial [259, 260]. The first trial evaluated the combination of tamsulosin with dutasteride and the impact of tamsulosin discontinuation after six months [259], with almost three quarters of patients reporting no worsening of symptoms. However, patients with severe symptoms (IPSS > 20) at baseline may benefit from longer combination therapy.

A more recent trial evaluated the symptomatic outcome of finasteride monotherapy at three and nine months after discontinuation of nine-month combination therapy [260]. Lower urinary tract symptom improvement after combination therapy was sustained at three months (IPSS difference 1.24) and nine months (IPSS difference 0.4). The limitations of the studies include the short duration of the studies and the short follow-up period after discontinuation.

In both the MTOPS and CombAT studies, combination therapy was superior to monotherapy in preventing clinical progression as defined by an IPSS increase of at least four points, AUR, UTI, incontinence, or an increase in creatinine > 50%. The MTOPS study found that the risk of long-term clinical progression (primarily due to increasing IPSS) was reduced by 66% with combined therapy vs. placebo and to a greater extent than with either finasteride or doxazosin monotherapy (34% and 39%, respectively) [65]. In addition, finasteride (alone or in combination), but not doxazosin alone, significantly reduced both the risks of AUR and the need

for BPO-related surgery over the four-year study. In the CombAT study, combination therapy reduced the relative risks of AUR by 68%, BPO-related surgery by 71%, and symptom deterioration by 41% compared with tamsulosin, after four years [261]. To prevent one case of urinary retention and/or surgical treatment thirteen patients need to be treated for four years with dutasteride and tamsulosin combination therapy compared to tamsulosin monotherapy while the absolute risk reduction (risk difference) was 7.7%.

The CONDUCT study compared efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin to a WW approach with the potential initiation of tamsulosin (step-up approach) in a two year RCT with a total of 742 patients. In both arms detailed lifestyle advice was given. This fixed-dose combination resulted in a rapid and sustained improvement in men with moderate LUTS at risk of disease progression, the difference in IPSS at 24 months was 5.4 in the active arm and 3.6 in the placebo arm ( $p < 0.001$ ) [262]. Furthermore, tamsulosin plus dutasteride significantly reduced the relative risk of clinical progression (mainly characterised as a worsening in symptoms) by 43.1% when compared with WW, with an absolute risk reduction of 11.3% (number needed to treat [NNT] = 9).

The influence of baseline variables on changes in IPSS after combination therapy with dutasteride plus tamsulosin or either monotherapy was tested based on the four year results of the CombAT study. Combination therapy provided consistent improvement of LUTS over tamsulosin across all analysed baseline variables at 48 months [263].

More recently, a combination of the 5-ARI finasteride and tadalafil 5 mg was tested in a large scale RCT against finasteride monotherapy. This study supports the concept of this novel combination therapy and is described in more detail in the chapter on PDE5Is [241].

**Tolerability and safety:** Adverse events for both drug classes have been reported with combination treatment [65, 147, 148]. The adverse events observed during combination treatment were typical of  $\alpha$ 1-blockers and 5-ARIs. The frequency of adverse events was significantly higher for combination therapy. The MTOPS study demonstrated that the incidence of treatment related adverse events is higher during the first year of combined treatment between doxazosin and finasteride [264]. A meta-analysis measuring the impact of medical treatments for LUTS/BPH on ejaculatory function, reported that combination therapy with  $\alpha$ 1-blockers and 5-ARIs resulted in a three-fold increased risk of EjD as compared with each of the monotherapies [157].

**Practical considerations:** Compared with  $\alpha$ 1-blockers or 5-ARI monotherapy, combination therapy results in a greater improvement in LUTS and increase in  $Q_{\max}$  and is superior in prevention of disease progression. However, combination therapy is also associated with a higher rate of adverse events. Combination therapy should therefore be prescribed primarily in men who have moderate-to-severe LUTS and are at risk of disease progression (higher prostate volume, higher PSA concentration, advanced age, higher PVR, lower  $Q_{\max}$ , etc.). Combination therapy should only be used when long-term treatment (more than twelve months) is intended and patients should be informed about this. Discontinuation of the  $\alpha$ 1-blocker after six months might be considered in men with moderate LUTS.

Summary of evidence	LE
Long-term data (four years) from the MTOPS and CombAT studies showed that combination treatment is superior to monotherapy for symptoms and $Q_{\max}$ , and superior to $\alpha$ 1-blocker alone in reducing the risk of AUR or need for surgery.	1b
The MTOPS study found that the risk of long-term clinical progression (primarily due to increasing IPSS) was reduced by 66% with combined therapy vs. placebo and to a greater extent than with either finasteride or doxazosin monotherapy.	1b
The CombAT study found that combination therapy reduced the relative risks of AUR by 68%, BPH-related surgery by 71%, and symptom deterioration by 41% compared with tamsulosin, after four years.	1b
Adverse events of both drug classes are seen with combined treatment using $\alpha$ 1-blockers and 5-ARIs.	1b

Recommendation	Strength rating
Offer combination treatment with an $\alpha$ 1-blocker and a 5 $\alpha$ -reductase inhibitor to men with moderate-to-severe LUTS and an increased risk of disease progression (e.g. prostate volume > 40 mL).	Strong

#### 5.2.7.2 $\alpha$ 1-blockers + muscarinic receptor antagonists

**Mechanism of action:** Combination treatment consists of an  $\alpha$ 1-blocker together with an antimuscarinic aiming to antagonise both  $\alpha$ 1-adrenoceptors and muscarinic receptors. The possible combinations have not all been tested in clinical trials yet.

**Efficacy:** Several RCTs and prospective studies investigated combination therapy, lasting four to twelve weeks, either as an initial treatment in men with OAB and presumed BPO or as a sequential treatment for storage symptoms persisting while on an  $\alpha$ 1-blocker [197, 261, 265-271]. One trial used the  $\alpha$ 1-blocker naftopidil (not registered in most European countries) with and without antimuscarinics [272]. A high proportion of men with voiding and storage LUTS need to add anticholinergics after  $\alpha$ 1-blocker monotherapy, particularly those with longer duration of symptoms at presentation, and men with storage symptoms and a small prostate volume [273].

Combination treatment is more efficacious in reducing urgency, UUI, voiding frequency, nocturia, or IPSS compared with  $\alpha$ 1-blockers or placebo alone, and improves QoL [197, 274]. Symptom improvement is higher regardless of PSA concentration with combination therapy, whereas tolterodine alone improved symptoms mainly in men with a serum PSA of < 1.3 ng/mL [200].

Persistent LUTS during  $\alpha$ 1-blocker treatment can be reduced by the additional use of an antimuscarinic, [261, 265, 271, 275, 276]. Two SRs of the efficacy and safety of antimuscarinics in men suggested that combination treatment provides significant benefit [277, 278]. In a meta-analysis of sixteen studies with 3,548 patients with BPH/OAB, initial combination treatment of an  $\alpha$ 1-blocker with anticholinergic medication improved storage symptoms and QoL compared to  $\alpha$ 1-blocker monotherapy without causing significant deterioration of voiding function [279]. There was no difference in total IPSS and  $Q_{max}$  between the two groups.

Effectiveness of therapy is evident primarily in those men with moderate-to-severe storage LUTS [280]. Long term use of combination therapy has been reported in patients receiving treatment for up to one year, showing symptomatic response is maintained, with a low incidence of AUR [281]. In men with moderate-to-severe storage symptoms, voiding symptoms and PVR < 150 mL, the reduction in symptoms using combination therapy is associated with patient-relevant improvements in health related quality of life compared with placebo and  $\alpha$ 1-blocker monotherapy [282].

**Tolerability and safety:** Adverse events of both drug classes are seen with combined treatment using  $\alpha$ 1-blockers and antimuscarinics. The most common side-effect is dry mouth. Some side-effects (e.g. dry mouth or ejaculation failure) may show increased incidence which cannot simply be explained by summing the incidence with the drugs used separately. Increased PVR may be seen, but is usually not clinically significant, and risk of AUR is low up to one year of treatment [277, 283]. Antimuscarinics do not cause evident deterioration in maximum flow rate used in conjunction with an  $\alpha$ 1-blocker in men with OAB symptoms [274, 284].

A recent RCT investigated safety in terms of maximum detrusor pressure and  $Q_{max}$  for solifenacin (6 mg or 9 mg) with tamsulosin in men with LUTS and BOO compared with placebo [285]. The combination therapy was not inferior to placebo for the primary urodynamic variables;  $Q_{max}$  was increased vs. placebo [285].

**Practical considerations:** Class effects are likely to underlie efficacy and QoL using an  $\alpha$ 1-blocker and antimuscarinic. Trials used mainly storage symptom endpoints, were of short duration, and included only men with low PVR volumes at baseline. Therefore, measuring PVR is recommended during combination treatment.

Summary of evidence	LE
Combination treatment with $\alpha$ 1-blockers and antimuscarinics is effective for improving LUTS-related QoL impairment.	2
Combination treatment with $\alpha$ 1-blockers and antimuscarinics is more effective for reducing urgency, UUI, voiding frequency, nocturia, or IPSS compared with $\alpha$ 1-blockers or placebo alone.	2
Adverse events of both drug classes are seen with combined treatment using $\alpha$ 1-blockers and antimuscarinics.	1
There is a low risk of AUR using $\alpha$ 1-blockers and antimuscarinics in men known to have a PVR urine volume of < 150 mL.	2

Recommendations	Strength rating
Use combination treatment of a $\alpha$ 1-blocker with a muscarinic receptor antagonist in patients with moderate-to-severe LUTS if relief of storage symptoms has been insufficient with monotherapy with either drug.	Strong
Do not prescribe combination treatment in men with a post-void residual volume > 150 mL.	Weak

**Note:** All patients should be counselled about pharmacological treatment related adverse events in order to select the most appropriate treatment for each individual patient.



### 5.3 Surgical treatment

Surgical treatment is one of the cornerstones of LUTS/BPO management. Based on its ubiquitous availability, as well as its efficacy, M-TURP has long been considered as the reference technique for the surgical management of LUTS/BPO. However, in recent years various techniques have been developed with the aim of providing a safe and effective alternative to M-TURP. Previously, the surgical section of the Guidelines was based on technology rather than surgical approach; additionally, most of the studies are restricted by prostate size, which is also reflected in the present Guidelines. Notably, **only a small fraction of RCTs are performed in patients with a prostate volume > 80 mL; therefore, high-level evidence for larger prostates is limited.** As the clinical reality is primarily reflected by surgical approach and not necessarily by a specific technology, the chapter on surgical management has been restructured. It is now divided into the following five sections:

1. Resection;
2. Enucleation;
3. Vaporisation;
4. Alternative ablative techniques; and
5. Non-ablative techniques.

Based on Panel consensus, timeframes defining short-, mid- and long-term follow-up of patients submitted to surgical treatments are 12, 36 and over 36 months, respectively. The durability of a technique is reflected by the re-operation rate during follow-up, the failure to wean patients off medication as well as the initiation of novel LUTS medication after surgery. However, for the majority of techniques only the re-operation rate is reported and clinicians should inform patients that long-term surgical RCTs are often lacking. Some patients value sexual function and perceived higher safety than maximum efficacy; therefore, it is not surprising that some patients consciously choose an alternative ablative or non-ablative technique despite the knowledge that it might not be their definitive treatment. In contrast, many urologists are critical about these 'lesser' procedures due to their inferior relief of BOO.

Recommendations on **new devices or interventions will only be included in the Guidelines once supported by a minimum level of evidence.** To clarify this the Panel have published their position on certainty of evidence (CoE) [286]. In summary, a device or technology is only included once supported by RCTs looking at both efficacy and safety, with adequate follow-up, and secondary studies to confirm the reproducibility and generalisability of the first pivotal studies [286]. Otherwise, there is a danger that a single pivotal study can be overexploited by device manufacturers. Studies that are needed include (1) proof of concept, (2) RCTs on efficacy and safety, as well as (3) cohort studies with a broad range of inclusion and exclusion criteria to confirm both reproducibility and generalisability of the benefits and harms [286]. The panel assesses the quality of all RCTs and if they do not meet the standard required the intervention will continue to have no recommendation i.e. a RCT does not guarantee inclusion in the Guidelines.

In addition, the Guidelines continues to include techniques under investigation. These are devices or technologies that have shown promising results in initial studies; however, they do not meet the aforementioned criteria yet to provide a CoE which allows the Panel to regard these devices or technologies as recommended alternatives. To account for evolving evidence, recommendations for some techniques under investigation have been made; however, these techniques remain under investigation until further studies provide the recommended CoE.

#### 5.3.1 Resection of the prostate

##### 5.3.1.1 Monopolar and bipolar transurethral resection of the prostate

**Mechanism of action:** Transurethral resection of the prostate (TURP) is performed using two techniques: monopolar TURP (M-TURP) and bipolar TURP (B-TURP). Monopolar transurethral resection of the prostate removes tissue from the transition zone of the gland. Bipolar TURP addresses a major limitation of M-TURP by allowing performance in normal saline. Prostatic tissue removal is identical to M-TURP. Contrary to M-TURP, in B-TURP systems, the energy does not travel through the body to reach a skin pad. Bipolar circuitry is completed locally; energy is confined between an active (resection loop) and a passive pole situated on the resectoscope tip ("true" bipolar systems) or the sheath ("quasi" bipolar systems). The various bipolar devices available differ in the way in which current flow is delivered [287, 288].

**Efficacy:** In a meta-analysis of 20 RCTs with a maximum follow-up of five years, M-TURP resulted in a substantial mean  $Q_{max}$  improvement (+162%), a significant reduction in IPSS (-70%), QoL score (-69%), and PVR (-77%) [289]. Monopolar-TURP delivers durable outcomes as shown by studies with a follow-up of 8-22 years. There are no similar data on durability for any other surgical treatment for BPO [290]. One study with a mean follow-up of thirteen years reported a significant and sustained decrease in most symptoms and improvement in urodynamic parameters. Failures were associated with DUA rather than re-development

of BPO [102]. A second prostatic operation, usually re-TURP, has been reported at a constant annual rate of approximately 1-2%. A review analysing 29 RCTs found a retreatment rate of 2.6% after a mean follow-up of sixteen months [291]. Data from an Austrian nationwide study of two cohorts totalling 41,059 men submitted to M-TURP showed that the overall retreatment rates (re-TURP, urethrotomy and bladder neck incision) remained unchanged during the last decade (0.9%, 3.7%, 9.5% and 12.7% at three months, one year, five years, and eight years, respectively), and that the respective incidence of re-TURP was 0.8%, 2.4%, 6.1% and 8.3%, respectively [292, 293].

Bipolar TURP is the most widely and thoroughly investigated alternative to M-TURP. Results from 56 RCTs have been reported [294], of which around half have been pooled in RCT-based meta-analyses [289, 295-299]. Early pooled results concluded that no clinically relevant differences exist in short-term efficacy (IPSS, QoL score and  $Q_{max}$ ) [296]. Subsequent meta-analyses supported these conclusions though trial quality was generally poor [289, 295, 297-299]. Data from RCTs with mid- to long-term follow-up (up to 60 months) showed no differences in efficacy parameters [300-308].

A meta-analysis was conducted to evaluate the quasi-bipolar transurethral resection in saline (TURis, Olympus Medical) system vs. M-TURP. Ten unique RCTs (1,870 patients) were included and it was concluded that TURis was of equivalent efficacy to M-TURP [309].

*Tolerability and safety:* Peri-operative mortality and morbidity of M-TURP have decreased over time, but morbidity remains considerable (0.1% and 11.1%, respectively) [310]. Data from an Austrian nationwide study of two cohorts totalling 41,059 men submitted to M-TURP showed a 20% reduction in mortality rate over time, to 0.1% at 30 days and 0.5% at 90 days [292, 293].

The risk of TUR-syndrome decreased to < 1.1% [291, 311]. Data from 10,654 M-TURPs reported bleeding requiring transfusion in 2.9% [310]. Short- to mid-term complications reported in an analysis of RCTs using M-TURP as a comparator were: bleeding requiring transfusion 2% (0-9%), TUR-syndrome 0.8% (0-5%), AUR 4.5% (0-13.3%), clot retention 4.9% (0-39%), and UTI 4.1% (0-22%) [289]. Long-term complications of M-TURP comprise urinary incontinence, urinary retention and UTIs, bladder neck contracture (BNC), urethral stricture, retrograde ejaculation and ED [291].

Early pooled results concluded that no differences exist in short-term urethral stricture/BNC rates, but B-TURP is preferable to M-TURP due to a more favourable peri-operative safety profile (elimination of TUR-syndrome; lower clot retention/blood transfusion rates; shorter irrigation, catheterisation, and possibly hospitalisation times) [296]. Subsequent meta-analyses supported these conclusions [289, 295, 297-299]; however, trial quality was relatively poor and limited follow-up might cause under-reporting of late complications, such as urethral stricture/BNC [296]. An RCT based meta-analysis has shown that TURis reduces the risk of TUR-syndrome and the need for blood transfusion compared to M-TURP [299]. It was concluded that TURis is associated with improved peri-operative safety, eliminating the risk of TUR syndrome, reducing the risk of blood transfusion/clot retention and hospital stay. No significant difference was detected in urethral stricture rates.

Data from the vast majority of individual RCTs with mid- to long-term follow-up (up to 60 months), showed no differences between M-TURP and B-TURP in urethral stricture/BNC rates [300-308], in accordance with all published meta-analyses. However, two individual RCTs have shown opposing results [307, 312]. A significantly higher stricture (urethral stricture + BNC) rate was detected in the B-TURP arm performed with a “quasi” bipolar system (TURis, Olympus Medical) in patients with a prostate volume > 70 mL at 36 months follow-up [307]. In addition, a significantly higher BNC, but not urethral stricture, rate was detected in the B-TURP arm performed with a “true” bipolar system (Gyrus PK SuperPulse, Olympus Medical) in 137 patients followed up to twelve months [312].

Randomised controlled trials using the erectile function domain of the IIEF (IIEF-ED) and the ejaculatory domain of the male sexual-health questionnaire (Ej-MSHQ) showed that M-TURP and B-TURP have a similar effect on erectile and ejaculatory function [313, 314]. Comparative evaluations of the effects on overall sexual function, quantified with IIEF-15, showed no differences between B-TURP and M-TURP at twelve months follow-up (erection, orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction) [314, 315].

*Practical considerations:* Monopolar-TURP is an effective treatment for moderate-to-severe LUTS secondary to BPO. The choice should be based primarily on prostate volume (30-80 mL suitable for M-TURP). No studies on the optimal cut-off value exist, but the complication rates increase with prostate size [310]. The upper limit for M-TURP is suggested as 80 mL (based on Panel expert opinion, under the assumption that this limit depends on the surgeon's experience, choice of resectoscope size and resection speed), as surgical duration increases, there is a significant increase in the rate of complications and the procedure is safest when performed in under 90 minutes [316].



Bipolar TURP in patients with moderate-to-severe LUTS secondary to BPO, has similar efficacy to M-TURP, but lower peri-operative morbidity. The duration of improvements with B-TURP were documented in a number of RCTs with mid-term follow-up. Long-term results (up to five years) for B-TURP showed that safety and efficacy are comparable to M-TURP [300-308]. The choice of B-TURP should be based on equipment availability, surgeon's experience, and patient's preference.

Summary of evidence	LE
Bipolar- or monopolar-TURP is the current standard surgical procedure for men with prostate sizes of 30-80 mL and bothersome moderate-to-severe LUTS secondary of BPO.	1a
Bipolar-TURP achieves short-, mid- and long-term results comparable with M-TURP, but B-TURP has a more favourable peri-operative safety profile.	1a

Recommendation	Strength rating
Offer bipolar- or monopolar-transurethral resection of the prostate to surgically treat moderate-to-severe LUTS in men with prostate size of 30-80 mL.	Strong

### 5.3.1.2 Holmium laser resection of the prostate

With the advent of holmium laser enucleation of the prostate (section 5.3.2.3) and the fact that no relevant publications on holmium laser resection of the prostate (HoLRP) have been published since 2004, HoLRP of the prostate does not play a role in contemporary treatment algorithms.

### 5.3.1.3 Thulium:yttrium-aluminium-garnet laser (Tm:YAG) vaporessection of the prostate

**Mechanism of action:** In the thulium lasers, a wavelength between 1,940 nm (thulium fiber laser) and 2,013 nm (Tm:YAG) is emitted in continuous wave mode. The laser is primarily used in front-fire applications [317]. Different applications such as vaporessection (ThuVARP) have been published [318].

**Efficacy:** Several meta-analyses with pooled data from both RCTs (generally low quality), and non-RCTs have evaluated ThuVARP vs. M-TURP [319-321], and B-TURP [322-324]. The largest meta-analyses included nine RCTs and seven non-RCTs and reported no clinically relevant differences in efficacy (IPSS, QoL score and  $Q_{max}$ ) between ThuVARP and M-TURP or B-TURP at twelve months [323]. Data from one RCT with long-term follow-up showed no difference in efficacy and re-operation rates between ThuVARP and M-TURP (2.1% vs. 4.1%, respectively) [325]. A prospective multicentre study on ThuVARP, including 2,216 patients, showed durable post-operative improvement in IPSS, QoL,  $Q_{max}$ , and PVR for the entire eight years of follow-up [326].

**Tolerability and safety:** In a number of meta-analyses longer operation times, shorter catheterisation/hospitalisation times and less blood loss without significant differences in transfusion rates or in any other short-term complication rates have been reported for ThuVARP compared to TURP [319-324]. A significantly higher transfusion rate was reported after M-TURP in two meta-analyses [321, 323]. However, overall RCT quality was relatively low with limited follow-up potentially accounting for under-reporting of late complications, such as urethral stricture/BNC [323]. Data from three RCTs with mid- to long-term follow-up (18 to 48 months) showed no differences in late complication rates between ThuVARP and TURP (BNC: 0.0%-2.1% vs. 0.0%-4.1%; stricture: 0.0%-2.2% vs. 0.0%-2.2%, respectively) [325, 327, 328].

Haemoglobin drop was significantly higher in the bridging group in a retrospectively analysed case series of 103 patients who underwent ThuVARP and received either low molecular weight heparin bridging or continued antiplatelet/anticoagulant therapy [329].

**Practical considerations:** As a limited number of RCTs with mid- to long-term follow-up support the efficacy of ThuVARP, there is a need for ongoing investigation of the technique.

Summary of evidence	LE
Laser vaporessection of the prostate using Tm:YAG laser (ThuVARP) has longer operation times and shorter catheterisation/hospitalisation times compared to TURP with no clinically relevant differences in short-term efficacy and safety. Mid- to long-term results on efficacy and safety compared to TURP are very limited.	1a

Recommendation	Strength rating
Offer laser resection of the prostate using Tm:YAG laser (ThuVARP) as an alternative to TURP.	Weak

#### 5.3.1.4 Transurethral incision of the prostate

**Mechanism of action:** Transurethral incision of the prostate (TUIP) involves incising the bladder outlet without tissue removal. Transurethral incision of the prostate is conventionally performed with Collins knife using monopolar electrocautery; however, alternative energy sources such as holmium laser may be used [330]. This technique may replace M-TURP in selected cases, especially in prostate sizes < 30 mL without a middle lobe.

**Efficacy:** An RCT comparing conventional TUIP vs. TUIP using holmium laser in prostates  $\leq 30$  mL with a follow-up of twelve months, found both procedures to be equally effective in relieving BOO with similarly low re-operation rates [330]. A meta-analysis of ten RCTs found similar LUTS improvements and lower but significant improvements in  $Q_{\max}$  for TUIP [331]. In this meta-analysis, an upper limit of prostate size was reported as an entry criterion for eight studies with five < 30 mL and three < 60 mL. A meta-analysis of six trials showed that re-operation was more common after TUIP (18.4%) than after M-TURP (7.2%) [331].

**Tolerability and safety:** An RCT comparing conventional TUIP vs. TUIP using holmium laser reported both procedures to be safe with low complication rates; however, the operation time and retrograde ejaculation rate was significantly lower in the conventional TUIP arm [330]. No cases of TUR-syndrome have been recorded after TUIP. The risk of bleeding after TUIP is small [331].

**Practical considerations:** Transurethral incision of the prostate is an effective treatment for moderate-to-severe LUTS secondary to BPO. The choice between M-TURP and TUIP should be based primarily on prostate volume (30 mL TUIP) [331].

Summary of evidence	LE
Transurethral incision of the prostate shows similar efficacy and safety to M-TURP for treating moderate-to-severe LUTS secondary to BPO in men with prostates < 30 mL.	1a
No case of TUR-syndrome has been recorded, the risk of bleeding requiring transfusion is negligible and retrograde ejaculation rate is significantly lower after TUIP, but the re-operation rate is higher compared to M-TURP.	1a
The choice between TUIP and TURP should be based primarily on prostate volume (< 30 mL and 30-80 mL suitable for TUIP and TURP, respectively).	4

Recommendation	Strength rating
Offer transurethral incision of the prostate to surgically treat moderate-to-severe LUTS in men with prostate size < 30 mL, without a middle lobe.	Strong

#### 5.3.2 Enucleation of the prostate

##### 5.3.2.1 Open prostatectomy

**Mechanism of action:** Open prostatectomy is the oldest surgical treatment for moderate-to-severe LUTS secondary to BPO. Obstructive adenomas are enucleated using the index finger, approaching from within the bladder (Freyer procedure) or through the anterior prostatic capsule (Millin procedure). It is used for substantially enlarged glands (> 80-100 mL).

**Efficacy:** Open prostatectomy reduces LUTS by 63-86% (12.5-23.3 IPSS points), improves QoL score by 60-87%, increases mean  $Q_{\max}$  by up to 375% (+16.5-20.2 mL/s), and reduces PVR by 86-98%. Efficacy is maintained for up to six years [332-337]. Data from an Austrian nationwide study of 1,286 men submitted to OP showed that the endourological re-intervention rates after primary OP were 0.9%, 3.0%, 6.0%, and 8.8%, at three months, one year, five years, and eight years, respectively. The respective incidence of re-TURP was 0.5%, 1.8%, 3.7% and 4.3%, respectively [9].

Two meta-analyses [338, 339] evaluated the overall efficacy of OP performed via a transvesical approach vs. two transurethral enucleation techniques for treating patients with large glands, namely bipolar transurethral enucleation of the prostate (B-TUEP) and holmium laser enucleation of the prostate (HoLEP). The larger study included nine RCTs involving 758 patients [339]. Five RCTs compared OP with B-TUEP [337, 340-343] and four RCTs compared OP with HoLEP [332, 333, 344, 345]. At three, six, twelve and 24-months follow-up there were no significant differences in  $Q_{\max}$  [339]. Post-void residual, PSA, IPSS and QoL score showed no significant differences at one, three, six and twelve months follow-up [339]. Randomised controlled trials indicate that OP is as effective as HoLEP for improving micturition in large prostates [332, 333], with similar improvement regarding  $Q_{\max}$ , IPSS score and re-operation rates after five years [332].

**Tolerability and safety:** Open prostatectomy mortality has decreased significantly during the past two decades (< 0.25%) [336]. Data from an Austrian nationwide study totalling 1,286 men submitted to OP showed mortality rates of 0.2% at 30 days and 0.4% at 90 days [293]. The estimated transfusion rate is about 7-14% [332, 335, 336, 338]. Long-term complications include transient urinary incontinence (up to 10%), BNC and urethral stricture (about 6%) [332-334, 338, 346].

Two meta-analyses evaluated the overall safety of OP performed via a transvesical approach vs. B-TUEP and HoLEP [338, 339]. Operation time did not differ significantly between OP and B-TUEP, but was significantly shorter for OP compared to HoLEP. Catheterisation and hospitalisation time were significantly longer for OP, which was also associated with more blood transfusions. There were no significant differences regarding other complications. There was no significant difference in IIEF-5 at three, six, twelve and 24-months follow-up.

**Practical considerations:** Open prostatectomy is the most invasive surgical method, but it is an effective and durable procedure for the treatment of LUTS/BPO. In the absence of an endourological armamentarium including a holmium laser or a bipolar system and with appropriate patient consent, OP is a reasonable surgical treatment of choice for men with prostates > 80 mL.

Summary of evidence	LE
Open prostatectomy is an effective and durable procedure for the treatment of LUTS/BPO, but it is the most invasive surgical method.	1b
Open prostatectomy shows similar short- and mid-term efficacy to B-TUEP and HoLEP for treating moderate-to-severe LUTS secondary to BPO in patients with large prostates.	1a
Open prostatectomy has a less favourable peri-operative safety profile compared to B-TUEP and HoLEP.	1a
The long-term functional results of OP are comparable to HoLEP.	1b

Recommendation	Strength rating
Offer open prostatectomy in the absence of bipolar transurethral enucleation of the prostate and holmium laser enucleation of the prostate to treat moderate-to-severe LUTS in men with prostate size > 80 mL.	Strong

### 5.3.2.2 Bipolar transurethral enucleation of the prostate (B-TUEP)

**Mechanism of action:** Following the principles of bipolar technology (section 5.3.1.1), the obstructive adenoma is enucleated endoscopically by the transurethral approach. Bipolar transurethral enucleation evolved from plasmakinetic (PK) B-TURP and was introduced by Gyrus ACMI. The technique, also referred to as PK enucleation of the prostate (PKEP), utilises a bipolar high-frequency generator and a variety of detaching instruments, for this true bipolar system, including a point source in the form of a axipolar cystoscope electrode suitable for enucleation [347] or a resectoscope tip/resection loop [348, 349]. More recently, a novel form of B-TUEP has been described, bipolar plasma enucleation of the prostate (BPEP), stemming from B-TURP (TURis, Olympus Medical), that utilises a bipolar high frequency generator and a variety of detaching instruments including a mushroom- or button-like vapo-electrode [343, 350] and a Plasmasect enucleation electrode [351] for this quasi-bipolar system. Bipolar transurethral enucleation of the prostate is followed by either morcellation [343, 347] or resection [348-350, 352-354] of the enucleated adenoma.

**Efficacy:** One RCT evaluating PKEP vs. M-TURP in 204 patients with mean prostate volume < 80 mL reported a significant improvement in IPSS, QoL, and  $Q_{max}$  with urodynamically proven de-obstruction favouring PKEP at 36 months follow-up [349]. The RCT concluded that the mid-term clinical efficacy of PKEP was comparable to M-TURP [349]. A meta-analysis evaluating data from five RCTs including 666 patients submitted to B-TUEP (PKEP or BPEP) vs. B-TURP, reported similar efficacy at twelve months in terms of IPSS, QoL and  $Q_{max}$  [355]. Two RCTs evaluated the mid-term efficacy of PKEP vs. B-TURP at 36 months [348, 353] and one RCT evaluated long-term efficacy at 60 months [354]. Efficacy was significantly better for PKEP in patients with large prostates at 36, 48 and 60 months [348, 354]. Comparative data on efficacy for B-TUEP vs. OP and the various forms of laser enucleation are presented in section 5.3.2.1 to 5.3.2.5, respectively.

**Tolerability and safety:** An RCT evaluating PKEP vs. M-TURP in patients with mean prostate volume < 80 mL and 36 month follow-up reported that PKEP is superior to M-TURP in terms of haemoglobin drop, irrigation, catheterisation and hospitalisation time [349]. No significant differences between the arms were reported in operation time, blood transfusion rates, sexual function or any other reported complications (TUR-syndrome, clot retention, incontinence, retrograde ejaculation, urethral structures/BNC) [349]. A meta-analysis including

five RCTs evaluating B-TUEP vs. B-TURP reported: similar operation, catheterisation and hospitalisation times; lower acute urine retention rates; significantly reduced haemoglobin drop and blood transfusion rates; no difference in erectile function; and no difference in all other reported complication rates including urethral stricture/BNC rates for B-TUEP at 24 months follow-up [355]. No difference in urethral stricture/BNC rates was reported at 60 months follow-up [354]. Comparative data on efficacy for B-TUEP vs. OP and the various forms of laser enucleation are presented in section 5.3.2.1 to 5.3.2.5, respectively.

Summary of evidence	LE
Bipolar transurethral (plasmakinetic) enucleation of the prostate shows favourable mid- to long-term efficacy compared to TURP.	1b
Bipolar transurethral (plasmakinetic) enucleation of the prostate has a favourable peri-operative safety profile and demonstrates similar mid- to long-term safety compared to TURP.	1b

Recommendation	Strength rating
Offer bipolar transurethral (plasmakinetic) enucleation of the prostate to men with moderate-to-severe LUTS as an alternative to transurethral resection of the prostate.	Weak

### 5.3.2.3 Holmium laser enucleation of the prostate

**Mechanism of action:** The holmium:yttrium-aluminium garnet (Ho:YAG) laser (wavelength 2,140 nm) is a pulsed solid-state laser that is absorbed by water and water-containing tissues. Tissue coagulation and necrosis are limited to 3-4 mm, which is enough to obtain adequate haemostasis [356].

**Efficacy:** An initial meta-analysis reported no significant differences in short-term efficacy ( $Q_{max}$ ) and re-intervention rates (4.3% vs. 8.8%) between HoLEP and M-TURP [357]; however, subsequent meta-analyses reported favourable short-term efficacy ( $Q_{max}$  and IPSS) for HoLEP [289, 320, 355, 358]. Two meta-analyses evaluating HoLEP vs. B-TURP showed no significant differences in short-term efficacy (IPSS, QoL score and  $Q_{max}$ ) [355, 359]. One RCT comparing HoLEP with M-TURP in a small number of patients with mean prostate volume < 80 mL and a seven year follow-up found that the functional long term results were comparable [360]. Another RCT comparing HoLEP with B-TURP in patients with prostate volume < 80 mL reported no significant difference in IPSS, QoL score and  $Q_{max}$  at 24 months [361]. Long-term (72 months) improvement in IPSS and  $Q_{max}$  was better for HoLEP, but there were no clinically relevant differences between the arms [362]. Comparative efficacy data for HoLEP vs. OP is presented in section 5.3.2.1. One small RCT evaluating HoLEP vs. PKEP in patients with mean prostate volume < 80 mL reported similar improvements in IPSS and  $Q_{max}$  as well as similar re-operation rates at twelve months follow-up [347].

**Tolerability and safety:** Meta-analyses found that HoLEP has longer operation times, shorter catheterisation and hospitalisation times, reduced blood loss, fewer blood transfusions and no significant differences in urethral strictures (2.6% vs. 4.4%) and stress urinary incontinence (1.5% vs. 1.5%) rates compared to M-TURP [320, 355, 357, 358, 363]. Two meta-analyses evaluated HoLEP vs. B-TURP [355, 359]. Zhang *et al.*, reported longer operation times for HoLEP, but no significant differences in hospitalisation time or complication rates whilst Qian *et al.*, reported no significant differences in operation and catheterisation times or short-term complication rates [355, 359]. A RCT comparing HoLEP with B-TURP in patients with prostate volume < 80 mL reported longer operation time, shorter catheterisation and hospitalisation times and a lower risk for haemorrhage for HoLEP with no significant differences in blood transfusion rates or other complication rates at 24 months [361]. Comparative data on safety of HoLEP vs. OP are presented in section 5.3.2.1. One small RCT evaluating HoLEP vs. PKEP in patients with mean prostate volume < 80 mL reported significantly shorter operation times for HoLEP, but similar catheterisation and hospitalisation times and complication rates at twelve months follow-up [347].

Holmium laser enucleation of the prostate has been safely performed in patients using anticoagulant and/or antiplatelet medications [364, 365]. However, current limitations include: a lack of RCTs; limited data on short- and mid-term complications and bridging therapy; data presentation does not allow for separate interpretation of either of the two substantially different topics of antiplatelet and anticoagulant therapy.

The impact on erectile function and retrograde ejaculation is comparable between HoLEP and TURP [366, 367]. Erectile function did not decrease from baseline in either group; three quarters of sexually active patients had retrograde ejaculation after HoLEP. Data have shown that ejaculation and orgasm perception are the two most impacted domains after HoLEP [368]. Attempts to maintain ejaculatory function with HoLEP have been reported to be successful in up to 46.2% of patients [369].

*Practical considerations:* Holmium laser enucleation of the prostate requires experience and relevant endoscopic skills. The experience of the surgeon is the most important factor affecting the overall occurrence of complications [370, 371]. Mentorship programmes are advised to improve surgical performance from both an institutional and personal learning curve perspective [372-374].

Summary of evidence	LE
Laser enucleation of the prostate using Ho:YAG laser (HoLEP) demonstrates similar mid- to long-term efficacy when compared to TURP.	1b
Laser enucleation of the prostate using Ho:YAG laser (HoLEP) demonstrates similar short-term safety when compared to TURP.	1a
Laser enucleation of the prostate using Ho:YAG laser (HoLEP) demonstrates longer operation times, but a more favourable peri-operative profile when compared to TURP.	1a

Recommendation	Strength rating
Offer laser enucleation of the prostate using Ho:YAG laser (HoLEP) to men with moderate-to-severe LUTS as an alternative to transurethral resection of the prostate or open prostatectomy.	Strong

#### 5.3.2.4 Thulium:yttrium-aluminium-garnet laser (Tm:YAG) enucleation of the prostate

*Mechanism of action:* The Tm:YAG laser has been described in section 5.3.1.3. Enucleation using the Tm:YAG laser includes ThuVEP (vapoenucleation i.e. excising technique) and ThuLEP (blunt enucleation).

*Efficacy:* A meta-analysis evaluating ThuLEP vs. M-TURP and B-TURP reported no clinically relevant differences in  $Q_{max}$ , IPSS and QoL score [355]. An RCT with five years follow-up comparing ThuLEP with B-TURP found no difference between the two procedures for  $Q_{max}$ , IPSS, PVR, and QoL [375]. A meta-analysis [376] evaluating ThuLEP vs. HoLEP showed no clinically relevant differences in IPSS, QoL score and  $Q_{max}$  at twelve months in accordance with one RCT showing similar results at eighteen months [377]. Furthermore, ThuLEP and PKEP were compared in one RCT with twelve months follow-up the outcome of which showed no difference with regard to efficacy [378].

There are mainly prospective case studies on ThuVEP showing a significant improvement in IPSS,  $Q_{max}$ , and PVR after treatment [379-382].

*Tolerability and safety:* A meta-analysis evaluating ThuLEP vs. M-TURP and B-TURP reported a longer operation time and a shorter hospitalisation time for ThuLEP compared to M-TURP and B-TURP, respectively with no difference in complication rates [355]. A meta-analysis [376] evaluating ThuLEP vs. HoLEP showed a significant difference is enucleation time favouring ThuLEP, but no significant differences in operation, catheterisation and hospitalisation times short-term complication rates, in accordance with one RCT showing similar results, including no urethral and bladder neck strictures, at eighteen months [377]. ThuLEP and PKEP were compared in one RCT with twelve months follow-up [378]. No significant difference in complication rates was detected, but haemoglobin level decrease and catheterisation time was significantly lower for ThuLEP.

In comparative studies ThuVEP show high intra-operative safety [383], as well as in case series in patients with large prostates [379] and anticoagulation or bleeding disorders [380, 384]. A study focusing on post-operative complications after ThuVEP reported adverse events in 31% of cases, with 6.6% complications greater than Clavien grade 2 [385]. One case control study on ThuVEP with 48-month follow-up reported long-term durability of voiding improvements and overall re-operation rates of 2.4% [384]. Two studies addressed the impact of ThuVEP on sexual function, demonstrating no effect on erectile function with increased prevalence of retrograde ejaculation post-operatively [386, 387].

*Practical considerations:* ThuLEP seems to offer similar efficacy and safety when compared to TURP, bipolar enucleation and HoLEP; whereas, ThuVEP is not supported by RCTs. Based on the limited number of RCTs and lack of long-term follow-up data there is a need for ongoing investigation of these techniques.

Summary of evidence	LE
Enucleation of the prostate using the Tm:YAG laser demonstrates similar efficacy when compared to M-TURP/bipolar transurethral (plasmakinetic) enucleation, HoLEP and B-TURP in the short-, mid-, and long-term, respectively.	1b
Enucleation of the prostate using the Tm:YAG laser (ThuLEP) demonstrates similar safety compared to TURP/bipolar transurethral (plasmakinetic) enucleation, and HoLEP in the short- and mid-term, respectively.	1b



Vapoenucleation of the prostate using a Tm:YAG laser (ThuVEP) seems to be safe in patients with large prostates and those receiving anticoagulant or antiplatelet therapy.	2b
--	----

Recommendations	Strength rating
Offer enucleation of the prostate using the Tm:YAG laser (ThuLEP, ThuVEP) to men with moderate-to-severe LUTS as an alternative to transurethral resection of the prostate, holmium laser enucleation or bipolar transurethral (plasmakinetic) enucleation.	Weak
Offer Tm:YAG laser enucleation of the prostate to patients receiving anticoagulant or antiplatelet therapy.	Weak

#### 5.3.2.5 Diode laser enucleation of the prostate

**Mechanism of action:** For prostate surgery, diode lasers with a wavelength of 940, 980, 1,318, and 1,470 nm (depending on the semiconductor used) are marketed for vaporisation and enucleation. Only a few have been evaluated in clinical trials [385].

**Efficacy:** One small RCT comparing 1,318 nm diode laser enucleation of the prostate (DiLEP) with B-TURP in patients with mean prostate volume < 80 mL reported no significant differences in IPSS, QoL score,  $Q_{\max}$  and PVR at six months follow-up [388]. Another RCT comparing 1,470 nm DiLEP with B-TURP in 157 patients with mean prostate volume < 80 mL also reported no significant differences in IPSS, QoL score,  $Q_{\max}$  and PVR at twelve months follow-up [389]. In addition, three RCTs comparing 980 nm DiLEP with PKEP in patients with mean prostate volume < 80 mL [390, 391] and > 80 mL [392] reported no significant differences in IPSS, QoL score,  $Q_{\max}$  and PVR at twelve months follow-up.

**Tolerability and safety:** One small RCT comparing 1,318 nm DiLEP with B-TURP in patients with mean prostate volume < 80 mL and six months follow-up reported a significantly longer operation time for DiLEP, but shorter catheterisation and hospitalisation times, as well as less blood loss (without differences in blood transfusion rates) [388]. No differences in complication rates were reported between the two arms [388]. Another RCT comparing 1,470 nm DiLEP with B-TURP in 157 patients with mean prostate volume < 80 mL and twelve months follow-up reported significantly shorter operation, catheterisation and hospitalisation times with less blood loss (without differences in blood transfusion rates) for DiLEP, with no differences in complication rates between the two arms [389]. Three RCTs comparing 980 nm DiLEP with PKEP in patients with mean prostate volume < 80 mL [390, 391] and > 80 mL [392] and twelve months follow-up reported conflicting peri-operative outcomes: operation time (no difference between arms [390], significantly shorter for DiLEP [391] or significantly longer for DiLEP [392]); catheterisation time (no difference between the two arms [390], significantly shorter for DiLEP [391, 392]); hospitalisation time (no difference between arms [390, 391], significantly shorter for DiLEP [392]); blood loss (no difference in haemoglobin drop between arms [390], significantly lower haemoglobin drop for DiLEP [391, 392]). All trials reported no differences in blood transfusion rates and complication rates [390-392].

**Practical considerations:** Diode laser enucleation seems to offer similar efficacy and safety when compared to either B-TURP or bipolar transurethral (plasmakinetic) enucleation. Based on the limited number, mainly low-quality RCTs, and controversial data on the retreatment rate, results for diode laser enucleation should be evaluated in further higher quality RCTs.

Summary of evidence	LE
Laser enucleation of the prostate using the 1,318 nm or 1,470 laser showed comparable short-term efficacy and safety to B-TURP. Peri-operative parameters like blood loss, catheterisation time and hospital stay are in favour of diode enucleation.	1b
Laser enucleation of the prostate using the 980 nm laser showed comparable short-term efficacy and safety to bipolar transurethral (plasmakinetic) enucleation.	1b

Recommendation	Strength rating
Offer 120-W 980 nm, 1,318 nm or 1,470 nm diode laser enucleation of the prostate to men with moderate-to-severe LUTS as a comparable alternative to bipolar transurethral (plasmakinetic) enucleation or bipolar transurethral resection of the prostate.	Weak

### 5.3.2.6 Enucleation techniques under investigation

#### 5.3.2.6.1 Minimal invasive simple prostatectomy

**Mechanism of action:** The term minimal invasive simple prostatectomy (MISP) includes laparoscopic simple prostatectomy (LSP) and robot-assisted simple prostatectomy (RASP). The technique for LSP was first described in 2002 [393], while the first RASP was reported in 2008 [394]. Both LSP and RASP are performed using different personalised techniques, based on the transcapsular (Millin) or transvesical (Freyer) techniques of OP. An extraperitoneal approach is mostly used for LSP, while a transperitoneal approach is mostly used for RASP.

**Efficacy:** A SR and meta-analysis showed that in 27 observational studies including 764 patients, the mean increase in  $Q_{\max}$  was 14.3 mL/s, and the mean improvement in IPSS was 17.2 [395]. Mean duration of operation was 141 minutes and the mean intra-operative blood loss was 284 mL. One hundred and four patients (13.6%) developed a surgical complication. In comparative studies to OP, length of hospital stay, length of catheter use and estimated blood loss were significantly lower in the MISP group, while the duration of operation was longer than in OP. There were no differences in improvements in  $Q_{\max}$ , IPSS and peri-operative complications between both procedures.

Two recent retrospective series on RASP were not included in the meta-analysis which confirm these findings [396, 397]. The largest retrospective series reports 1,330 consecutive cases including 487 robotic (36.6%) and 843 laparoscopic (63.4%) simple prostatectomy cases. The authors confirm that both techniques can be safely and effectively done in selected centres [396].

**Tolerability and safety:** In the largest series, the post-operative complication rate was 10.6% (7.1% for LSP and 16.6% for RASP), most of the complications being of low grade. The most common complications in the RASP series were haematuria requiring irrigation, UTI and AUR; in the LSP series, the most common complications were UTI, ileus and AUR. In the most recent, largest comparative analysis of robotic vs. OP for large-volume prostates, a propensity score-matched analysis was performed with five covariates. Robotic compared with OP demonstrated a significant shorter average length of hospital stay, but longer mean operative time. The robotic approach was also associated with a lower estimated blood loss. Improvements in maximal flow rate, IPSS, QoL, PVR and post-operative PSA levels were similar before and after surgery for both groups. There was no difference in complications between the groups [398].

**Practical considerations:** Minimal invasive simple prostatectomy seems comparable to OP in terms of efficacy and safety, providing similar improvements in  $Q_{\max}$  and IPSS [395]. However, most studies are of a retrospective nature. High-quality studies are needed to compare the efficacy, safety, and hospitalisation times of MISP and both OP and endoscopic methods. Long-term outcomes, learning curve and cost of MISP should also be evaluated.

Summary of evidence	LE
Minimal invasive simple prostatectomy is feasible in men with prostate sizes > 80 mL needing surgical treatment; however, RCTs are needed.	1a

#### 5.3.2.6.2 532 nm ('Greenlight') laser enucleation of the prostate

**Mechanism of action:** The Potassium-Titanyl-Phosphate (KTP) and the lithium triborate (LBO) lasers work at a wavelength of 532 nm. Laser energy is absorbed by haemoglobin, but not by water. Vaporisation leads to immediate removal of prostatic tissue. Three "Greenlight" lasers exist, which differ not only in maximum power output, but more significantly in fibre design and the associated energy tissue interaction of each. The standard Greenlight device today is the 180-W XPS laser, but the majority of evidence is published with the former 80-W KTP or 120-W HPS (LBO) laser systems.

Two approaches for KTP/LBO laser based enucleation technique exist [399]. GreenLEP is an anatomical enucleation technique following the principle of blunt dissection of the adenoma with the sheath and laser energy for incision as described for ThuLEP [400]. *En bloc* GreenLEP preparation has been popularised with the same approach. A variation of the most commonly applied GreenLEP technique, with tissue morcellation, is the *in situ* vaporisation of apically enucleated tissue, also referred to as anatomic vaporisation-incision technique [400, 401]. Lithium triborate/Greenlight vapoenucleation on the other hand uses vapoincising laser energy to cut out the tissue [402]. To date no RCTs evaluating enucleation using the KTP/LBO laser exist [403].



### 5.3.3 Vaporisation of the prostate

#### 5.3.3.1 Bipolar transurethral vaporisation of the prostate

*Mechanism of action:* Bipolar transurethral vaporisation of the prostate (B-TUVP) was introduced in the late 1990s (“PK” B-TUVP). The technique was derived from PK B-TURP and utilised a bipolar electrode and a high-frequency generator to create a plasma effect able to vaporise prostatic tissue [404]. With minimal direct tissue contact (near-contact; hovering technique) and heat production the bipolar electrode produces a constant plasma field (thin layer of highly ionized particles; plasma corona), allowing it to glide over the tissue and vaporise a limited layer of prostate cells without affecting the underlying tissue whilst achieving haemostasis, leaving behind a TURP-like cavity [405]. A distinct difference between B-TUVP and its ancestor (monopolar TUVP), is that B-TUVP displays thinner (< 2 mm) coagulation zones [406], compared to the disproportionate extent of those created by the former (up to 10 mm) [407], that potentially lead to mostly irritative side-effects and stress urinary incontinence [406, 408, 409].

*Efficacy:* Bipolar-TUVP has been evaluated as a TURP alternative for treating moderate-to-severe LUTS in thirteen RCTs to date, including a total of 1,244 men with a prostate size of < 80 mL [303, 410-421]. Early RCTs evaluated the PK B-TUVP system [410-414]; however, during the last decade, only the “plasma” B-TUVP system with the “mushroom- or button-like” electrode (Olympus, Medical) has been evaluated [303, 415-421]. Results have been pooled in three RCT-based meta-analyses [289, 422, 423], and a narrative synthesis has been produced in two SRs [289, 424]. The follow-up in most RCTs is twelve months [410-413, 415-417, 419, 421]. The longest follow-up is 36 months in a small RCT (n = 40) and eighteen months in a subsequent RCT (n = 340); evaluating PK [414] and plasma B-TUVP [303], respectively.

Early pooled results concluded that no significant differences exist in short-term efficacy (IPSS, QoL score,  $Q_{max}$  and PVR) between PK B-TUVP and TURP [289]. However, the promising initial efficacy profile of the former may be compromised by inferior clinical outcomes (IPSS,  $Q_{max}$ ) at mid-term. Larger RCTs with longer follow-up are necessary to draw definite conclusions [289, 414]. A SR of seven RCTs comparing PK and plasma B-TUVP with TURP concluded that functional outcomes of B-TUVP and TURP do not differ [424]. The poor quality of the included RCTs and the fact that most data was derived from a single institution was highlighted [424]. A similar SR of eight RCTs comparing both B-TUVP techniques with TURP concluded that not enough consistent data suitable for a meta-analysis exists; that main functional results are contradictory; and that heterogeneity of RCTs, non-standardised techniques and methodological limitations do not permit firm conclusions [289]. A meta-analysis of six RCTs specifically evaluating plasma B-TUVP vs. TURP, concluded that both techniques result in a similar improvement of LUTS [423].

*Tolerability and safety:* Early pooled results concluded that no statistically significant differences exist collectively for intra-operative and short-term complications between PK B-TUVP and TURP, but peri-operative complications are significantly fewer after B-TUVP [289]. However, the results of a statistical analysis comparing pooled specific complication rates were not directly reported in this meta-analysis [289]. Mid-term safety results (urethral stricture, ED, and retrograde ejaculation) have also been reported to be similar [414], but larger RCTs with longer follow-up are necessary to draw definite conclusions [289, 414]. A SR of seven RCTs comparing PK and plasma B-TUVP with TURP concluded that most RCTs suggest a better haemostatic efficiency for B-TUVP, resulting in shorter catheterisation (42.5 vs. 77.5 hours) and hospitalisation times (3.1 vs. 4.4 days) [424]. A similar SR of eight RCTs comparing both B-TUVP techniques with TURP concluded that not enough consistent data suitable for a meta-analysis exists and that heterogeneity of RCTs, non-standardised techniques and methodological limitations do not permit firm conclusions [289]. A meta-analysis of six RCTs specifically evaluating plasma B-TUVP vs. TURP, concluded that no significant differences exist between the techniques in overall complication and transfusion rates [423]. However, a statistically significant difference was detected collectively in major complication rates (Clavien 3, 4; including urethral stricture, severe bleeding necessitating re-operation and urinary incontinence) and in the duration of catheterisation favouring plasma B-TUVP.

*Practical considerations:* Bipolar-TUVP and TURP have similar short-term efficacy. Plasmakinetic B-TUVP has a favourable peri-operative profile, similar mid-term safety, but inferior mid-term efficacy compared to TURP. Plasma B-TUVP has a lower short-term major morbidity compared to TURP. Randomised controlled trials of higher quality, multicentre RCTs, and longer follow-up periods are needed to evaluate B-TUVP in comparison to TURP.

Summary of evidence	LE
Bipolar-TUVP and TURP have similar short-term efficacy.	1a
Plasmakinetic B-TUVP has a favourable peri-operative profile, similar mid-term safety, but inferior mid-term efficacy compared to TURP.	1a
Plasma B-TUVP has a lower short-term major morbidity rate compared to TURP.	1a

Recommendation	Strength rating
Offer bipolar transurethral vaporisation of the prostate as an alternative to monopolar transurethral resection of the prostate to surgically treat moderate-to-severe LUTS in men with a prostate volume of 30-80 mL.	Weak

### 5.3.3.2 532 nm ('Greenlight') laser vaporisation of the prostate

**Mechanism of action:** The Potassium-Titanyl-Phosphate (KTP) and the lithium triborate (LBO) lasers have been described in section 5.3.2.6.2.

**Efficacy:** A meta-analysis of the nine available RCTs comparing photoselective vaporisation of the prostate (PVP) using the 80-W and 120-W lasers with TURP was performed in 2012 [425]. No differences were found in  $Q_{max}$  and IPSS between 80-W PVP and TURP, but only three RCTs provided sufficient twelve month data to be included in the meta-analysis [426-428]. Another meta-analysis from 2016, of four RCTs including 559 patients, on the 120-W laser, demonstrated no significant difference in functional and symptomatic parameters at 6-, 12-, and 24-month follow-up when compared to TURP [429].

The only available RCT for the 180-W laser reported non-inferiority to TURP in terms of IPSS,  $Q_{max}$ , PVR volume, prostate volume reduction, PSA decrease and QoL questionnaires. Efficacy outcomes were similar to TURP with stable results at 24 months follow-up [430].

The longest RCT comparing the 120-W HPS laser with TURP had a follow-up of 36 months and showed a comparable improvement in IPSS,  $Q_{max}$ , and PVR [431]. Comparable improvements in IPSS, QoL,  $Q_{max}$ , or urodynamic parameters were reported from two RCTs with a maximum follow-up of 24 months [427, 432]. A SR and meta-analysis of eleven RCTs comparing M-TURP with the 80-W KTP or 120-W HPS system found no significant difference with respect to IPSS and  $Q_{max}$  improvement [433].

One RCT comparing HoLEP to PVP, in patients with prostates > 60 mL, showed comparable symptom improvement, but significantly higher flow rates and lower PVR volume after HoLEP at short-term follow-up; in addition, PVP showed a 22% conversion rate to TURP [434].

**Tolerability and safety:** A meta-analysis of RCTs comparing the 80-W and 120-W lasers with TURP showed a significantly longer operating time, but shorter catheterisation time and length of hospital stay after PVP [289]. Blood transfusions and clot retention were less with PVP. No difference was noted in post-operative urinary retention, infection, meatal stenosis, urethral stricture, or bladder neck stenosis [289]. In a meta-analysis including trials with the 120-W laser, patients in the PVP group demonstrated significantly lower transfusion rates, shorter catheterisation time and shorter duration of hospital stay compared to TURP. Re-operation rates and operation time were in favour of TURP. No significant differences were demonstrated for treatment for urethral stricture, BNC, incidence of incontinence and infection [429]. A SR and meta-analysis of eleven RCTs comparing M-TURP with the 80-W KTP or 120-W HPS system found that PVP was superior to M-TURP with regard to transfusion rate, clot retention, catheterisation and hospitalisation time [433].

180-W Greenlight laser prostatectomy is non-inferior to TURP in terms of peri-operative complications. Re-operation free survival during 24 months follow-up was comparable between the TURP-arm and the 180-W XPS laser-arm [430]. In an RCT comparing the 120-W HPS laser with TURP, with a follow-up of 36 months, the re-operation rate was significantly higher after PVP (11% vs. 1.8%;  $p = 0.04$ ) [431].

Based mostly on case series the 80-, 120- and 180-W Greenlight laser appears to be safe in high-risk patients undergoing anticoagulation treatment [435-438]; however, patients under anticoagulation therapy were either excluded from or represented a very small sample in currently available RCTs. In one study, anticoagulant patients had significantly higher rates of bladder irrigation (17.2%) compared with those not taking anticoagulants (5.4%) [438]. In contrast, another retrospective study focusing on the 180-W LBO laser did not find any significant differences between patients receiving or not receiving anticoagulants [439]. A retrospective study of a mixed cohort of patients, treated with 80-W KTP PVP and 120-W LBO HPS, revealed that delayed gross haematuria was common in patients (33.8%) during an average follow-up of 33 months [440]. A retrospective review of a database of patients undergoing 180-W PVP, without interruption of anticoagulation therapy, had a 30.5% rate of peri-operative adverse events with a significant occurrence of high grade Clavien Dindo events [441].

Safety in patients with urinary retention, impaired detrusor contractility, elderly patients or prostates > 80 mL was shown in various prospective short-term non-randomised trials. No RCT including prostates > 100 mL has been reported; therefore, comparison of retreatment rates between prostate volumes of different sizes is not possible [442-444].

An RCT with twelve months follow-up reported a retrograde ejaculation rate of 49.9% following PVP with an 80-W laser vs. 56.7% for TURP, there was no impact on erectile function in either arm of the trial [445]. Additional studies have also reported no difference between OP/TURP and Greenlight PVP for erectile function [446, 447]. However, IIEF-5 scores were significantly decreased at 6-, 12-, and 24- months in patients with pre-operative IIEF-5 greater than 19 [448].

*Practical considerations:* The 180-W XPS represents the current standard of generators for PVP; however, the number and quality of supporting publications are low, especially for large glands (> 100 mL), with no long-term follow up.

Summary of evidence	LE
Laser vaporisation of the prostate using the 80-W KTP and the 120-W LBO laser (PVP) demonstrated higher intra-operative safety with regard to haemostatic properties when compared to TURP. Peri-operative parameters such as catheterisation time and hospital stay are in favour of PVP, whereas operation time and risk of re-operation are in favour of TURP. Short-term results for the 80-W KTP laser and mid-term results for the 120-W LBO laser were comparable to TURP.	1a
Laser vaporisation of the prostate using the 180-W LBO laser (PVP) demonstrated higher intra-operative safety with regard to haemostatic properties when compared to TURP. Peri-operative parameters such as catheterisation time and hospital stay were in favour of PVP, whereas operation time was in favour of TURP. Short- to mid-term results are comparable to TURP.	1b
Laser vaporisation of the prostate using the 80-W KTP and 120-W LBO lasers seems to be safe for the treatment of patients receiving antiplatelet or anticoagulant therapy.	2
Laser vaporisation of the prostate using the 180-W LBO laser seems to be safe for the treatment of patients receiving antiplatelet or anticoagulant therapy; however, the level of available evidence is low.	3

Recommendations	Strength rating
Offer 80-W 532-nm Potassium-Titanyl-Phosphate (KTP) laser vaporisation of the prostate to men with moderate-to-severe LUTS with a prostate volume of 30-80 mL as an alternative to transurethral resection of the prostate (TURP).	Strong
Offer 120-W 532-nm Lithium Borate (LBO) laser vaporisation of the prostate to men with moderate-to-severe LUTS with a prostate volume of 30-80 mL as an alternative to TURP.	Strong
Offer 180-W 532-nm LBO laser vaporisation of the prostate to men with moderate-to-severe LUTS with a prostate volume of 30-80 mL as an alternative to TURP.	Strong
Offer laser vaporisation of the prostate using 80-W KTP, 120- or 180-W LBO lasers for the treatment of patients receiving antiplatelet or anticoagulant therapy with a prostate volume < 80 mL.	Weak

### 5.3.3.3 Vaporisation techniques under investigation

#### 5.3.3.3.1 Diode laser vaporisation of the prostate

*Mechanism of action:* For prostate surgery, diode lasers with a wavelength of 980 nm are marketed for vaporisation; however, only a few have been evaluated in clinical trials [317].

*Efficacy:* Two RCTs for 120-W 980 nm diode laser vaporisation vs. M-TURP are available [449, 450]. The first RCT with 24 month follow-up reported equal symptomatic and clinical parameters at one and six months. However, at 12- and 24-months the results were significantly in favour of TURP, repeat TURP was more frequent in the diode laser group [449]. The second RCT reported equivocal results for both interventions at 3-month follow-up [450].

*Tolerability and safety:* Published studies on 980 nm diode laser vaporisation indicate high haemostatic potential, although anticoagulants or platelet aggregation inhibitors were taken in 24% and 52% of patients, respectively [451, 452]. In a number of studies, a high rate of post-operative dysuria was reported [449, 451-453]. In an RCT reflecting on peri-operative and post-operative complications no significant differences were demonstrated for clot retention, re-catheterisation, UUI and UTI [449]. Moreover, for late complications no significant differences could be demonstrated for re-operation rate, urethral stricture, bladder neck sclerosis, *de novo* sexual dysfunction and mean time of dysuria [449].

Fibre modifications can potentially reduce surgical time [454]. Early publications on diode vaporisation reported high re-operation rates (8-33%) and persisting stress urinary incontinence (9.1%) [449, 451-453].

*Practical considerations:* Diode laser vaporisation leads to similar improvements in clinical and symptomatic parameters during short-term follow-up and provides good haemostatic properties. Based on the limited number, mainly low quality RCTs, and controversial data on the retreatment rate, results for diode laser vaporisation should be evaluated in further higher quality RCTs.

Summary of evidence	LE
Laser vaporisation of the prostate using the 120-W 980 nm diode laser demonstrated high intra-operative safety with regard to haemostatic properties when compared to TURP. Peri-operative parameters like catheterisation time and hospital stay were in favour of diode lasers. Evidence is limited by the number and quality of the available studies.	1b
In a number of studies severe post-operative complications such as severe storage symptoms and persisting incontinence occurred with laser vaporisation of the prostate using the 120-W 980 nm diode laser.	3
Laser vaporisation using the 120-W 980 nm diode laser seems to be safe with regard to haemostasis in patients receiving anticoagulant therapy.	3

### 5.3.4 **Alternative ablative techniques**

#### 5.3.4.1 *Aquablation – image guided robotic waterjet ablation: AquaBeam*

**Mechanism of action:** AquaBeam uses the principle of hydro-dissection to ablate prostatic parenchyma while sparing collagenous structures like blood vessels and the surgical capsule. A targeted high velocity saline stream ablates prostatic tissue without the generation of thermal energy under real-time transrectal ultrasound guidance; therefore, it is truly a robotic operation. After completion of ablation haemostasis is performed with a Foley balloon catheter on light traction or diathermy or low-powered laser, if necessary [455].

**Efficacy:** In a double-blind, multicentre, prospective RCT 181 patients were randomised to TURP or Aquablation [456, 457]. Mean total operative time was similar for Aquablation and TURP (33 vs. 36 minutes), but resection time was significantly lower for Aquablation (4 vs. 27 minutes). At six months patients treated with Aquablation and TURP experienced large IPSS improvements (-16.9 and -15.1, respectively). The study non-inferiority hypothesis was satisfied. Larger prostates (50-80 mL) demonstrated a more pronounced benefit. At one year follow-up, mean IPSS reduction was 15.1 in the Aquablation group and 15.1 in the TURP group with a mean percent reduction in IPSS score of 67% in both groups. Ninety three percent and 86.7% of patients had improvements of at least five points from baseline, respectively. No significant difference in improvement of IPSS, QoL,  $Q_{max}$  and reduction of PVR was reported between the groups. One TURP subject (1.5%) and three Aquablation subjects (2.6%) underwent re-TURP within one year of the study procedure [458]. In the American cohort of this study (90 patients) one year data showed less anejaculation in patients treated with aquablation (9%) compared with TURP (45%) in sexually active subjects [457].

A subgroup analysis of the WATER study [456] reported that in men with larger more complex prostates Aquablation was associated with both superior symptom improvement and a better safety profile with less post-operative anejaculation [459].

In a cohort study of 101 men with a prostate volume between 80-150 mL mean IPSS improved from 23.2 at baseline to 5.9 at six months. Improvement in IPSS, QoL,  $Q_{max}$  and reduction of PVR were also significant at six months. No secondary procedures for tissue removal occurred as of the six months [460].

Another RCT comparing Aquablation with TURP performed urodynamic studies on 66 patients at six months follow-up and reported significant changes in pdet $Q_{max}$  (reductions of 35 and 34 cm H<sub>2</sub>O, respectively) and large improvements in BOO Index in both groups [461].

**Tolerability and safety:** An RCT has shown that fewer men in the Aquablation group had a persistent Clavien-Dindo grade 1 or 2 or higher adverse event compared to TURP (26% vs. 42%) at three months following treatment. Among sexually active men the rate of anejaculation was lower in those treated with Aquablation compared to TURP (10% vs. 36%, respectively). There were no procedure-related adverse events after six months [458]. In patients with a prostate volume between 80-150 mL, bleeding related events were observed in fourteen patients (13.9%) of which eight (7.9%) occurred prior to discharge and six (5.9%) occurred within one month of discharge. Blood transfusions were required in eight (7.9%) patients, return to the theatre for fulguration in three (3.0%) patients, and both transfusion and fulguration in two patients (2.0%). Ejaculatory dysfunction occurred in 19% of sexually active men [460].

**Practical considerations:** During short-term follow-up, Aquablation provides non-inferior functional outcomes compared to TURP in patients with LUTS and a prostate volume between 30-80 mL. Longer term follow-up is necessary to assess the clinical value of Aquablation.

Summary of evidence	LE
Aquablation appears to be as effective as TURP both subjectively and objectively; however, there are still some concerns about the best methods of achieving post-treatment haemostasis.	1b



Recommendations	Strength rating
Offer Aquablation* to patients with moderate-to-severe LUTS and a prostate volume of 30-80 mL as an alternative to TURP.	Weak
Inform patients about the risk of bleeding and the lack of long-term follow-up data.	Strong

\*Approach remains under investigation

#### 5.3.4.2 Prostatic artery embolisation

**Mechanism of action:** Prostatic artery embolisation (PAE) can be performed as a day case procedure under local anaesthesia with access through the femoral or radial arteries. Digital subtraction angiography displays arterial anatomy and the appropriate prostatic arterial supply is selectively embolised to effect stasis in treated prostatic vessels. Different techniques have been used for PAE. Atherosclerosis, excessive tortuosity of the arterial supply and the presence of adverse collaterals are anatomical obstacles for the technical approach. Cone beam computed tomography and contrast enhanced MR angiography can help identify prostatic arteries and prevent off-target embolisation particularly in patients with challenging anatomical configurations [462, 463].

**Efficacy:** Two RCTs were conducted for direct comparison of PAE with TURP [464, 465]. Both studies observed significant treatment outcomes for both procedures as compared to baseline values, but TURP was superior when considering urodynamic parameters such as  $Q_{max}$  and PVR. Improvement of LUTS as determined by IPSS and QoL was slightly more pronounced after TURP and reduction of prostate volume was significantly more efficient after TURP than PAE.

Another RCT comparing PAE with TURP in 99 patients showed a mean reduction in IPSS from baseline to twelve weeks of -9.23 points after PAE and -10.77 points after TURP. At twelve weeks, PAE was less effective than TURP regarding improvements in  $Q_{max}$  (5.19 mL/s vs. 15.34 mL/s), PVR (-86.36 mL vs. -199.98 mL), prostate volume (-12.17 mL vs. -30.27 mL), and significant de-obstructive effectiveness according to pressure flow studies (56% vs. 93% shift towards less obstructive category). For secondary outcomes, compared with PAE, procedural time was shorter for TURP, but in PAE patients, bladder catheter indwelling time, and duration of hospital stay were significantly shorter [462].

Another SR and meta-analysis including the three above mentioned RCTs and two non-randomised comparative studies ( $n = 708$  patients), showed that TURP achieved a significantly higher mean post-operative difference for IPSS and IPSS-QoL, 3.80 and 0.73 points, respectively compared to PAE [466]. All of the functional outcomes assessed were significantly superior after TURP: 3.62 mL/s for  $Q_{max}$ , 11.51 mL for prostate volume, 11.86 mL for PVR, and 1.02 ng/mL for PSA [466].

**Tolerability and safety:** In a SR of comparative studies PAE resulted in significantly more adverse events than TURP/OP (41.6% vs. 30.4%). The frequency of AUR after the procedures was significantly higher in the PAE group (9.4% vs. 2.0%) [467].

Another RCT however, reported fewer adverse events occurred after PAE than after TURP (36 vs. 70 events;  $p = 0.003$ ). For secondary outcomes, PAE showed favourable results in terms of blood loss [462]. A SR and meta-analysis of four studies (506 patients) comparing PAE and TURP found no significant difference in the post-operative complication rate between TURP and PAE [468]. A SR of 708 patients whilst confirming that PAE was not as effective as TURP, it did report fewer side effects than established surgical procedures [466]. Post-operative erectile function measured by IIEF-5 was in favour of PAE with mean difference in change of 2.56 points. Concerns still exist about non-target embolisation, reported in earlier studies [469]; however, more recent studies report less incidents [466, 470].

**Practical considerations:** A multidisciplinary team approach of urologists and radiologists is mandatory and patient selection should be done by urologists and interventional radiologists together. The investigation of patients with LUTS to indicate suitability for invasive techniques should be performed by urologists only. This technically demanding procedure should only be done by an interventional radiologist with specific mentored training and expertise in PAE [471]. Patients with larger prostates ( $> 80$  mL) may have the most to gain from PAE. The selection of LUTS patients who will benefit from PAE still needs to be better defined [466]. Further data with medium- and long-term follow-up are still required and comparison with other minimally invasive techniques would be valuable. However, current evidence of safety and efficacy of PAE appears adequate to support the use of this procedure for men with moderate-to-severe LUTS provided proper arrangements for consent and audit are in place; therefore, a recommendation has been given, but PAE remains under investigation.

Summary of evidence	LE
Prostatic artery embolisation is less effective than TURP at improving symptoms and urodynamic parameters such as flow rate.	1a
Procedural time is longer for PAE compared to TURP, but blood loss, catheterisation and hospitalisation time are in favour of PAE.	1b

Recommendations	Strength rating
Offer prostatic artery embolisation (PAE)* to men with moderate-to-severe LUTS who wish to consider minimally invasive treatment options and accept less optimal outcomes compared with transurethral resection of the prostate.	Weak
Perform PAE only in units where the work up and follow-up is performed by urologists working collaboratively with trained interventional radiologists for the identification of PAE suitable patients.	Strong

\*Approach remains under investigation

#### 5.3.4.3 Alternative ablative techniques under investigation

##### 5.3.4.3.1 Convective water vapour energy (WAVE) ablation: The Rezum system

**Mechanism of action:** The Rezum system uses radiofrequency power to create thermal energy in the form of water vapour, which in turn deposits the stored thermal energy when the steam phase shifts to liquid upon cell contact. The steam disperses through the tissue interstices and releases stored thermal energy onto prostatic tissue effecting cell necrosis. The procedure can be performed in an office based setting. Usually, one to three injections are needed for each lateral lobe and one to two injections may be delivered into the median lobe.

**Efficacy:** In a multicentre, randomised, controlled study 197 men were enrolled and randomised in a 2:1 ratio to treatment with water vapour energy ablation or sham treatment [472]. At three months relief of symptoms, measured by a change in IPSS and  $Q_{max}$  were significantly improved and maintained compared to the sham arm, although only the active treatment arm was followed up to twelve months. No relevant impact was observed on PVR. Quality of life outcome was significantly improved with a meaningful treatment response of 52% at twelve months. Further validated objective outcome measures such as BPH impact index (BPHII), Overactive Bladder Questionnaire Short Form for OAB bother, and impact on QoL and International Continence Society Male Item Short Form Survey for male incontinence demonstrated significant amelioration of symptoms at three months follow-up with sustained efficacy throughout the study period of twelve months. The reported two year results in the Rezum cohort arm of the same study and the recently reported four year results confirmed durability of the positive clinical outcome after convective water vapour energy ablation [473, 474]. Surgical retreatment rate was 4.4% over four years [474].

**Tolerability and safety:** Safety profile was favourable with adverse events documented to be mild-to-moderate and resolving rapidly. Preservation of erectile and ejaculatory function after convective water vapour thermal therapy was demonstrated utilising validated outcome instruments such as IIEF and Male Sexual Health Questionnaire-Ejaculation Disorder Questionnaire [472].

**Practical considerations:** Randomised controlled trials against a reference technique are needed to confirm the first promising clinical results and to evaluate mid- and long-term efficacy and safety of water vapour energy treatment.

#### 5.3.5 Non-ablative techniques

##### 5.3.5.1 Prostatic urethral lift

**Mechanism of action:** The prostatic urethral lift (PUL) represents a novel minimally invasive approach under local or general anaesthesia. Encroaching lateral lobes are compressed by small permanent suture-based implants delivered under cystoscopic guidance (Urolift®) resulting in an opening of the prostatic urethra leaving a continuous anterior channel through the prostatic fossa extending from the bladder neck to the verumontanum.

**Efficacy:** In general, PUL achieves a significant improvement in IPSS (-39% to -52%),  $Q_{max}$  (+32% to +59%) and QoL (-48% to -53%) [475-480]. Prostatic urethral lift was initially evaluated vs. sham in a multicentre study with one [477] three [481] and five [482] years follow-up. The primary endpoint was met at three months with a 50% reduction in IPSS. In addition,  $Q_{max}$  increased significantly from 8.1 to 12.4 mL/s compared to baseline at three months and this result was confirmed at twelve months. The difference in clinical response for  $Q_{max}$  between both groups was of statistical significance. A relevant benefit with regard to PVR was not demonstrated compared to baseline or sham. At three years, average improvements from baseline were significant for total IPSS, QoL,  $Q_{max}$  and individual IPSS symptoms. There was no *de novo*, sustained



ejaculatory or erectile dysfunction events and all sexual function assessments showed average stability or improvement after PUL. Improvements in IPSS, QoL, BPHII and  $Q_{max}$  were durable throughout the five years with improvement rates of 36%, 50%, 52%, and 44%, respectively. The re-treatment rate was 13.6% over five years. Adverse events were mild to moderate and transient. Sexual function was stable over five years with no *de novo*, sustained erectile, or ejaculatory dysfunction.

Another RCT of 80 patients was conducted in three European countries, comparing PUL to TURP. At twelve months, IPSS improvement was -11.4 for PUL and -15.4 for TURP. There was no retrograde ejaculation among PUL patients with 40% in the TURP patients. Surgical recovery was measured using a validated instrument and confirmed that recovery from PUL is more rapid and more extensive in the first three to six months [483]. However, TURP resulted in much greater improvements in  $Q_{max}$  after twelve months compared to PUL. At 24 months, significant improvements in IPSS, IPSS QoL, BPHII, and  $Q_{max}$  were observed in both arms. Change in IPSS and  $Q_{max}$  in the TURP arm were superior to the PUL arm [484]. Improvements in QoL and BPHII score were not statistically different between the study arms. Prostatic urethral lift resulted in superior quality of recovery and ejaculatory function preservation. Ejaculatory function and bother scores did not change significantly in either treatment arm.

In a meta-analysis of retrospective and prospective trials, pooled estimates showed an overall improvement following PUL, including IPSS,  $Q_{max}$ , and QoL [480]. Sexual function was preserved with a small improvement estimated at twelve months.

**Tolerability and safety:** The most common complications reported post-operatively included haematuria (16-63%), dysuria (25-58%), pelvic pain (5-17.9%), urgency (7.1-10%), transient incontinence (3.6-16%), and UTI (2.9-11%) [477, 480-482]. Most symptoms were mild-to-moderate in severity and resolved within two to four weeks after the procedure.

Prostatic urethral lift seems to have no significant impact on sexual function. Evaluation of sexual function as measured by IIEF-5, Male Sexual Health Questionnaire-Ejaculatory Dysfunction, and Male Sexual Health Questionnaire-Bother in patients undergoing PUL showed that erectile and ejaculatory function were preserved [475-479].

**Practical considerations:** There are only limited data on treating patients with an obstructed/protruding middle lobe [485]. It appears that they can be effectively treated with a variation in the standard technique, but further data are needed [485]. The effectiveness in large prostate glands has not been shown yet. Long-term studies are needed to evaluate the duration of the effect in comparison to other techniques.

Summary of evidence	LE
Prostatic urethral lift improves IPSS, $Q_{max}$ and QoL; however, these improvements are inferior to TURP at 24 months.	1b
Prostatic urethral lift has a low incidence of sexual side effects.	1b
Patients should be informed that long-term effects including the risk of retreatment have not been evaluated.	4

Recommendation	Strength rating
Offer Prostatic urethral lift (Urolift®) to men with LUTS interested in preserving ejaculatory function, with prostates < 70 mL and no middle lobe.	Strong

### 5.3.5.2 Intra-prostatic injections

**Mechanism of action:** Various substances have been injected directly into the prostate in order to improve LUTS, these include Botulinum toxin-A (BoNT-A), fexapotide trifluate (NX-1207) and PRX302. The primary mechanism of action of BoNT-A is through the inhibition of neurotransmitter release from cholinergic neurons [486]. The detailed mechanisms of action for the injectables NX-1207 and PRX302 are not completely understood, but experimental data associates apoptosis-induced atrophy of the prostate with both drugs [486].

**Efficacy:** Results from clinical trials have shown only modest clinical benefits, that do not seem to be superior to placebo, for BoNT-A [487, 488]. A recent SR and meta-analysis showed no differences in efficacy compared with placebo and concluded that there is no evidence of clinical benefits in medical practice [489]. The positive results from Phase II-studies have not been confirmed in Phase III-trials for PRX302 [490, 491]. NX-1207 was evaluated in two multicentre placebo controlled double-blind randomised parallel group trials including a total of 995 patients with a mean follow-up of 3.6 years, IPSS change from baseline was significantly higher and AUR rate was significantly reduced in the treatment arm. The authors concluded that NX-1207 is an effective transrectal injectable for long-term treatment for LUTS and that treated patients have reduced need for further intervention [492].

**Safety:** Studies including safety assessments have reported only a few mild and self-limiting adverse events for all injectable drugs [486]. A recent SR and meta-analysis showed low incident rates of procedure-related adverse events [489]. Two multicentre placebo controlled double-blind randomised parallel group trials with long-term follow-up evaluating NX-1207 detected no significant safety differences between the study arms [492].

**Practical considerations:** Although experimental evidence for compounds such as BoNT-A and PRX302 were promising for their transition to clinical use positive results from Phase II-studies have not been confirmed in Phase III-trials. Randomised controlled trials against a reference technique are needed to confirm the first promising clinical results of NX-1207.

Summary of evidence	LE
Results from clinical trials have shown no clinical benefits for BoNT-A compared to placebo for the management of LUTS due to BPO.	1a
Results from clinical trials have shown clinical benefits for NX-1207 compared to placebo for the management of LUTS due to BPO.	1b

Recommendation	Strength rating
Do not offer intraprostatic Botulinum toxin-A injection treatment to patients with male LUTS.	Strong

### 5.3.5.3 Non-ablative techniques under investigation

#### 5.3.5.3.1 (i)TIND

**Mechanism of action:** The iTIND is a device designed to remodel the bladder neck and the prostatic urethra and is composed of three elongated struts and an anchoring leaflet, all made of nitinol. Under direct visualisation the iTIND is deployed inside the prostate in expanded configuration. The intended mode of action is to compress obstructive tissue by the expanded device, thereby exerting radial force leading to ischaemic necrosis in defined areas of interest. The iTIND is left in position for five days. The resulting incisions may be similar to a Turner Warwick incision. In an outpatient setting the device is removed by standard urethroscopy.

**Efficacy:** A single-arm, prospective study of 32 patients with a follow-up of three years was conducted to evaluate feasibility and safety of the procedure [493]. The change from baseline in IPSS, QoL score and  $Q_{max}$  was significant at every follow-up time point [494].

**Tolerability and safety:** The device has been reported to be well tolerated by all patients. Four early complications (12.5%) were recorded, including one case of urinary retention (3.1%), one case of transient incontinence due to device displacement (3.1%), and two cases of infection (6.2%). No further complications were recorded during the 36-month follow-up period.

**Practical considerations:** Randomised controlled trials comparing iTIND to a reference technique are ongoing.


## 5.4 Patient selection

The choice of treatment depends on the assessed findings of patient evaluation, ability of the treatment to change the findings, treatment preferences of the individual patient, and the expectations to be met in terms of speed of onset, efficacy, side effects, QoL, and disease progression.

Behavioural modifications, with or without medical treatments, are usually the first choice of therapy. Figure 3 provides a flow chart illustrating treatment choice according to evidence-based medicine and patient profiles. Surgical treatment is usually required when patients have experienced recurrent or refractory urinary retention, overflow incontinence, recurrent UTIs, bladder stones or diverticula, treatment-resistant macroscopic haematuria due to BPH/BPE, or dilatation of the upper urinary tract due to BPO, with or without renal insufficiency (absolute operation indications, need for surgery).


Additionally, surgery is usually needed when patients have not obtained adequate relief from LUTS or PVR using conservative or medical treatments (relative operation indications). The choice of surgical technique depends on prostate size, comorbidities of the patient, ability to have anaesthesia, patients' preferences, willingness to accept surgery-associated specific side-effects, availability of the surgical armamentarium, and experience of the surgeon with these surgical techniques. An algorithm for surgical approaches according to evidence-based medicine and the patient's profile is provided in Figure 4.

**Figure 3: Treatment algorithm of male LUTS using medical and/or conservative treatment options.**  
 Treatment decisions depend on results assessed during initial evaluation.  
 Note that patients' preferences may result in different treatment decisions.



*PDE5I = phosphodiesterase type 5 inhibitors.*

**Figure 4: Treatment algorithm of bothersome LUTS refractory to conservative/medical treatment or in cases of absolute operation indications. The flowchart is stratified by the patient's ability to have anaesthesia, cardiovascular risk, and prostate size.**



(1) Current standard/first choice. The alternative treatments are presented in alphabetical order.

Laser vaporisation includes GreenLight, thulium, and diode laser vaporisation. Laser enucleation includes holmium and thulium laser enucleation.

HoLEP = holmium laser enucleation; TUIP = transurethral incision of the prostate; TURP = transurethral resection of the prostate and PU = prostatic urethral.

## 5.5 Management of Nocturia in men with lower urinary tract symptoms

The following section reports a SR of therapy for the management of nocturia in men with LUTS. It also emphasises the need to consider the wide range of possible causes of nocturia [495].

Nocturia is defined as the complaint of waking at night to void [6]. It reflects the relationship between the amount of urine produced while asleep, and the ability of the bladder to store the urine received. Nocturia can occur as part of lower urinary tract dysfunction (LUTD), such as OAB and chronic pelvic pain syndrome. Nocturia can also occur in association with other forms of LUTD, such as BOO, but here it is debated whether the link is one of causation or simply the co-existence of two common conditions. Crucially, nocturia may have behavioural, sleep disturbance (primary or secondary) or systemic causes unrelated to LUTD (Table 2). Differing causes often co-exist and each has to be considered in all cases. Only where LUTD is contributory should nocturia be termed a LUTS.

**Table 2: Categories of nocturia**

CATEGORY	Disproportionate urine production (at all times, or during sleep)	Low volume of each void (at all times, or overnight)
<i>Behavioural</i>	Inappropriate fluid intake	“Bladder awareness” due to secondary sleep disturbance
<i>Systemic</i>	Water, salt and metabolite output	
<i>Sleep disorder</i>	Variable water and salt output	“Bladder awareness” due to primary sleep disturbance
<i>LUTD</i>		Impaired storage function and increased filling sensation

### 5.5.1 Diagnostic assessment

Evaluation is outlined in Figure 5;

1. Evaluate for LUTD according to the relevant guidelines. The severity and bother of individual LUTS should be identified with a symptom score, supplemented by directed questioning if needed. A validated bladder diary is mandatory.
2. Review whether behavioural factors affecting fluid balance and sleep are contributing.
3. Review of medical history and medications, including directed evaluation for key conditions, such as renal failure, diabetes mellitus, cardiac failure, and obstructive sleep apnoea. If systemic factors or sleep disorders are potentially important, consider involving appropriate medical expertise (see Figure 6). This is appropriate where a known condition is suboptimally managed, or symptoms and signs suggest an undiagnosed condition.

### 5.5.2 Medical conditions and sleep disorders Shared Care Pathway

Causative categories for nocturia comprise [496]:


1. bladder storage problems;
2. 24-hour polyuria (> 40 mL/kg urine output over a 24-hour period);
3. nocturnal polyuria (NP; nocturnal output exceeding 20% of 24-hour urine output in the young, or 33% of urine output in people > 65 [6]);
4. sleep disorders;
5. mixed aetiology.

Potentially relevant systemic conditions are those which impair physiological fluid balance, including influences on: levels of free water, salt, other solutes and plasma oncotic pressure; endocrine regulation e.g. by antidiuretic hormone; natriuretic peptides; cardiovascular and autonomic control; renal function; neurological regulation, e.g. circadian regulation of the pineal gland, and renal innervation. As nocturia is commonly referred to the specialty without full insight into cause, the urologist must review the likely mechanisms underlying a presentation with nocturia and instigate review by relevant specialties accordingly. Thus, the managing urologist needs to evaluate nocturia patients in a context where additional medical expertise is available (Table 3). They should not proceed along any LUTD management pathway unless a causative link with LUTD is justifiably suspected, and systemic or sleep abnormalities have been considered.

In patients with non-bothersome nocturia, the medical evaluation (history and physical examination) should consider the possibility of early stages of systemic disease, and whether there is possibility of earlier diagnosis or therapy adjustment.

Some important potentially treatable non-urological causes of nocturia include; obstructive sleep apnoea, congestive cardiac failure, poorly controlled diabetes mellitus and medications (e.g. diuretics, or lithium).

**Figure 5. Evaluation of Nocturia in non-neurogenic Male LUTS.**



Assessment must establish whether the patient has polyuria, LUTS, a sleep disorder or a combination. Therapy may be driven by the bother it causes, but non-bothersome nocturia may warrant assessment with a frequency volume chart (indicated by the dotted line) depending on history and clinical examination since potential presence of a serious underlying medical condition must be considered.

FVC = frequency volume chart; DRE = digital rectal examination; NP = nocturnal polyuria; MoA = mechanism of action; PVR = post-void residual; PSA = prostate-specific antigen; US = ultrasound.



**Table 3:** Shared care pathway for nocturia, highlighting the need to manage potentially complex patients using relevant expertise for the causative factors.

UROLOGICAL CONTRIBUTION	SHARED CARE	MEDICAL CONTRIBUTION
<b>Diagnosis of LUTD</b> <ul style="list-style-type: none"> <li>• Urological/LUTS evaluation</li> <li>• Nocturia symptom scores</li> <li>• Bladder diary</li> </ul>		<b>Diagnosis of conditions causing NP</b> <ul style="list-style-type: none"> <li>• Evaluate patient's known conditions</li> <li>• Screening for sleep disorders</li> <li>• Screening for potential causes of polyuria*</li> </ul>
<b>Conservative management</b> Behavioural therapy <ul style="list-style-type: none"> <li>• Fluid/sleep habits advice</li> <li>• Drugs for storage LUTS</li> <li>• Drugs for voiding LUTS</li> <li>• ISC/catherisation</li> <li>• Increased exercise</li> <li>• Leg elevation</li> <li>• Weight loss</li> </ul> Interventional therapy <ul style="list-style-type: none"> <li>• Therapy of refractory storage LUTS</li> <li>• Therapy of refractory voiding LUTS</li> </ul>	<b>Conservative management</b> <ul style="list-style-type: none"> <li>• Antidiuretic</li> <li>• Diuretics</li> <li>• Drugs to aid sleep</li> </ul>	<b>Management</b> <ul style="list-style-type: none"> <li>• Initiation of therapy for new diagnosis</li> <li>• Optimised therapy of known conditions</li> </ul> <p>* Potential causes of polyuria</p> <p>NEPHROLOGICAL DISEASE</p> <ul style="list-style-type: none"> <li>• Tubular dysfunction</li> <li>• Global renal dysfunction</li> </ul> <p>CARDIOVASCULAR DISEASE</p> <ul style="list-style-type: none"> <li>• Cardiac disease</li> <li>• Vascular disease</li> </ul> <p>ENDOCRINE DISEASE</p> <ul style="list-style-type: none"> <li>• Diabetes insipidus/mellitus</li> <li>• Hormones affecting diuresis/natriuresis</li> </ul> <p>NEUROLOGICAL DISEASE</p> <ul style="list-style-type: none"> <li>• Pituitary and renal innervation</li> <li>• Autonomic dysfunction</li> </ul> <p>RESPIRATORY DISEASE</p> <ul style="list-style-type: none"> <li>• Obstructive sleep apnoea</li> </ul> <p>BIOCHEMICAL</p> <ul style="list-style-type: none"> <li>• Altered blood oncotic pressure</li> </ul>

### 5.5.3 **Treatment for Nocturia**

#### 5.5.3.1 *Antidiuretic therapy*

The antidiuretic hormone arginine vasopressin (AVP) plays a key role in body water homeostasis and control of urine production by binding to V2 receptors in the renal collecting ducts. Arginine vasopressin increases water re-absorption and urinary osmolality, so decreasing water excretion and total urine volume. Arginine vasopressin also has V1 receptor mediated vasoconstrictive/hypertensive effects and a very short serum half-life, which makes the hormone unsuitable for treating nocturia/nocturnal polyuria.

Desmopressin is a synthetic analogue of AVP with high V2 receptor affinity and no relevant V1 receptor affinity. It has been investigated for treating nocturia [497], with specific doses, titrated dosing, differing formulations, and options for route of administration. Most studies have short follow-up. Global interpretation of existing studies is difficult due to the limitations, imprecision, heterogeneity and inconsistencies of the studies.

A SR of randomised or quasi-randomised trials in men with nocturia found that desmopressin may decrease the number of nocturnal voids by -0.46 compared to placebo over short-term follow-up (up to three months); over intermediate-term follow-up (three to twelve months) there was a change of -0.85 in nocturnal voids in a substantial number of participants without increase in major adverse events [498].

Another SR of comparative trials of men with nocturia as the primary presentation and LUTS including nocturia or nocturnal polyuria found that antidiuretic therapy using dose titration was more effective than placebo in relation to nocturnal voiding frequency and duration of undisturbed sleep [495]. Adverse events include headache, hyponatremia, insomnia, dry mouth, hypertension, abdominal pain, peripheral edema, and nausea. Three studies evaluating titrated-dose desmopressin in which men were included, reported seven serious adverse events in 530 patients (1.3%), with one death. There were seventeen cases of hyponatraemia (3.2%) and seven of hypertension (1.3%). Headache was reported in 53 (10%) and nausea in fifteen (2.8%) [495]. Hyponatremia is the most important concern, especially in patients > 65 years of age, with potential life threatening consequences. Baseline values of sodium over 130 mmol/L have been used as inclusion criteria in some research protocols. Assessment of sodium levels must be undertaken at baseline, after initiation of treatment or dose titration and during treatment. Desmopressin is not recommended in high-risk groups [495].

Desmopressin oral disintegrating tablets (ODT) have been studied separately in the sex-specific pivotal trials CS41 and CS40 in patients with nocturia [499, 500]. Almost 87% of included patients had nocturnal polyuria and approximately 48% of the patients were > 65 years. The co-primary endpoints in both trials were change in number of nocturia episodes per night from baseline and at least a 33% decrease in the mean number of nocturnal voids from baseline during three months of treatment. The mean change in nocturia episodes from baseline was greater with desmopressin ODT compared to placebo (difference: women = -0.3 [95% CI: -0.5, -0.1]; men = -0.4 [95% CI: -0.6, -0.2]). The 33% responder rate was also greater with desmopressin ODT compared to placebo (women: 78% vs. 62%; men: 67% vs. 50%).

Analysis of three published placebo-controlled trials of desmopressin ODT for nocturia showed that clinically significant hyponatraemia was more frequent in patients aged  $\geq 65$  years than in those aged < 65 years in all dosage groups, including those receiving the minimum effective dose for desmopressin (11% of men aged  $\geq 65$  years vs. 0% of men aged < 65 years receiving 50 mcg; 4% of women  $\geq 65$  aged years vs. 2% of women aged < 65 years receiving 25 mcg). Severe hyponatraemia, defined as  $\leq 125$  mmol/L serum sodium, was rare, affecting 22/1,431 (2%) patients overall [501].

Low dose desmopressin (ODT) has been approved in Europe, Canada and Australia for the treatment of nocturia with  $\geq 2$  episodes in gender-specific low doses 50 mcg for men and 25 mcg for women; however, it initially failed to receive FDA approval, with the FDA citing uncertain benefit relative to risks as the reason. Following resubmission to the FDA in June 2018 desmopressin acetate sublingual tablet, 50 mcg for men and 25 mcg for women, was approved for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void with a boxed warning for hyponatremia.

Desmopressin acetate nasal spray is a new low-dose formulation of desmopressin and differs from other types of desmopressin formulation due to its bioavailability and route of administration. Desmopressin acetate nasal spray has been investigated in two RCTs including men and women with nocturia (over two episodes per night) and a mean age of 66 years. The average benefit of treatment relative to placebo was statistically significant but low, -0.3 and -0.2 for the 1.5 mcg and 0.75 mcg doses of desmopressin acetate, respectively. The number of patients with a reduction of more than 50% of nocturia episodes was 48.5% and 37.9%, respectively compared with 30% in the placebo group [502]. The reported adverse event rate of the studies was rather low and the risk of hyponatremia was 1.2% and 0.9% for desmopressin acetate 1.5 mcg and 0.75 mcg, respectively. Desmopressin acetate nasal spray was approved by the FDA in 2017 for the treatment of nocturia due to nocturnal polyuria, but it is not available in Europe.

#### *Practical considerations*

A complete medical assessment should be made, to exclude potentially non-urological underlying causes, e.g. sleep apnea, before prescribing desmopressin in men with nocturia due to nocturnal polyuria. The optimal dose differs between patients, in men < 65 years desmopressin treatment should be initiated at a low dose (0.1 mg/day) and may be gradually increased up to a dosage of 0.4 mg/day every week until maximum efficacy is reached. Desmopressin is taken once daily before sleeping. Patients should avoid drinking fluids at least one hour before and for eight hours after dosing. Low dose desmopressin may be prescribed in patients > 65 years. In men  $\geq 65$  years or older, low dose desmopressin should not be used if the serum sodium concentration is below normal: all patients should be monitored for hyponatremia. Urologists should be cautious when prescribing low-dose desmopressin in patients under-represented in trials (e.g. patients > 75 years) who may have an increased risk of hyponatremia.

#### *5.5.3.2 Medications to treat LUTD*

Where LUTD is diagnosed and considered causative of nocturia, relevant medications for storage (and voiding) LUTS may be considered. Applicable medications include; selective  $\alpha_1$ -adrenergic antagonists [503], antimuscarinics [504-506], 5-ARIs [507] and PDE5Is [508]. However, effect size of these medications is generally small, or not significantly different from placebo when used to treat nocturia [495]. Data on OAB medications (antimuscarinics, beta-3 agonist) generally had a female-predominant population. No studies specifically addressing the impact of OAB medications on nocturia in men were identified [495]. Benefits with combination therapies were not consistently observed.

#### *5.5.3.3 Other medications*

Agents to promote sleep [509], diuretics [510], non-steroidal anti-inflammatory agents (NSAIDs) [511] and phytotherapy [512] were reported as being associated with response or QoL improvement [495]. Effect size of these medications in nocturia is generally small, or not significantly different from placebo. Larger responses have been reported for some medications, but larger scale confirmatory RCTs are lacking. Agents to promote sleep do not appear to reduce nocturnal voiding frequency, but may help patients return to sleep.

Summary of evidence	LE
No clinical trial of pathophysiology-directed primary therapy has been undertaken.	4
No robust clinical trial of behavioural therapy as primary intervention has been undertaken.	4
Antidiuretic therapy reduces nocturnal voiding frequency in men with baseline severity of two or more voids per night.	1b
There is an increased risk of hyponatremia in patients 65 years of age or older under antidiuretic therapy.	1b
Antidiuretic therapy increases duration of undisturbed sleep.	1b
Alpha 1-blocker use is associated with improvements in undisturbed sleep duration and nocturnal voiding frequency, which are generally of only marginal clinical significance.	2
Antimuscarinic medications can reduce night-time urinary urgency severity, but the reduction in overall nocturia frequency is small or non-significant.	2
Antimuscarinic medications are associated with higher incidence of dry mouth compared with placebo.	2
5 $\alpha$ -reductase inhibitors reduce nocturia severity in men with baseline nocturia severity of two or more voids per night.	2
A trial of timed diuretic therapy may be offered to men with nocturia due to nocturnal polyuria.	1b
Screening for hyponatremia should be undertaken at baseline and during treatment.	

Recommendations	Strength rating
Treat underlying causes of nocturia, including behavioural, systemic condition(s), sleep disorders, lower urinary tract dysfunction, or a combination of factors.	Weak
Discuss behavioural changes with the patient to reduce nocturnal urine volume and episodes of nocturia, and improve sleep quality.	Weak
Offer desmopressin to decrease nocturia due to nocturnal polyuria in men < 65 years of age.	Weak
Offer low dose desmopressin for men > 65 years of age with nocturia at least twice per night due to nocturnal polyuria.	Weak
Screen for hyponatremia at baseline, day three and day seven, one month after initiating therapy and periodically during treatment. Measure serum sodium more frequently in patients > 65 years of age and in patients at increased risk of hyponatremia.	Strong
Discuss with the patient the potential clinical benefit relative to the associated risks from the use of desmopressin, especially in men > 65 years of age.	Strong
Offer $\alpha$ 1-adrenergic antagonists for treating nocturia in men who have nocturia associated with LUTS.	Weak
Offer antimuscarinic drugs for treating nocturia in men who have nocturia associated with overactive bladder.	Weak
Offer 5 $\alpha$ -reductase inhibitors for treating nocturia in men who have nocturia associated with LUTS and an enlarged prostate (> 40 mL).	Weak
Do not offer phosphodiesterase type 5 inhibitors for the treatment of nocturia.	Weak

## 6. FOLLOW-UP

### 6.1 Watchful waiting (behavioural)

Patients who elect to pursue a WW policy should be reviewed at six months and then annually, provided there is no deterioration of symptoms or development of absolute indications for surgical treatment. The following are recommended at follow-up visits: history, IPSS, uroflowmetry, and PVR volume.

### 6.2 Medical treatment

Patients receiving  $\alpha$ 1-blockers, muscarinic receptor antagonists, beta-3 agonists, PDE5Is or the combination of  $\alpha$ 1-blockers and 5-ARIs or muscarinic receptor antagonists should be reviewed four to six weeks after drug initiation to determine the treatment response. If patients gain symptomatic relief in the absence of troublesome adverse events, drug therapy may be continued. Patients should be reviewed at six months and then annually, provided there is no deterioration of symptoms or development of absolute indications for surgical treatment. The following are recommended at follow-up visits: history, IPSS, uroflowmetry, and PVR volume. Frequency volume charts or bladder diaries should be used to assess response to treatment for predominant storage symptoms or nocturnal polyuria.

Patients receiving 5-ARIs should be reviewed after twelve weeks and six months to determine their response and adverse events. The following are recommended at follow-up visits: history, IPSS, uroflowmetry and PVR volume. Men taking 5-ARIs should be followed up regularly using serial PSA testing if life expectancy is greater than ten years and if a diagnosis of PCa could alter management. A new baseline PSA should be determined at six months, and any confirmed increase in PSA while on 5-ARIs should be evaluated.

In patients receiving desmopressin, serum sodium concentration should be measured at day three and seven, one month after initiating therapy and periodically during treatment. If serum sodium concentration has remained normal during periodic screening follow-up screening can be carried out every three months subsequently. However, serum sodium concentration should be monitored more frequently in patients  $\geq 65$  years of age and in patients at increased risk of hyponatremia. The following tests are recommended at follow-up visits: serum-sodium concentration and FVC. The follow-up sequence should be restarted after dose escalation.

### 6.3 Surgical treatment

After prostate surgery, patients should be reviewed four to six weeks after catheter removal to evaluate treatment response and adverse events. If patients have symptomatic relief and are without adverse events, no further re-assessment is necessary. The following tests are recommended at follow-up visit after four to six weeks: IPSS, uroflowmetry and PVR volume.

Summary of evidence	LE
Follow-up for all conservative, medical, or operative treatment modalities is based on empirical data or theoretical considerations, but not on evidence-based studies.	4

Recommendations	Strength rating
Follow-up all patients who receive conservative, medical or surgical management.	Weak
Define follow-up intervals and examinations according to the specific treatment.	Weak

## 7. REFERENCES

1. Committee on Herbal Medicinal Products. European Union herbal monograph on *Serenoa repens* (W. Bartram) Small, fructus. EMA/HMPC/280079/2013, 2015.
2. Guyatt, G.H., *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*, 2008. 336: 924.  
<https://www.ncbi.nlm.nih.gov/pubmed/18436948>
3. Guyatt, G.H., *et al.* What is "quality of evidence" and why is it important to clinicians? *BMJ*, 2008. 336: 995.  
<https://www.ncbi.nlm.nih.gov/pubmed/18456631>
4. Phillips B, *et al.* Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.  
<https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>
5. Guyatt, G.H., *et al.* Going from evidence to recommendations. *BMJ*, 2008. 336: 1049.  
<https://www.ncbi.nlm.nih.gov/pubmed/18467413>
6. Abrams, P., *et al.* The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *Neurourol Urodyn*, 2002. 21: 167.  
<https://www.ncbi.nlm.nih.gov/pubmed/11857671>
7. Martin, S.A., *et al.* Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. *World J Urol*, 2011. 29: 179.  
<https://www.ncbi.nlm.nih.gov/pubmed/20963421>
8. Société Internationale d'Urologie (SIU), Lower Urinary Tract Symptoms (LUTS): An International Consultation on Male LUTS., C. Chapple & P. Abrams, Editors. 2013.
9. Kupelian, V., *et al.* Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. *Arch Intern Med*, 2006. 166: 2381.  
<https://www.ncbi.nlm.nih.gov/pubmed/17130393>

10. Agarwal, A., *et al.* What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. *Eur Urol*, 2014. 65: 1211.  
<https://www.ncbi.nlm.nih.gov/pubmed/24486308>
11. De Ridder, D., *et al.* Urgency and other lower urinary tract symptoms in men aged  $\geq 40$  years: a Belgian epidemiological survey using the ICIQ-MLUTS questionnaire. *Int J Clin Pract*, 2015. 69: 358.  
<https://www.ncbi.nlm.nih.gov/pubmed/25648652>
12. Taub, D.A., *et al.* The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. *Curr Urol Rep*, 2006. 7: 272.  
<https://www.ncbi.nlm.nih.gov/pubmed/16930498>
13. Gacci, M., *et al.* Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. *BJU Int*, 2015. 115: 24.  
<https://www.ncbi.nlm.nih.gov/pubmed/24602293>
14. Gacci, M., *et al.* Male Lower Urinary Tract Symptoms and Cardiovascular Events: A Systematic Review and Meta-analysis. *Eur Urol*, 2016. 70: 788.  
<https://www.ncbi.nlm.nih.gov/pubmed/27451136>
15. Kogan, M.I., *et al.* Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. *Curr Med Res Opin*, 2014. 30: 2119.  
<https://www.ncbi.nlm.nih.gov/pubmed/24932562>
16. Chapple, C.R., *et al.* Lower urinary tract symptoms revisited: a broader clinical perspective. *Eur Urol*, 2008. 54: 563.  
<https://www.ncbi.nlm.nih.gov/pubmed/18423969>
17. Ficarra, V., *et al.* The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. *Curr Urol Rep*, 2014. 15: 463.  
<https://www.ncbi.nlm.nih.gov/pubmed/25312251>
18. He, Q., *et al.* Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. *Prostate Cancer Prostatic Dis*, 2016. 19: 7.  
<https://www.ncbi.nlm.nih.gov/pubmed/26391088>
19. Drake, M.J. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. *Neurourol Urodyn*, 2014. 33: 622.  
<https://www.ncbi.nlm.nih.gov/pubmed/24838519>
20. Chapple, C.R., *et al.* Terminology report from the International Continence Society (ICS) Working Group on Underactive Bladder (UAB). *Neurourol Urodyn*, 2018. 37: 2928.  
<https://www.ncbi.nlm.nih.gov/pubmed/30203560>
21. Novara, G., *et al.* Critical Review of Guidelines for BPH Diagnosis and Treatment Strategy. *Eur Urol Suppl* 2006. 4: 418.  
<https://www.eu-openscience.europeanurology.com/action/showPdf?pii=S1569-9056%2806%2900012-1>
22. McVary, K.T., *et al.* Update on AUA guideline on the management of benign prostatic hyperplasia. *J Urol*, 2011. 185: 1793.  
<https://www.ncbi.nlm.nih.gov/pubmed/21420124>
23. Bosch, J., *et al.* Etiology, Patient Assessment and Predicting Outcome from Therapy. International Consultation on Urological Diseases Male LUTS Guideline 2013. 2013 (in press).  
<https://snucm.elsevierpure.com/en/publications/lower-urinary-tract-symptoms-in-men-male-luts-etiology-patient-as>
24. Martin, R.M., *et al.* Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. *Int J Cancer*, 2008. 123: 1924.  
<https://www.ncbi.nlm.nih.gov/pubmed/18661522>
25. Young, J.M., *et al.* Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. *BJU Int*, 2000. 85: 1037.  
<https://www.ncbi.nlm.nih.gov/pubmed/10848691>
26. De Nunzio, C., *et al.* Erectile Dysfunction and Lower Urinary Tract Symptoms. *Eur Urol Focus*, 2017. 3: 352.  
<https://www.ncbi.nlm.nih.gov/pubmed/29191671>
27. Barqawi, A.B., *et al.* Methods of developing UWIN, the modified American Urological Association symptom score. *J Urol*, 2011. 186: 940.  
<https://www.ncbi.nlm.nih.gov/pubmed/21791346>



28. Barry, M.J., *et al.* The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol, 1992. 148: 1549.  
<https://www.ncbi.nlm.nih.gov/pubmed/1279218>
29. Donovan, J.L., *et al.* Scoring the short form ICSmaleSF questionnaire. International Continence Society. J Urol, 2000. 164: 1948.  
<https://www.ncbi.nlm.nih.gov/pubmed/11061889>
30. Epstein, R.S., *et al.* Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol, 1992. 45: 1431.  
<https://www.ncbi.nlm.nih.gov/pubmed/1281223>
31. Homma, Y., *et al.* Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology, 2006. 68: 318.  
<https://www.ncbi.nlm.nih.gov/pubmed/16904444>
32. Schou, J., *et al.* The value of a new symptom score (DAN-PSS) in diagnosing uro-dynamic infravesical obstruction in BPH. Scand J Urol Nephrol, 1993. 27: 489.  
<https://www.ncbi.nlm.nih.gov/pubmed/7512747>
33. Homma, Y., *et al.* Core Lower Urinary Tract Symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int J Urol, 2008. 15: 816.  
<https://www.ncbi.nlm.nih.gov/pubmed/18657204>
34. D'Silva, K.A., *et al.* Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The Rational Clinical Examination: a systematic review. JAMA, 2014. 312: 535.  
<https://www.ncbi.nlm.nih.gov/pubmed/25096693>
35. Bryan, N.P., *et al.* Frequency volume charts in the assessment and evaluation of treatment: how should we use them? Eur Urol, 2004. 46: 636.  
<https://www.ncbi.nlm.nih.gov/pubmed/15474275>
36. Gisolf, K.W., *et al.* Analysis and reliability of data from 24-hour frequency-volume charts in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol, 2000. 38: 45.  
<https://www.ncbi.nlm.nih.gov/pubmed/10859441>
37. Cornu, J.N., *et al.* A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. Eur Urol, 2012. 62: 877.  
<https://www.ncbi.nlm.nih.gov/pubmed/22840350>
38. Weiss, J.P. Nocturia: "do the math". J Urol, 2006. 175: S16.  
<https://www.ncbi.nlm.nih.gov/pubmed/16458734>
39. Weiss, J.P., *et al.* Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011. Neurourol Urodyn, 2012. 31: 330.  
<https://www.ncbi.nlm.nih.gov/pubmed/22415907>
40. Vaughan, C.P., *et al.* Military exposure and urinary incontinence among American men. J Urol, 2014. 191: 125.  
<https://www.ncbi.nlm.nih.gov/pubmed/23871759>
41. Bright, E., *et al.* Urinary diaries: evidence for the development and validation of diary content, format, and duration. Neurourol Urodyn, 2011. 30: 348.  
<https://www.ncbi.nlm.nih.gov/pubmed/21284023>
42. Yap, T.L., *et al.* A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration. BJU Int, 2007. 99: 9.  
<https://www.ncbi.nlm.nih.gov/pubmed/16956355>
43. Bright, E., *et al.* Developing and validating the International Consultation on Incontinence Questionnaire bladder diary. Eur Urol, 2014. 66: 294.  
<https://www.ncbi.nlm.nih.gov/pubmed/24647230>
44. Weissfeld, J.L., *et al.* Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials, 2000. 21: 390s.  
<https://www.ncbi.nlm.nih.gov/pubmed/11189690>
45. Roehrborn, C.G. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology, 1998. 51: 19.  
<https://www.ncbi.nlm.nih.gov/pubmed/9586592>
46. Roehrborn, C.G., *et al.* Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. Urology, 2001. 57: 1087.  
<https://www.ncbi.nlm.nih.gov/pubmed/11377314>

47. Bosch, J.L., *et al.* Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. *Eur Urol*, 2004. 46: 753.  
<https://www.ncbi.nlm.nih.gov/pubmed/15548443>
48. Babjuk, M., *et al.* EAU Guidelines on Non-muscle-invasive Bladder Cancer Edn. presented at EAU Annual Congress, Milan, 2021.  
<https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/>
49. Bonkat, G., *et al.* EAU Guidelines on Urological Infections Edn. presented at EAU Annual Congress, Milan, 2021.  
<https://uroweb.org/guideline/urological-infections/>
50. Palou, J., *et al.* ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate. *Eur Urol*, 2013. 63: 81.  
<https://www.ncbi.nlm.nih.gov/pubmed/22938869>
51. Roupret, M., *et al.* EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma Edn. presented at EAU Annual Congress, Milan, 2021.  
<https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/>
52. Roehrborn, C.G., *et al.* Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. *Urology*, 2001. 58: 642.  
<https://www.ncbi.nlm.nih.gov/pubmed/11711329>
53. Abrams, P., *et al.* Evaluation and treatment of lower urinary tract symptoms in older men. *J Urol*, 2013. 189: S93.  
<https://www.ncbi.nlm.nih.gov/pubmed/23234640>
54. European urinalysis guidelines. *Scand J Clin Lab Invest Suppl*, 2000. 231: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/12647764>
55. Khasriya, R., *et al.* The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with lower urinary tract symptoms without acute frequency and dysuria. *J Urol*, 2010. 183: 1843.  
<https://www.ncbi.nlm.nih.gov/pubmed/20303096>
56. Roehrborn, C.G., *et al.* Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. *Urology*, 1999. 53: 581.  
<https://www.ncbi.nlm.nih.gov/pubmed/10096388>
57. Bohnen, A.M., *et al.* Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. *Eur Urol*, 2007. 51: 1645.  
<https://www.ncbi.nlm.nih.gov/pubmed/17320271>
58. Kayikci, A., *et al.* Free prostate-specific antigen is a better tool than total prostate-specific antigen at predicting prostate volume in patients with lower urinary tract symptoms. *Urology*, 2012. 80: 1088.  
<https://www.ncbi.nlm.nih.gov/pubmed/23107399>
59. Morote, J., *et al.* Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable? *Eur Urol*, 2000. 38: 91.  
<https://www.ncbi.nlm.nih.gov/pubmed/10859448>
60. Mottet, N., *et al.* EAU Guidelines on Prostate Cancer Edn. presented at EAU Annual Congress, Milan, 2021.  
<https://uroweb.org/guideline/prostate-cancer/>
61. Roehrborn, C.G., *et al.* Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. *J Urol*, 2000. 163: 13.  
<https://www.ncbi.nlm.nih.gov/pubmed/10604304>
62. Roehrborn, C.G., *et al.* Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. *Urology*, 1999. 54: 662.  
<https://www.ncbi.nlm.nih.gov/pubmed/10510925>
63. Djavan, B., *et al.* Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. *Urology*, 2004. 64: 1144.  
<https://www.ncbi.nlm.nih.gov/pubmed/15596187>
64. Patel, D.N., *et al.* PSA predicts development of incident lower urinary tract symptoms: Results from the REDUCE study. *Prostate Cancer Prostatic Dis*, 2018. 21: 238.  
<https://www.ncbi.nlm.nih.gov/pubmed/29795141>
65. McConnell, J.D., *et al.* The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med*, 2003. 349: 2387.  
<https://www.ncbi.nlm.nih.gov/pubmed/14681504>

66. Roehrborn, C.G. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. *BJU Int*, 2006. 97: 734.  
<https://www.ncbi.nlm.nih.gov/pubmed/16536764>
67. Jacobsen, S.J., *et al.* Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. *J Urol*, 1999. 162: 1301.  
<https://www.ncbi.nlm.nih.gov/pubmed/10492184>
68. Lim, K.B., *et al.* Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. *Int J Urol*, 2006. 13: 1509.  
<https://www.ncbi.nlm.nih.gov/pubmed/17118026>
69. Meigs, J.B., *et al.* Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. *J Clin Epidemiol*, 2001. 54: 935.  
<https://www.ncbi.nlm.nih.gov/pubmed/11520654>
70. Gerber, G.S., *et al.* Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urology*, 1997. 49: 697.  
<https://www.ncbi.nlm.nih.gov/pubmed/9145973>
71. Oelke, M., *et al.* Can we identify men who will have complications from benign prostatic obstruction (BPO)? ICI-RS 2011. *Neurourol Urodyn*, 2012. 31: 322.  
<https://www.ncbi.nlm.nih.gov/pubmed/22415947>
72. Comiter, C.V., *et al.* Urodynamic risk factors for renal dysfunction in men with obstructive and nonobstructive voiding dysfunction. *J Urol*, 1997. 158: 181.  
<https://www.ncbi.nlm.nih.gov/pubmed/9186351>
73. Koch, W.F., *et al.* The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. *J Urol*, 1996. 155: 186.  
<https://www.ncbi.nlm.nih.gov/pubmed/7490828>
74. Rule, A.D., *et al.* The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. *Kidney Int*, 2005. 67: 2376.  
<https://www.ncbi.nlm.nih.gov/pubmed/15882282>
75. Hong, S.K., *et al.* Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia. *BJU Int*, 2010. 105: 1424.  
<https://www.ncbi.nlm.nih.gov/pubmed/19874305>
76. Lee, J.H., *et al.* Relationship of estimated glomerular filtration rate with lower urinary tract symptoms/benign prostatic hyperplasia measures in middle-aged men with moderate to severe lower urinary tract symptoms. *Urology*, 2013. 82: 1381.  
<https://www.ncbi.nlm.nih.gov/pubmed/24063940>
77. Mebust, W.K., *et al.* Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. *J Urol*, 1989. 141: 243.  
<https://www.ncbi.nlm.nih.gov/pubmed/2643719>
78. Rule, A.D., *et al.* Longitudinal changes in post-void residual and voided volume among community dwelling men. *J Urol*, 2005. 174: 1317.  
<https://www.ncbi.nlm.nih.gov/pubmed/16145411>
79. Sullivan, M.P., *et al.* Detrusor contractility and compliance characteristics in adult male patients with obstructive and nonobstructive voiding dysfunction. *J Urol*, 1996. 155: 1995.  
<https://www.ncbi.nlm.nih.gov/pubmed/8618307>
80. Oelke, M., *et al.* Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. *Eur Urol*, 2007. 52: 827.  
<https://www.ncbi.nlm.nih.gov/pubmed/17207910>
81. Emberton, M. Definition of at-risk patients: dynamic variables. *BJU Int*, 2006. 97 Suppl 2: 12.  
<https://www.ncbi.nlm.nih.gov/pubmed/16507047>
82. Mochtar, C.A., *et al.* Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. *J Urol*, 2006. 175: 213.  
<https://www.ncbi.nlm.nih.gov/pubmed/16406914>
83. Jorgensen, J.B., *et al.* Age-related variation in urinary flow variables and flow curve patterns in elderly males. *Br J Urol*, 1992. 69: 265.  
<https://www.ncbi.nlm.nih.gov/pubmed/1373664>
84. Kranse, R., *et al.* Causes for variability in repeated pressure-flow measurements. *Urology*, 2003. 61: 930.  
<https://www.ncbi.nlm.nih.gov/pubmed/12736007>

85. Reynard, J.M., *et al.* The ICS-'BPH' Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. *Br J Urol*, 1998. 82: 619.  
<https://www.ncbi.nlm.nih.gov/pubmed/9839573>
86. Idzenga, T., *et al.* Accuracy of maximum flow rate for diagnosing bladder outlet obstruction can be estimated from the ICS nomogram. *Neurourol Urodyn*, 2008. 27: 97.  
<https://www.ncbi.nlm.nih.gov/pubmed/17600368>
87. Siroky, M.B., *et al.* The flow rate nomogram: I. Development. *J Urol*, 1979. 122: 665.  
<https://www.ncbi.nlm.nih.gov/pubmed/159366>
88. Siroky, M.B., *et al.* The flow rate nomogram: II. Clinical correlation. *J Urol*, 1980. 123: 208.  
<https://www.ncbi.nlm.nih.gov/pubmed/7354519>
89. Grossfeld, G.D., *et al.* Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging. *Radiol Clin North Am*, 2000. 38: 31.  
<https://www.ncbi.nlm.nih.gov/pubmed/10664665>
90. Thorpe, A., *et al.* Benign prostatic hyperplasia. *Lancet*, 2003. 361: 1359.  
<https://www.ncbi.nlm.nih.gov/pubmed/12711484>
91. Wilkinson, A.G., *et al.* Is pre-operative imaging of the urinary tract worthwhile in the assessment of prostatism? *Br J Urol*, 1992. 70: 53.  
<https://www.ncbi.nlm.nih.gov/pubmed/1379105>
92. Loch, A.C., *et al.* Technical and anatomical essentials for transrectal ultrasound of the prostate. *World J Urol*, 2007. 25: 361.  
<https://www.ncbi.nlm.nih.gov/pubmed/17701043>
93. Stravodimos, K.G., *et al.* TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up? *Int Urol Nephrol*, 2009. 41: 767.  
<https://www.ncbi.nlm.nih.gov/pubmed/19350408>
94. Shoukry, I., *et al.* Role of uroflowmetry in the assessment of lower urinary tract obstruction in adult males. *Br J Urol*, 1975. 47: 559.  
<https://www.ncbi.nlm.nih.gov/pubmed/1191927>
95. Anikwe, R.M. Correlations between clinical findings and urinary flow rate in benign prostatic hypertrophy. *Int Surg*, 1976. 61: 392.  
<https://www.ncbi.nlm.nih.gov/pubmed/61184>
96. el Din, K.E., *et al.* The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score. *J Urol*, 1996. 156: 1020.  
<https://www.ncbi.nlm.nih.gov/pubmed/8709300>
97. Oelke, M., *et al.* Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. *Eur Urol*, 2008. 54: 419.  
<https://www.ncbi.nlm.nih.gov/pubmed/18325657>
98. Oh, M.M., *et al.* Is there a correlation between the presence of idiopathic detrusor overactivity and the degree of bladder outlet obstruction? *Urology*, 2011. 77: 167.  
<https://www.ncbi.nlm.nih.gov/pubmed/20934743>
99. Jeong, S.J., *et al.* Prevalence and Clinical Features of Detrusor Underactivity among Elderly with Lower Urinary Tract Symptoms: A Comparison between Men and Women. *Korean J Urol*, 2012. 53: 342.  
<https://www.ncbi.nlm.nih.gov/pubmed/22670194>
100. Thomas, A.W., *et al.* The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. *BJU Int*, 2004. 93: 745.  
<https://www.ncbi.nlm.nih.gov/pubmed/15049984>
101. Al-Hayek, S., *et al.* Natural history of detrusor contractility--minimum ten-year urodynamic follow-up in men with bladder outlet obstruction and those with detrusor. *Scand J Urol Nephrol Suppl*, 2004: 101.  
<https://www.ncbi.nlm.nih.gov/pubmed/15545204>
102. Thomas, A.W., *et al.* The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction. *J Urol*, 2005. 174: 1887.  
<https://www.ncbi.nlm.nih.gov/pubmed/16217330>
103. North Bristol NHS Trust. Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM). *ClinicalTrials.gov*, 2019. NCT02193451.  
<https://clinicaltrials.gov/ct2/show/NCT02193451>

104. Lewis, A.L., *et al.* Clinical and Patient-reported Outcome Measures in Men Referred for Consideration of Surgery to Treat Lower Urinary Tract Symptoms: Baseline Results and Diagnostic Findings of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM). *Eur Urol Focus*, 2019. 5: 340.  
<https://www.ncbi.nlm.nih.gov/pubmed/31047905>
105. Clement, K.D., *et al.* Invasive urodynamic studies for the management of lower urinary tract symptoms (LUTS) in men with voiding dysfunction. *Cochrane Database Syst Rev*, 2015: CD011179.  
<https://www.ncbi.nlm.nih.gov/pubmed/25918922>
106. Kim, M., *et al.* Effect of urodynamic preoperative detrusor overactivity on the outcomes of transurethral surgery in patients with male bladder outlet obstruction: a systematic review and meta-analysis. *World J Urol*, 2019. 37: 529.  
<https://www.ncbi.nlm.nih.gov/pubmed/30006907>
107. Blok, B., *et al.* EAU Guidelines on Neuro-urology Edn. presented at the EAU Annual Congress, Milan, 2021.  
<https://uroweb.org/guideline/neuro-urology/>
108. Kojima, M., *et al.* Correlation of presumed circle area ratio with infravesical obstruction in men with lower urinary tract symptoms. *Urology*, 1997. 50: 548.  
<https://www.ncbi.nlm.nih.gov/pubmed/9338730>
109. Chia, S.J., *et al.* Correlation of intravesical prostatic protrusion with bladder outlet obstruction. *BJU Int*, 2003. 91: 371.  
<https://www.ncbi.nlm.nih.gov/pubmed/12603417>
110. Keqin, Z., *et al.* Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement. *Urology*, 2007. 70: 1096.  
<https://www.ncbi.nlm.nih.gov/pubmed/18158025>
111. Mariappan, P., *et al.* Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study. *J Urol*, 2007. 178: 573.  
<https://www.ncbi.nlm.nih.gov/pubmed/17570437>
112. Tan, Y.H., *et al.* Intravesical prostatic protrusion predicts the outcome of a trial without catheter following acute urine retention. *J Urol*, 2003. 170: 2339.  
<https://www.ncbi.nlm.nih.gov/pubmed/14634410>
113. Arnolds, M., *et al.* Positioning invasive versus noninvasive urodynamics in the assessment of bladder outlet obstruction. *Curr Opin Urol*, 2009. 19: 55.  
<https://www.ncbi.nlm.nih.gov/pubmed/19057217>
114. Manieri, C., *et al.* The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness. *J Urol*, 1998. 159: 761.  
<https://www.ncbi.nlm.nih.gov/pubmed/9474143>
115. Kessler, T.M., *et al.* Ultrasound assessment of detrusor thickness in men-can it predict bladder outlet obstruction and replace pressure flow study? *J Urol*, 2006. 175: 2170.  
<https://www.ncbi.nlm.nih.gov/pubmed/16697831>
116. Blatt, A.H., *et al.* Ultrasound measurement of bladder wall thickness in the assessment of voiding dysfunction. *J Urol*, 2008. 179: 2275.  
<https://www.ncbi.nlm.nih.gov/pubmed/18423703>
117. Oelke, M. International Consultation on Incontinence-Research Society (ICI-RS) report on non-invasive urodynamics: the need of standardization of ultrasound bladder and detrusor wall thickness measurements to quantify bladder wall hypertrophy. *Neurourol Urodyn*, 2010. 29: 634.  
<https://www.ncbi.nlm.nih.gov/pubmed/20432327>
118. Kojima, M., *et al.* Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: a preliminary report. *Urology*, 1996. 47: 942.  
<https://www.ncbi.nlm.nih.gov/pubmed/8677600>
119. Kojima, M., *et al.* Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight. *J Urol*, 1997. 157: 476.  
<https://www.ncbi.nlm.nih.gov/pubmed/8996337>
120. Akino, H., *et al.* Ultrasound-estimated bladder weight predicts risk of surgery for benign prostatic hyperplasia in men using alpha-adrenoceptor blocker for LUTS. *Urology*, 2008. 72: 817.  
<https://www.ncbi.nlm.nih.gov/pubmed/18597835>
121. McIntosh, S.L., *et al.* Noninvasive assessment of bladder contractility in men. *J Urol*, 2004. 172: 1394.  
<https://www.ncbi.nlm.nih.gov/pubmed/15371853>



122. Drinnan, M.J., *et al.* Inter-observer agreement in the estimation of bladder pressure using a penile cuff. *Neurourol Urodyn*, 2003. 22: 296.  
<https://www.ncbi.nlm.nih.gov/pubmed/12808703>
123. Griffiths, C.J., *et al.* A nomogram to classify men with lower urinary tract symptoms using urine flow and noninvasive measurement of bladder pressure. *J Urol*, 2005. 174: 1323.  
<https://www.ncbi.nlm.nih.gov/pubmed/16145412>
124. Clarkson, B., *et al.* Continuous non-invasive measurement of bladder voiding pressure using an experimental constant low-flow test. *Neurourol Urodyn*, 2012. 31: 557.  
<https://www.ncbi.nlm.nih.gov/pubmed/22190105>
125. Van Mastrigt, R., *et al.* Towards a noninvasive urodynamic diagnosis of infravesical obstruction. *BJU Int*, 1999. 84: 195.  
<https://www.ncbi.nlm.nih.gov/pubmed/10444152>
126. Pel, J.J., *et al.* Development of a non-invasive strategy to classify bladder outlet obstruction in male patients with LUTS. *Neurourol Urodyn*, 2002. 21: 117.  
<https://www.ncbi.nlm.nih.gov/pubmed/11857664>
127. Shinbo, H., *et al.* Application of ultrasonography and the resistive index for evaluating bladder outlet obstruction in patients with benign prostatic hyperplasia. *Curr Urol Rep*, 2011. 12: 255.  
<https://www.ncbi.nlm.nih.gov/pubmed/21475953>
128. Ku, J.H., *et al.* Correlation between prostatic urethral angle and bladder outlet obstruction index in patients with lower urinary tract symptoms. *Urology*, 2010. 75: 1467.  
<https://www.ncbi.nlm.nih.gov/pubmed/19962734>
129. Malde, S., *et al.* Systematic Review of the Performance of Noninvasive Tests in Diagnosing Bladder Outlet Obstruction in Men with Lower Urinary Tract Symptoms. *Eur Urol*, 2016.  
<https://www.ncbi.nlm.nih.gov/pubmed/27687821>
130. Ball, A.J., *et al.* The natural history of untreated "prostatism". *Br J Urol*, 1981. 53: 613.  
<https://www.ncbi.nlm.nih.gov/pubmed/6172172>
131. Kirby, R.S. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? *Urology*, 2000. 56: 3.  
<https://www.ncbi.nlm.nih.gov/pubmed/11074195>
132. Isaacs, J.T. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. *Prostate Suppl*, 1990. 3: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/1689166>
133. Netto, N.R., Jr., *et al.* Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting. *Urology*, 1999. 53: 314.  
<https://www.ncbi.nlm.nih.gov/pubmed/9933046>
134. Flanigan, R.C., *et al.* 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. *J Urol*, 1998. 160: 12.  
<https://www.ncbi.nlm.nih.gov/pubmed/9628595>
135. Wasson, J.H., *et al.* A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. *N Engl J Med*, 1995. 332: 75.  
<https://www.ncbi.nlm.nih.gov/pubmed/7527493>
136. Brown, C.T., *et al.* Self management for men with lower urinary tract symptoms: randomised controlled trial. *Bmj*, 2007. 334: 25.  
<https://www.ncbi.nlm.nih.gov/pubmed/17118949>
137. Yap, T.L., *et al.* The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures. *BJU Int*, 2009. 104: 1104.  
<https://www.ncbi.nlm.nih.gov/pubmed/19485993>
138. Brown, C.T., *et al.* Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach. *Eur Urol*, 2004. 46: 254.  
<https://www.ncbi.nlm.nih.gov/pubmed/15245822>
139. Michel, M.C., *et al.* Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. *Br J Pharmacol*, 2006. 147 Suppl 2: S88.  
<https://www.ncbi.nlm.nih.gov/pubmed/16465187>
140. Kortmann, B.B., *et al.* Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. *Urology*, 2003. 62: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/12837408>

141. Barendrecht, M.M., *et al.* Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? *Neurourol Urodyn*, 2008. 27: 226.  
<https://www.ncbi.nlm.nih.gov/pubmed/17638312>
142. Djavan, B., *et al.* State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. *Urology*, 2004. 64: 1081.  
<https://www.ncbi.nlm.nih.gov/pubmed/15596173>
143. Michel, M.C., *et al.* Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. *Prostate Cancer Prostatic Dis*, 1998. 1: 332.  
<https://www.ncbi.nlm.nih.gov/pubmed/12496876>
144. Fusco, F., *et al.* alpha1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies. *Eur Urol*, 2016. 69: 1091.  
<https://www.ncbi.nlm.nih.gov/pubmed/26831507>
145. Boyle, P., *et al.* Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. *Urology*, 2001. 58: 717.  
<https://www.ncbi.nlm.nih.gov/pubmed/11711348>
146. Roehrborn, C.G. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. *Prostate Cancer Prostatic Dis*, 2006. 9: 121.  
<https://www.ncbi.nlm.nih.gov/pubmed/16304557>
147. Roehrborn, C.G., *et al.* The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. *J Urol*, 2008. 179: 616.  
<https://www.ncbi.nlm.nih.gov/pubmed/18082216>
148. Roehrborn, C.G., *et al.* The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. *Eur Urol*, 2010. 57: 123.  
<https://www.ncbi.nlm.nih.gov/pubmed/19825505>
149. Karavitakis, M., *et al.* Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis. *Eur Urol*, 2019.  
<https://www.ncbi.nlm.nih.gov/pubmed/30773327>
150. Nickel, J.C., *et al.* A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. *Int J Clin Pract*, 2008. 62: 1547.  
<https://www.ncbi.nlm.nih.gov/pubmed/18822025>
151. Barendrecht, M.M., *et al.* Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. *BJU Int*, 2005. 95 Suppl 4: 19.  
<https://www.ncbi.nlm.nih.gov/pubmed/15871732>
152. Chapple, C.R., *et al.* Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. *Eur Urol*, 2011. 59: 342.  
<https://www.ncbi.nlm.nih.gov/pubmed/21109344>
153. Welk, B., *et al.* The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist: a population based cohort study. *BMJ*, 2015. 351: h5398.  
<https://www.ncbi.nlm.nih.gov/pubmed/26502947>
154. Chang, D.F., *et al.* Intraoperative floppy iris syndrome associated with tamsulosin. *J Cataract Refract Surg*, 2005. 31: 664.  
<https://www.ncbi.nlm.nih.gov/pubmed/15899440>
155. Chatziralli, I.P., *et al.* Risk factors for intraoperative floppy iris syndrome: a meta-analysis. *Ophthalmology*, 2011. 118: 730.  
<https://www.ncbi.nlm.nih.gov/pubmed/21168223>
156. van Dijk, M.M., *et al.* Effects of alpha(1)-adrenoceptor antagonists on male sexual function. *Drugs*, 2006. 66: 287.  
<https://www.ncbi.nlm.nih.gov/pubmed/16526818>
157. Gacci, M., *et al.* Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. *J Sex Med*, 2014. 11: 1554.  
<https://www.ncbi.nlm.nih.gov/pubmed/24708055>

158. Andriole, G., *et al.* Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. *J Urol*, 2004. 172: 1399.  
<https://www.ncbi.nlm.nih.gov/pubmed/15371854>
159. Rittmaster, R.S., *et al.* Evidence for atrophy and apoptosis in the prostates of men given finasteride. *J Clin Endocrinol Metab*, 1996. 81: 814.  
<https://www.ncbi.nlm.nih.gov/pubmed/8636309>
160. Naslund, M.J., *et al.* A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. *Clin Ther*, 2007. 29: 17.  
<https://www.ncbi.nlm.nih.gov/pubmed/17379044>
161. Andersen, J.T., *et al.* Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. *Urology*, 1995. 46: 631.  
<https://www.ncbi.nlm.nih.gov/pubmed/7495111>
162. Kirby, R.S., *et al.* Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. *Urology*, 2003. 61: 119.  
<https://www.ncbi.nlm.nih.gov/pubmed/12559281>
163. Lepor, H., *et al.* The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. *N Engl J Med*, 1996. 335: 533.  
<https://www.ncbi.nlm.nih.gov/pubmed/8684407>
164. Marberger, M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. *Urology*, 1998. 51: 677.  
<https://www.ncbi.nlm.nih.gov/pubmed/9610579>
165. McConnell, J.D., *et al.* The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. *N Engl J Med*, 1998. 338: 557.  
<https://www.ncbi.nlm.nih.gov/pubmed/9475762>
166. Nickel, J.C., *et al.* Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. *CMAJ*, 1996. 155: 1251.  
<https://www.ncbi.nlm.nih.gov/pubmed/8911291>
167. Roehrborn, C.G., *et al.* Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. *Urology*, 2002. 60: 434.  
<https://www.ncbi.nlm.nih.gov/pubmed/12350480>
168. Nickel, J.C., *et al.* Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). *BJU Int*, 2011. 108: 388.  
<https://www.ncbi.nlm.nih.gov/pubmed/21631695>
169. Boyle, P., *et al.* Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. *Urology*, 1996. 48: 398.  
<https://www.ncbi.nlm.nih.gov/pubmed/8804493>
170. Gittelman, M., *et al.* Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement. *J Urol*, 2006. 176: 1045.  
<https://www.ncbi.nlm.nih.gov/pubmed/16890688>
171. Roehrborn, C.G., *et al.* Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. *BJU Int*, 2005. 96: 572.  
<https://www.ncbi.nlm.nih.gov/pubmed/16104912>
172. Roehrborn, C.G., *et al.* The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. *Eur Urol*, 2009. 55: 461.  
<https://www.ncbi.nlm.nih.gov/pubmed/19013011>
173. Roehrborn, C.G. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. *BJU Int*, 2008. 101 Suppl 3: 17.  
<https://www.ncbi.nlm.nih.gov/pubmed/18307681>
174. Andersen, J.T., *et al.* Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. *Urology*, 1997. 49: 839.  
<https://www.ncbi.nlm.nih.gov/pubmed/9187688>

175. Kirby, R.S., *et al.* Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study. *Eur Urol*, 1993. 24: 20.  
<https://www.ncbi.nlm.nih.gov/pubmed/7689971>
176. Tammela, T.L., *et al.* Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia. *J Urol*, 1995. 154: 1466.  
<https://www.ncbi.nlm.nih.gov/pubmed/7544845>
177. Donohue, J.F., *et al.* Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. *J Urol*, 2002. 168: 2024.  
<https://www.ncbi.nlm.nih.gov/pubmed/12394700>
178. Khwaja, M.A., *et al.* The Effect of Two Weeks Preoperative Finasteride Therapy in Reducing Prostate Vascularity. *J Coll Physicians Surg Pak*, 2016. 26: 213.  
<https://www.ncbi.nlm.nih.gov/pubmed/26975954>
179. Corona, G., *et al.* Sexual dysfunction in subjects treated with inhibitors of 5alpha-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. *Andrology*, 2017. 5: 671.  
<https://www.ncbi.nlm.nih.gov/pubmed/28453908>
180. Andriole, G.L., *et al.* Effect of dutasteride on the risk of prostate cancer. *N Engl J Med*, 2010. 362: 1192.  
<https://www.ncbi.nlm.nih.gov/pubmed/20357281>
181. Thompson, I.M., *et al.* The influence of finasteride on the development of prostate cancer. *N Engl J Med*, 2003. 349: 215.  
<https://www.ncbi.nlm.nih.gov/pubmed/12824459>
182. Hsieh, T.F., *et al.* Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. *PLoS One*, 2015. 10: e0119694.  
<https://www.ncbi.nlm.nih.gov/pubmed/25803433>
183. Skeldon, S.C., *et al.* The Cardiovascular Safety of Dutasteride. *J Urol*, 2017. 197: 1309.  
<https://www.ncbi.nlm.nih.gov/pubmed/27866006>
184. Chess-Williams, R., *et al.* The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. *J Auton Pharmacol*, 2001. 21: 243.  
<https://www.ncbi.nlm.nih.gov/pubmed/12123469>
185. Matsui, M., *et al.* Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. *Proc Natl Acad Sci U S A*, 2000. 97: 9579.  
<https://www.ncbi.nlm.nih.gov/pubmed/10944224>
186. Kono, M., *et al.* Central muscarinic receptor subtypes regulating voiding in rats. *J Urol*, 2006. 175: 353.  
<https://www.ncbi.nlm.nih.gov/pubmed/16406941>
187. Wuest, M., *et al.* Effect of rilmakalim on detrusor contraction in the presence and absence of urothelium. *Naunyn Schmiedebergs Arch Pharmacol*, 2005. 372: 203.  
<https://www.ncbi.nlm.nih.gov/pubmed/16283254>
188. Goldfischer, E.R., *et al.* Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: A randomized, double-blind, placebo-controlled study. *Neurourol Urodyn*, 2015. 34: 37.  
<https://www.ncbi.nlm.nih.gov/pubmed/24133005>
189. Baldwin, C.M., *et al.* Transdermal oxybutynin. *Drugs*, 2009. 69: 327.  
<https://www.ncbi.nlm.nih.gov/pubmed/19275276>
190. Chapple, C.R., *et al.* A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. *Eur Urol*, 2006. 49: 651.  
<https://www.ncbi.nlm.nih.gov/pubmed/16530611>
191. Michel, M.C., *et al.* Does gender or age affect the efficacy and safety of tolterodine? *J Urol*, 2002. 168: 1027.  
<https://www.ncbi.nlm.nih.gov/pubmed/12187215>
192. Chapple, C., *et al.* Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review. *Curr Med Res Opin*, 2015. 31: 1201.  
<https://www.ncbi.nlm.nih.gov/pubmed/25798911>
193. Dmochowski, R., *et al.* Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. *Eur Urol*, 2007. 51: 1054.  
<https://www.ncbi.nlm.nih.gov/pubmed/17097217>
194. Herschorn, S., *et al.* Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. *Urology*, 2010. 75: 1149.  
<https://www.ncbi.nlm.nih.gov/pubmed/19914702>

195. Hofner, K., *et al.* Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. *World J Urol*, 2007. 25: 627. <https://www.ncbi.nlm.nih.gov/pubmed/17906864>
196. Roehrborn, C.G., *et al.* Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. *BJU Int*, 2006. 97: 1003. <https://www.ncbi.nlm.nih.gov/pubmed/16643482>
197. Kaplan, S.A., *et al.* Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. *Jama*, 2006. 296: 2319. <https://www.ncbi.nlm.nih.gov/pubmed/17105794>
198. Kaplan, S.A., *et al.* Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. *J Urol*, 2005. 174: 2273. <https://www.ncbi.nlm.nih.gov/pubmed/16280803>
199. Kaplan, S.A., *et al.* Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. *Aging Male*, 2010. 13: 100. <https://www.ncbi.nlm.nih.gov/pubmed/20001469>
200. Roehrborn, C.G., *et al.* Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. *Urology*, 2008. 72: 1061. <https://www.ncbi.nlm.nih.gov/pubmed/18817961>
201. Yokoyama, T., *et al.* Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. *Scand J Urol Nephrol*, 2009. 43: 307. <https://www.ncbi.nlm.nih.gov/pubmed/19396723>
202. Abrams, P., *et al.* Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. *J Urol*, 2006. 175: 999. <https://www.ncbi.nlm.nih.gov/pubmed/16469601>
203. Andersson, K.E. On the Site and Mechanism of Action of beta3-Adrenoceptor Agonists in the Bladder. *Int Neurourol J*, 2017. 21: 6. <https://www.ncbi.nlm.nih.gov/pubmed/28361520>
204. Chapple, C.R., *et al.* Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. *Eur Urol*, 2013. 63: 296. <https://www.ncbi.nlm.nih.gov/pubmed/23195283>
205. Herschorn, S., *et al.* A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. *Urology*, 2013. 82: 313. <https://www.ncbi.nlm.nih.gov/pubmed/23769122>
206. Khullar, V., *et al.* Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. *Eur Urol*, 2013. 63: 283. <https://www.ncbi.nlm.nih.gov/pubmed/23182126>
207. Nitti, V.W., *et al.* Results of a randomized phase III trial of mirabegron in patients with overactive bladder. *J Urol*, 2013. 189: 1388. <https://www.ncbi.nlm.nih.gov/pubmed/23079373>
208. Yamaguchi, O., *et al.* Efficacy and Safety of the Selective beta3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study. *Low Urin Tract Symptoms*, 2015. 7: 84. <https://www.ncbi.nlm.nih.gov/pubmed/26663687>
209. Sebastianelli, A., *et al.* Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. *Int J Urol*, 2018. 25: 196. <https://www.ncbi.nlm.nih.gov/pubmed/29205506>
210. Liao, C.H., *et al.* Mirabegron 25mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction. *Urology*, 2018. 117: 115. <https://www.ncbi.nlm.nih.gov/pubmed/29630956>
211. Drake, M.J., *et al.* Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). *Eur Urol*, 2016. 70: 136. <https://www.ncbi.nlm.nih.gov/pubmed/26965560>



212. Kuo, H.C., *et al.* Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. *Neurourol Urodyn*, 2015. 34: 685.  
<https://www.ncbi.nlm.nih.gov/pubmed/25130281>
213. Abrams, P., *et al.* Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). *World J Urol*, 2017. 35: 827.  
<https://www.ncbi.nlm.nih.gov/pubmed/27514371>
214. Khullar, V., *et al.* Patient-reported outcomes with the beta3 -adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. *Neurourol Urodyn*, 2016. 35: 987.  
<https://www.ncbi.nlm.nih.gov/pubmed/26288118>
215. Yamaguchi, O., *et al.* Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). *BJU Int*, 2015. 116: 612.  
<https://www.ncbi.nlm.nih.gov/pubmed/25639296>
216. Ichihara, K., *et al.* A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. *J Urol*, 2015. 193: 921.  
<https://www.ncbi.nlm.nih.gov/pubmed/25254938>
217. Matsuo, T., *et al.* The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with alpha1-adrenergic receptor blocker monotherapy: Prospective analysis of elderly men. *BMC Urol*, 2016. 16: 45.  
<https://www.ncbi.nlm.nih.gov/pubmed/27473059>
218. Matsukawa, Y., *et al.* Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies. *Neurourol Urodyn*, 2019.  
<https://www.ncbi.nlm.nih.gov/pubmed/30779375>
219. White, W.B., *et al.* Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. *J Am Soc Hyperten*, 2018. 12: 768.  
<https://www.ncbi.nlm.nih.gov/pubmed/30181042>
220. Nitti, V.W., *et al.* Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. *J Urol*, 2013. 190: 1320.  
<https://www.ncbi.nlm.nih.gov/pubmed/23727415>
221. Lee, Y.K., *et al.* Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. *Geriatr Gerontol Int*, 2018. 18: 1330.  
<https://www.ncbi.nlm.nih.gov/pubmed/29931793>
222. Wagg, A., *et al.* Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. *Current Med Res Opin*, 2016. 32: 621.  
<https://www.ncbi.nlm.nih.gov/pubmed/26828974>
223. Herschorn, S., *et al.* Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). *BJU Int*, 2017. 120: 562.  
<https://www.ncbi.nlm.nih.gov/pubmed/28418102>
224. Chapple, C.R., *et al.* Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. *Eur Urol*, 2017. 72: 389.  
<https://www.ncbi.nlm.nih.gov/pubmed/28196724>
225. Van Gelderen, M., *et al.* Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men. *Int J Clin Pharmacol Ther*, 2014. 52: 693.  
<https://www.ncbi.nlm.nih.gov/pubmed/24755125>
226. Giuliano, F., *et al.* The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. *Eur Urol*, 2013. 63: 506.  
<https://www.ncbi.nlm.nih.gov/pubmed/23018163>
227. Morelli, A., *et al.* Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. *J Sex Med*, 2011. 8: 2746.  
<https://www.ncbi.nlm.nih.gov/pubmed/21812935>

228. Vignozzi, L., *et al.* PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. *Prostate*, 2013. 73: 1391.  
<https://www.ncbi.nlm.nih.gov/pubmed/23765639>
229. Pattanaik, S., *et al.* Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. *Cochrane Database Syst Rev*, 2018. 2018: CD010060.  
<https://www.ncbi.nlm.nih.gov/pubmed/30480763>
230. Gacci, M., *et al.* A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. *Eur Urol*, 2012. 61: 994.  
<https://www.ncbi.nlm.nih.gov/pubmed/22405510>
231. Wang, Y., *et al.* Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. *Low Urin Tract Symptoms*, 2018. 10: 84.  
<https://www.ncbi.nlm.nih.gov/pubmed/29341503>
232. Oelke, M., *et al.* Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. *Eur Urol*, 2012. 61: 917.  
<https://www.ncbi.nlm.nih.gov/pubmed/22297243>
233. Oelke, M., *et al.* Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. *J Urol*, 2015. 193: 1581.  
<https://www.ncbi.nlm.nih.gov/pubmed/25437533>
234. Donatucci, C.F., *et al.* Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. *BJU Int*, 2011. 107: 1110.  
<https://www.ncbi.nlm.nih.gov/pubmed/21244606>
235. Porst, H., *et al.* Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. *Urology*, 2013. 82: 667.  
<https://www.ncbi.nlm.nih.gov/pubmed/23876588>
236. Vlachopoulos, C., *et al.* Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials. *Int J Clin Pract*, 2015. 69: 1496.  
<https://www.ncbi.nlm.nih.gov/pubmed/26299520>
237. Brock, G.B., *et al.* Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. *J Urol*, 2014. 191: 405.  
<https://www.ncbi.nlm.nih.gov/pubmed/24096120>
238. Roehrborn, C.G., *et al.* Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. *J Urol*, 2014. 191: 1045.  
<https://www.ncbi.nlm.nih.gov/pubmed/24445278>
239. Oelke, M., *et al.* Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged  $\geq 75$  years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. *BJU Int*, 2017. 119: 793.  
<https://www.ncbi.nlm.nih.gov/pubmed/27988986>
240. Matsukawa, Y., *et al.* Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study. *Int J Urol*, 2018. 25: 246.  
<https://www.ncbi.nlm.nih.gov/pubmed/29164680>
241. Casabe, A., *et al.* Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. *J Urol*, 2014. 191: 727.  
<https://www.ncbi.nlm.nih.gov/pubmed/24096118>
242. Gacci, M., *et al.* The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. *Res Rep Urol*, 2013. 5: 99.  
<https://www.ncbi.nlm.nih.gov/pubmed/24400241>
243. Madersbacher, S., *et al.* Plant extracts: sense or nonsense? *Curr Opin Urol*, 2008. 18: 16.  
<https://www.ncbi.nlm.nih.gov/pubmed/18090484>

244. Buck, A.C. Is there a scientific basis for the therapeutic effects of *Serenoa repens* in benign prostatic hyperplasia? Mechanisms of action. *J Urol*, 2004. 172: 1792.  
<https://www.ncbi.nlm.nih.gov/pubmed/15540722>
245. Levin, R.M., *et al.* A scientific basis for the therapeutic effects of *Pygeum africanum* and *Serenoa repens*. *Urol Res*, 2000. 28: 201.  
<https://www.ncbi.nlm.nih.gov/pubmed/10929430>
246. Habib, F.K., *et al.* Not all brands are created equal: a comparison of selected components of different brands of *Serenoa repens* extract. *Prostate Cancer Prostatic Dis*, 2004. 7: 195.  
<https://www.ncbi.nlm.nih.gov/pubmed/15289814>
247. Scaglione, F., *et al.* Comparison of the potency of different brands of *Serenoa repens* extract on 5 $\alpha$ -reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. *Pharmacology*, 2008. 82: 270.  
<https://www.ncbi.nlm.nih.gov/pubmed/18849646>
248. De Monte, C., *et al.* Modern extraction techniques and their impact on the pharmacological profile of *Serenoa repens* extracts for the treatment of lower urinary tract symptoms. *BMC Urol*, 2014. 14: 63.  
<https://www.ncbi.nlm.nih.gov/pubmed/25112532>
249. Committee on Herbal Medicinal Products. Community herbal monograph on *Cucurbita pepo* L., semen. EMA/HMPC/136024/2010, 2012.  
[https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-cucurbita-pepo-l-semen\\_en.pdf](https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-cucurbita-pepo-l-semen_en.pdf)
250. Committee on Herbal Medicinal Products. European Union herbal monograph on *Prunus africana* (Hook f.) Kalkm., cortex. EMA/HMPC/680626/2013, 2016.  
[https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-prunus-africana-hook-f-kalkm-cortex\\_en.pdf](https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbal-monograph-prunus-africana-hook-f-kalkm-cortex_en.pdf)
251. Committee on Herbal Medicinal Products. Community herbal monograph on *Urtica dioica* L., *Urtica urens* L., their hybrids or their mixtures, radix. EMA/HMPC/461160/2008, 2012.  
[https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-their-hybrids-their-mixtures-radix\\_en.pdf](https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-urtica-dioica-l-urtica-urens-l-their-hybrids-their-mixtures-radix_en.pdf)
252. Committee on Herbal Medicinal Products. European Union herbal monograph on *Epilobium angustifolium* L. and/or *Epilobium parviflorum* Schreb., herba. EMA/HMPC/712511/2014, 2015.  
[https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-epilobium-angustifolium-l/epilobium-parviflorum-schreb-herba\\_en.pdf](https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-epilobium-angustifolium-l/epilobium-parviflorum-schreb-herba_en.pdf)
253. Tacklind, J., *et al.* *Serenoa repens* for benign prostatic hyperplasia. *Cochrane Database Syst Rev*, 2009: CD001423.  
<https://www.ncbi.nlm.nih.gov/pubmed/19370565>
254. Novara, G., *et al.* Efficacy and Safety of Hexanic Lipidosterolic Extract of *Serenoa repens* (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. *Eur Urol Focus*, 2016. 2: 553.  
<https://www.ncbi.nlm.nih.gov/pubmed/28723522>
255. Vela-Navarrete, R., *et al.* Efficacy and safety of a hexanic extract of *Serenoa repens* (Permixon(R)) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. *BJU Int*, 2018. 122: 1049.  
<https://www.ncbi.nlm.nih.gov/pubmed/29694707>
256. Russo, G.I., *et al.* Clinical Efficacy of *Serenoa repens* Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials. *Eur Urol Focus*, 2020.  
<https://www.ncbi.nlm.nih.gov/pubmed/31952967>
257. Boeri, L., *et al.* Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of *Serenoa Repens* or Silodosin Alone. *Sci Rep*, 2017. 7: 15179.  
<https://www.ncbi.nlm.nih.gov/pubmed/29123161>
258. Debruyne, F.M., *et al.* Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. *Eur Urol*, 1998. 34: 169.  
<https://www.ncbi.nlm.nih.gov/pubmed/9732187>
259. Barkin, J., *et al.* Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 $\alpha$ -reductase inhibitor dutasteride. *Eur Urol*, 2003. 44: 461.  
<https://www.ncbi.nlm.nih.gov/pubmed/14499682>
260. Nickel, J.C., *et al.* Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. *Can Urol Assoc J*, 2008. 2: 16.  
<https://www.ncbi.nlm.nih.gov/pubmed/18542722>

261. Athanasopoulos, A., *et al.* Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. *J Urol*, 2003. 169: 2253.  
<https://www.ncbi.nlm.nih.gov/pubmed/12771763>
262. Roehrborn, C.G., *et al.* Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(R)) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. *BJU Int*, 2015. 116: 450.  
<https://www.ncbi.nlm.nih.gov/pubmed/25565364>
263. Roehrborn, C.G., *et al.* Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. *BJU Int*, 2014. 113: 623.  
<https://www.ncbi.nlm.nih.gov/pubmed/24127818>
264. Kaplan, S.A., *et al.* Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial. *J Urol*, 2016. 195: 1825.  
<https://www.ncbi.nlm.nih.gov/pubmed/26678956>
265. Chapple, C., *et al.* Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. *Eur Urol*, 2009. 56: 534.  
<https://www.ncbi.nlm.nih.gov/pubmed/19070418>
266. Kaplan, S.A., *et al.* Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. *J Urol*, 2009. 182: 2825.  
<https://www.ncbi.nlm.nih.gov/pubmed/19837435>
267. Lee, J.Y., *et al.* Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. *BJU Int*, 2004. 94: 817.  
<https://www.ncbi.nlm.nih.gov/pubmed/15476515>
268. Lee, K.S., *et al.* Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. *J Urol*, 2005. 174: 1334.  
<https://www.ncbi.nlm.nih.gov/pubmed/16145414>
269. MacDiarmid, S.A., *et al.* Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. *Mayo Clin Proc*, 2008. 83: 1002.  
<https://www.ncbi.nlm.nih.gov/pubmed/18775200>
270. Saito, H., *et al.* A comparative study of the efficacy and safety of tamsulosin hydrochloride (Harnal capsules) alone and in combination with propiverine hydrochloride (BUP-4 tablets) in patients with prostatic hypertrophy associated with pollakisuria and/or urinary incontinence. *Jpn J Urol Surg*, 1999. 12: 525. [No abstract available].
271. Yang, Y., *et al.* Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. *Chin Med J (Engl)*, 2007. 120: 370.  
<https://www.ncbi.nlm.nih.gov/pubmed/17376305>
272. Maruyama, O., *et al.* Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. *Int J Urol*, 2006. 13: 1280.  
<https://www.ncbi.nlm.nih.gov/pubmed/17010005>
273. Lee, H.N., *et al.* Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms. *Int J Clin Pract*, 2015. 69: 444.  
<https://www.ncbi.nlm.nih.gov/pubmed/25363606>
274. van Kerrebroeck, P., *et al.* Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. *Eur Urol*, 2013. 64: 1003.  
<https://www.ncbi.nlm.nih.gov/pubmed/23932438>
275. Kaplan, S.A., *et al.* Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms. *BJU Int*, 2012. 109: 1831.  
<https://www.ncbi.nlm.nih.gov/pubmed/21966995>

276. Kim, T.H., *et al.* Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an alpha-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial. *BJU Int*, 2016. 117: 307.  
<https://www.ncbi.nlm.nih.gov/pubmed/26305143>
277. Athanasopoulos, A., *et al.* The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. *Eur Urol*, 2011. 60: 94.  
<https://www.ncbi.nlm.nih.gov/pubmed/21497434>
278. Kaplan, S.A., *et al.* Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. *Int J Clin Pract*, 2011. 65: 487.  
<https://www.ncbi.nlm.nih.gov/pubmed/21210910>
279. Kim, H.J., *et al.* Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. *PLoS One*, 2017. 12: e0169248.  
<https://www.ncbi.nlm.nih.gov/pubmed/28072862>
280. Van Kerrebroeck, P., *et al.* Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). *Eur Urol*, 2013. 64: 398.  
<https://www.ncbi.nlm.nih.gov/pubmed/23537687>
281. Drake, M.J., *et al.* Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: Results from the NEPTUNE study and NEPTUNE II open-label extension. *Eur Urol*, 2015. 67: 262.  
<https://www.ncbi.nlm.nih.gov/pubmed/25070148>
282. Drake, M.J., *et al.* Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin OCAS: results from the NEPTUNE study. *BJU Int*, 2015.  
<https://www.ncbi.nlm.nih.gov/pubmed/25907003>
283. Drake, M.J., *et al.* Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. *PLoS One*, 2017. 12: e0170726.  
<https://www.ncbi.nlm.nih.gov/pubmed/28166296>
284. Gong, M., *et al.* Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. *Curr Med Res Opin*, 2015. 31: 1781.  
<https://www.ncbi.nlm.nih.gov/pubmed/26211817>
285. Kaplan, S.A., *et al.* Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. *Eur Urol*, 2013. 63: 158.  
<https://www.ncbi.nlm.nih.gov/pubmed/22831853>
286. Speakman, M.J., *et al.* What Is the Required Certainty of Evidence for the Implementation of Novel Techniques for the Treatment of Benign Prostatic Obstruction? *Eur Urol Focus*, 2019. 5: 351.  
<https://www.ncbi.nlm.nih.gov/pubmed/31204291>
287. Issa, M.M. Technological advances in transurethral resection of the prostate: bipolar versus monopolar TURP. *J Endourol*, 2008. 22: 1587.  
<https://www.ncbi.nlm.nih.gov/pubmed/18721041>
288. Rassweiler, J., *et al.* Bipolar transurethral resection of the prostate--technical modifications and early clinical experience. *Minim Invasive Ther Allied Technol*, 2007. 16: 11.  
<https://www.ncbi.nlm.nih.gov/pubmed/17365673>
289. Cornu, J.N., *et al.* A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. *Eur Urol*, 2015. 67: 1066.  
<https://www.ncbi.nlm.nih.gov/pubmed/24972732>
290. Reich, O., *et al.* Techniques and long-term results of surgical procedures for BPH. *Eur Urol*, 2006. 49: 970.  
<https://www.ncbi.nlm.nih.gov/pubmed/16481092>
291. Madersbacher, S., *et al.* Is transurethral resection of the prostate still justified? *BJU Int*, 1999. 83: 227.  
<https://www.ncbi.nlm.nih.gov/pubmed/10233485>



292. Madersbacher, S., *et al.* Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. *Eur Urol*, 2005. 47: 499.  
<https://www.ncbi.nlm.nih.gov/pubmed/15774249>
293. Eredics, K., *et al.* Reoperation Rates and Mortality After Transurethral and Open Prostatectomy in a Long-term Nationwide Analysis: Have We Improved Over a Decade? *Urology*, 2018. 118: 152.  
<https://www.ncbi.nlm.nih.gov/pubmed/29733869>
294. Alexander, C.E., *et al.* Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. *Cochrane Database Syst Rev*, 2019. CD009629.  
<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009629.pub4/full>
295. Burke, N., *et al.* Systematic review and meta-analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction. *Urology*, 2010. 75: 1015.  
<https://www.ncbi.nlm.nih.gov/pubmed/19854492>
296. Mamoulakis, C., *et al.* Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. *Eur Urol*, 2009. 56: 798.  
<https://www.ncbi.nlm.nih.gov/pubmed/19595501>
297. Omar, M.I., *et al.* Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP). *BJU Int*, 2014. 113: 24.  
<https://www.ncbi.nlm.nih.gov/pubmed/24053602>
298. Inzunza, G., *et al.* Bipolar or monopolar transurethral resection for benign prostatic hyperplasia? *Medwave*, 2018. 18: e7134.  
<https://www.ncbi.nlm.nih.gov/pubmed/29351269>
299. Treharne, C., *et al.* Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review, Meta-analysis, and Cost-Consequence Model. *Eur Urol Focus*, 2016.  
<https://www.ncbi.nlm.nih.gov/pubmed/28753756>
300. Autorino, R., *et al.* Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. *Eur Urol*, 2009. 55: 922.  
<https://www.ncbi.nlm.nih.gov/pubmed/19185975>
301. Chen, Q., *et al.* Bipolar transurethral resection in saline vs traditional monopolar resection of the prostate: results of a randomized trial with a 2-year follow-up. *BJU Int*, 2010. 106: 1339.  
<https://www.ncbi.nlm.nih.gov/pubmed/20477825>
302. Fagerstrom, T., *et al.* Complications and clinical outcome 18 months after bipolar and monopolar transurethral resection of the prostate. *J Endourol*, 2011. 25: 1043.  
<https://www.ncbi.nlm.nih.gov/pubmed/21568691>
303. Geavlete, B., *et al.* Bipolar plasma vaporization vs monopolar and bipolar TURP-A prospective, randomized, long-term comparison. *Urology*, 2011. 78: 930.  
<https://www.ncbi.nlm.nih.gov/pubmed/21802121>
304. Giulianelli, R., *et al.* Comparative randomized study on the efficaciousness of endoscopic bipolar prostate resection versus monopolar resection technique. 3 year follow-up. *Arch Ital Urol Androl*, 2013. 85: 86.  
<https://www.ncbi.nlm.nih.gov/pubmed/23820656>
305. Mamoulakis, C., *et al.* Midterm results from an international multicentre randomised controlled trial comparing bipolar with monopolar transurethral resection of the prostate. *Eur Urol*, 2013. 63: 667.  
<https://www.ncbi.nlm.nih.gov/pubmed/23102675>
306. Xie, C.Y., *et al.* Five-year follow-up results of a randomized controlled trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. *Yonsei Med J*, 2012. 53: 734.  
<https://www.ncbi.nlm.nih.gov/pubmed/22665339>
307. Komura, K., *et al.* Incidence of urethral stricture after bipolar transurethral resection of the prostate using TURis: results from a randomised trial. *BJU Int*, 2015. 115: 644.  
<https://www.ncbi.nlm.nih.gov/pubmed/24909399>
308. Kumar, N., *et al.* Prospective Randomized Comparison of Monopolar TURP, Bipolar TURP and Photoselective Vaporization of the Prostate in Patients with Benign Prostatic Obstruction: 36 Months Outcome. *Low Urin Tract Symp*, 2018. 10: 17.  
<https://www.ncbi.nlm.nih.gov/pubmed/27168018>
309. National Institute for Health and Care Excellence. The TURis system for transurethral resection of the prostate. NICE GUIDelines, 2015.  
<https://www.nice.org.uk/guidance/mtg23>

310. Reich, O., *et al.* Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. *J Urol*, 2008. 180: 246.  
<https://www.ncbi.nlm.nih.gov/pubmed/18499179>
311. Rassweiler, J., *et al.* Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. *Eur Urol*, 2006. 50: 969.  
<https://www.ncbi.nlm.nih.gov/pubmed/16469429>
312. Stucki, P., *et al.* Bipolar versus monopolar transurethral resection of the prostate: a prospective randomized trial focusing on bleeding complications. *J Urol*, 2015. 193: 1371.  
<https://www.ncbi.nlm.nih.gov/pubmed/25464004>
313. Akman, T., *et al.* Effects of bipolar and monopolar transurethral resection of the prostate on urinary and erectile function: a prospective randomized comparative study. *BJU Int*, 2013. 111: 129.  
<https://www.ncbi.nlm.nih.gov/pubmed/22672229>
314. El-Assmy, A., *et al.* Erectile and ejaculatory functions changes following bipolar versus monopolar transurethral resection of the prostate: a prospective randomized study. *Int Urol Nephrol*, 2018. 50: 1569.  
<https://www.ncbi.nlm.nih.gov/pubmed/30083842>
315. Mamoulakis, C., *et al.* Bipolar vs monopolar transurethral resection of the prostate: evaluation of the impact on overall sexual function in an international randomized controlled trial setting. *BJU Int*, 2013. 112: 109.  
<https://www.ncbi.nlm.nih.gov/pubmed/23490008>
316. Riedinger, C.B., *et al.* The impact of surgical duration on complications after transurethral resection of the prostate: an analysis of NSQIP data. *Prostate Cancer Prostatic Dis*, 2019. 22: 303.  
<https://www.ncbi.nlm.nih.gov/pubmed/30385836>
317. Bach, T., *et al.* Laser treatment of benign prostatic obstruction: basics and physical differences. *Eur Urol*, 2012. 61: 317.  
<https://www.ncbi.nlm.nih.gov/pubmed/22033173>
318. Xia, S.J., *et al.* Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. *Eur Urol*, 2008. 53: 382.  
<https://www.ncbi.nlm.nih.gov/pubmed/17566639>
319. Jiang, H., *et al.* Safety and Efficacy of Thulium Laser Prostatectomy Versus Transurethral Resection of Prostate for Treatment of Benign Prostate Hyperplasia: A Meta-Analysis. *Low Urin Tract Symp*, 2016. 8: 165.  
<https://www.ncbi.nlm.nih.gov/pubmed/27619781>
320. Zhang, X., *et al.* Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysis. *Sci Rep*, 2016. 6: 23503.  
<https://www.ncbi.nlm.nih.gov/pubmed/27009501>
321. Zhu, Y., *et al.* Thulium laser versus standard transurethral resection of the prostate for benign prostatic obstruction: a systematic review and meta-analysis. *World J Urol*, 2015. 33: 509.  
<https://www.ncbi.nlm.nih.gov/pubmed/25298242>
322. Zhao, C., *et al.* Thulium Laser Resection Versus Plasmakinetic Resection of Prostates in the Treatment of Benign Prostate Hyperplasia: A Meta-Analysis. *J Laparoen Adv Surg Tech Part A*, 2016. 26: 789.  
<https://www.ncbi.nlm.nih.gov/pubmed/27500451>
323. Deng, Z., *et al.* Thulium laser VapoResection of the prostate versus traditional transurethral resection of the prostate or transurethral plasmakinetic resection of prostate for benign prostatic obstruction: a systematic review and meta-analysis. *World J Urol*, 2018. 36: 1355.  
<https://www.ncbi.nlm.nih.gov/pubmed/29651642>
324. Lan, Y., *et al.* Thulium (Tm:YAG) laser vaporesction of prostate and bipolar transurethral resection of prostate in patients with benign prostate hyperplasia: a systematic review and meta-analysis. *Lasers Med Sci*, 2018. 33: 1411.  
<https://www.ncbi.nlm.nih.gov/pubmed/29947009>
325. Cui, D., *et al.* A randomized trial comparing thulium laser resection to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: four-year follow-up results. *World J Urol*, 2014. 32: 683.  
<https://www.ncbi.nlm.nih.gov/pubmed/23913094>
326. Sun, F., *et al.* Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers. *World J Urol*, 2015. 33: 503.  
<https://www.ncbi.nlm.nih.gov/pubmed/25487702>

327. Yang, Z., *et al.* Thulium laser enucleation versus plasmakinetic resection of the prostate: a randomized prospective trial with 18-month follow-up. *Urology*, 2013. 81: 396.  
<https://www.ncbi.nlm.nih.gov/pubmed/23374815>
328. Wei, H., *et al.* Thulium laser resection versus plasmakinetic resection of prostates larger than 80 ml. *World J Urol*, 2014. 32: 1077.  
<https://www.ncbi.nlm.nih.gov/pubmed/24264126>
329. Sener, T.E., *et al.* Thulium laser vaporessection of the prostate: Can we operate without interrupting oral antiplatelet/ anticoagulant therapy? *Invest Clin Urol*, 2017. 58: 192.  
<https://www.ncbi.nlm.nih.gov/pubmed/28480345>
330. Bansal, A., *et al.* Holmium Laser vs Monopolar Electrocautery Bladder Neck Incision for Prostates Less Than 30 Grams: A Prospective Randomized Trial. *Urology*, 2016. 93: 158.  
<https://www.ncbi.nlm.nih.gov/pubmed/27058689>
331. Lourenco, T., *et al.* The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials. *World J Urol*, 2010. 28: 23.  
<https://www.ncbi.nlm.nih.gov/pubmed/20033744>
332. Kuntz, R.M., *et al.* Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. *Eur Urol*, 2008. 53: 160.  
<https://www.ncbi.nlm.nih.gov/pubmed/17869409>
333. Naspro, R., *et al.* Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. *Eur Urol*, 2006. 50: 563.  
<https://www.ncbi.nlm.nih.gov/pubmed/16713070>
334. Skolarikos, A., *et al.* Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. *J Endourol*, 2008. 22: 2333.  
<https://www.ncbi.nlm.nih.gov/pubmed/18837655>
335. Varkarakis, I., *et al.* Long-term results of open transvesical prostatectomy from a contemporary series of patients. *Urology*, 2004. 64: 306.  
<https://www.ncbi.nlm.nih.gov/pubmed/15302484>
336. Gratzke, C., *et al.* Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. *J Urol*, 2007. 177: 1419.  
<https://www.ncbi.nlm.nih.gov/pubmed/17382744>
337. Chen, S., *et al.* Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: a randomized noninferiority controlled trial with long-term results at 6 years. *Eur Urol*, 2014. 66: 284.  
<https://www.ncbi.nlm.nih.gov/pubmed/24502959>
338. Li, M., *et al.* Endoscopic enucleation versus open prostatectomy for treating large benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. *PLoS One*, 2015. 10: e0121265.  
<https://www.ncbi.nlm.nih.gov/pubmed/25826453>
339. Lin, Y., *et al.* Transurethral enucleation of the prostate versus transvesical open prostatectomy for large benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. *World J Urol*, 2016. 34: 1207.  
<https://www.ncbi.nlm.nih.gov/pubmed/26699627>
340. Ou, R., *et al.* Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes >80 mL: a prospective randomized study. *BJU Int*, 2013. 112: 239.  
<https://www.ncbi.nlm.nih.gov/pubmed/23795788>
341. Rao, J.M., *et al.* Plasmakinetic enucleation of the prostate versus transvesical open prostatectomy for benign prostatic hyperplasia >80 mL: 12-month follow-up results of a randomized clinical trial. *Urology*, 2013. 82: 176.  
<https://www.ncbi.nlm.nih.gov/pubmed/23601443>
342. Geavlete, B., *et al.* Bipolar vaporization, resection, and enucleation versus open prostatectomy: optimal treatment alternatives in large prostate cases? *J Endourol*, 2015. 29: 323.  
<https://www.ncbi.nlm.nih.gov/pubmed/25111385>
343. Geavlete, B., *et al.* Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison. *BJU Int*, 2013. 111: 793.  
<https://www.ncbi.nlm.nih.gov/pubmed/23469933>

344. Salonia, A., *et al.* Holmium laser enucleation versus open prostatectomy for benign prostatic hyperplasia: an inpatient cost analysis. *Urology*, 2006. 68: 302.  
<https://www.ncbi.nlm.nih.gov/pubmed/16904441>
345. Zhang, Y., *et al.* [Transurethral holmium laser enucleation for prostate adenoma greater than 100 g]. *Zhonghua Nan Ke Xue*, 2007. 13: 1091.  
<https://www.ncbi.nlm.nih.gov/pubmed/18284057>
346. Tubaro, A., *et al.* A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. *J Urol*, 2001. 166: 172.  
<https://www.ncbi.nlm.nih.gov/pubmed/11435849>
347. Neill, M.G., *et al.* Randomized trial comparing holmium laser enucleation of prostate with plasmakinetic enucleation of prostate for treatment of benign prostatic hyperplasia. *Urology*, 2006. 68: 1020.  
<https://www.ncbi.nlm.nih.gov/pubmed/17095078>
348. Li, K., *et al.* A Novel Modification of Transurethral Enucleation and Resection of the Prostate in Patients With Prostate Glands Larger than 80 mL: Surgical Procedures and Clinical Outcomes. *Urology*, 2018. 113: 153.  
<https://www.ncbi.nlm.nih.gov/pubmed/29203184>
349. Zhao, Z., *et al.* A prospective, randomised trial comparing plasmakinetic enucleation to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: three-year follow-up results. *Eur Urol*, 2010. 58: 752.  
<https://www.ncbi.nlm.nih.gov/pubmed/20800340>
350. Zhang, K., *et al.* Plasmakinetic Vapor Enucleation of the Prostate with Button Electrode versus Plasmakinetic Resection of the Prostate for Benign Prostatic Enlargement >90 ml: Perioperative and 3-Month Follow-Up Results of a Prospective, Randomized Clinical Trial. *Urol Int*, 2015. 95: 260.  
<https://www.ncbi.nlm.nih.gov/pubmed/26044933>
351. Wang, Z., *et al.* A prospective, randomised trial comparing transurethral enucleation with bipolar system (TUEB) to monopolar resectoscope enucleation of the prostate for symptomatic benign prostatic hyperplasia. *Biomed Res*, 2017. 28.  
<https://www.alliedacademies.org/articles/a-prospective-randomised-trial-comparing-transurethral-enucleation-with-bipolar-system-tueb-to-monopolar-resectoscope-enucleation-.html>
352. Ran, L., *et al.* Comparison of fluid absorption between transurethral enucleation and transurethral resection for benign prostate hyperplasia. *Urol Int*, 2013. 91: 26.  
<https://www.ncbi.nlm.nih.gov/pubmed/23571450>
353. Luo, Y.H., *et al.* Plasmakinetic enucleation of the prostate vs plasmakinetic resection of the prostate for benign prostatic hyperplasia: comparison of outcomes according to prostate size in 310 patients. *Urology*, 2014. 84: 904.  
<https://www.ncbi.nlm.nih.gov/pubmed/25150180>
354. Zhu, L., *et al.* Electrosurgical enucleation versus bipolar transurethral resection for prostates larger than 70 ml: a prospective, randomized trial with 5-year followup. *J Urol*, 2013. 189: 1427.  
<https://www.ncbi.nlm.nih.gov/pubmed/23123549>
355. Zhang, Y., *et al.* Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. *Prostate Cancer Prostatic Dis*, 2019.  
<https://www.ncbi.nlm.nih.gov/pubmed/30816336>
356. Gilling, P.J., *et al.* Combination holmium and Nd:YAG laser ablation of the prostate: initial clinical experience. *J Endourol*, 1995. 9: 151.  
<https://www.ncbi.nlm.nih.gov/pubmed/7633476>
357. Tan, A., *et al.* Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. *Br J Surg*, 2007. 94: 1201.  
<https://www.ncbi.nlm.nih.gov/pubmed/17729384>
358. Yin, L., *et al.* Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. *J Endourol*, 2013. 27: 604.  
<https://www.ncbi.nlm.nih.gov/pubmed/23167266>
359. Qian, X., *et al.* Functional outcomes and complications following B-TURP versus HoLEP for the treatment of benign prostatic hyperplasia: a review of the literature and Meta-analysis. *Aging Male*, 2017. 20: 184.  
<https://www.ncbi.nlm.nih.gov/pubmed/28368238>

360. Gilling, P.J., *et al.* Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. *BJU Int*, 2012. 109: 408.  
<https://www.ncbi.nlm.nih.gov/pubmed/21883820>
361. Chen, Y.B., *et al.* A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup. *J Urol*, 2013. 189: 217.  
<https://www.ncbi.nlm.nih.gov/pubmed/23174256>
362. Gu, M., *et al.* Comparison of Holmium Laser Enucleation and Plasmakinetic Resection of Prostate: A Randomized Trial with 72-Month Follow-Up. *J Endourol*, 2018. 32: 139.  
<https://www.ncbi.nlm.nih.gov/pubmed/29239228>
363. Lourenco, T., *et al.* Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials. *Bmj*, 2008. 337: a449.  
<https://www.ncbi.nlm.nih.gov/pubmed/18595932>
364. El Tayeb, M.M., *et al.* Holmium Laser Enucleation of the Prostate in Patients Requiring Anticoagulation. *J Endourol*, 2016. 30: 805.  
<https://www.ncbi.nlm.nih.gov/pubmed/27065437>
365. Sun, J., *et al.* Safety and feasibility study of holmium laser enucleation of the prostate (HoLEP) on patients receiving dual antiplatelet therapy (DAPT). *World J Urol*, 2018. 36: 271.  
<https://www.ncbi.nlm.nih.gov/pubmed/29138929>
366. Briganti, A., *et al.* Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial. *J Urol*, 2006. 175: 1817.  
<https://www.ncbi.nlm.nih.gov/pubmed/16600770>
367. Li, Z., *et al.* The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function: A systematic review and network meta-analysis. *Medicine (Baltimore)*, 2016. 95: e3862.  
<https://www.ncbi.nlm.nih.gov/pubmed/27310968>
368. Elshal, A.M., *et al.* Prospective controlled assessment of men's sexual function changes following Holmium laser enucleation of the prostate for treatment of benign prostate hyperplasia. *Int Urol Nephrol*, 2017. 49: 1741.  
<https://www.ncbi.nlm.nih.gov/pubmed/28780626>
369. Kim, M., *et al.* Pilot study of the clinical efficacy of ejaculatory hood sparing technique for ejaculation preservation in Holmium laser enucleation of the prostate. *Int J Impot Res*, 2015. 27: 20.  
<https://www.ncbi.nlm.nih.gov/pubmed/25007827>
370. Elzayat, E.A., *et al.* Holmium laser enucleation of the prostate (HoLEP): long-term results, reoperation rate, and possible impact of the learning curve. *Eur Urol*, 2007. 52: 1465.  
<https://www.ncbi.nlm.nih.gov/pubmed/17498867>
371. Du, C., *et al.* Holmium laser enucleation of the prostate: the safety, efficacy, and learning experience in China. *J Endourol*, 2008. 22: 1031.  
<https://www.ncbi.nlm.nih.gov/pubmed/18377236>
372. Robert, G., *et al.* Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP). *BJU Int*, 2016. 117: 495.  
<https://www.ncbi.nlm.nih.gov/pubmed/25781490>
373. Aho, T., *et al.* Description of a modular mentorship programme for holmium laser enucleation of the prostate. *World J Urol*, 2015. 33: 497.  
<https://www.ncbi.nlm.nih.gov/pubmed/25271105>
374. Enikeev, D., *et al.* A Randomized Trial Comparing The Learning Curve of 3 Endoscopic Enucleation Techniques (HoLEP, ThuFLEP, and MEP) for BPH Using Mentoring Approach-Initial Results. *Urology*, 2018. 121: 51.  
<https://www.ncbi.nlm.nih.gov/pubmed/30053397>
375. Yang, Z., *et al.* Comparison of thulium laser enucleation and plasmakinetic resection of the prostate in a randomized prospective trial with 5-year follow-up. *Lasers Med Sci*, 2016. 31: 1797.  
<https://www.ncbi.nlm.nih.gov/pubmed/27677474>
376. Xiao, K.W., *et al.* Enucleation of the prostate for benign prostatic hyperplasia thulium laser versus holmium laser: a systematic review and meta-analysis. *Lasers Med Sci*, 2019.  
<https://www.ncbi.nlm.nih.gov/pubmed/30604345>
377. Zhang, F., *et al.* Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center. *Urology*, 2012. 79: 869.  
<https://www.ncbi.nlm.nih.gov/pubmed/22342411>



378. Feng, L., *et al.* Thulium Laser Enucleation Versus Plasmakinetic Enucleation of the Prostate: A Randomized Trial of a Single Center. *J Endourol*, 2016. 30: 665.  
<https://www.ncbi.nlm.nih.gov/pubmed/26886719>
379. Bach, T., *et al.* Thulium:YAG vapoenucleation in large volume prostates. *J Urol*, 2011. 186: 2323.  
<https://www.ncbi.nlm.nih.gov/pubmed/22014812>
380. Hauser, S., *et al.* Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage. *Urol Int*, 2012. 88: 390.  
<https://www.ncbi.nlm.nih.gov/pubmed/22627127>
381. Netsch, C., *et al.* Comparison of 120-200 W 2 mum thulium:yttrium-aluminum-garnet vapoenucleation of the prostate. *J Endourol*, 2012. 26: 224.  
<https://www.ncbi.nlm.nih.gov/pubmed/22191688>
382. Netsch, C., *et al.* 120-W 2-microm thulium:yttrium-aluminium-garnet vapoenucleation of the prostate: 12-month follow-up. *BJU Int*, 2012. 110: 96.  
<https://www.ncbi.nlm.nih.gov/pubmed/22085294>
383. Chang, C.H., *et al.* Vapoenucleation of the prostate using a high-power thulium laser: a one-year follow-up study. *BMC Urol*, 2015. 15: 40.  
<https://www.ncbi.nlm.nih.gov/pubmed/25956819>
384. Netsch, C., *et al.* Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. *World J Urol*, 2014. 32: 165.  
<https://www.ncbi.nlm.nih.gov/pubmed/23657354>
385. Gross, A.J., *et al.* Complications and early postoperative outcome in 1080 patients after thulium vapoenucleation of the prostate: results at a single institution. *Eur Urol*, 2013. 63: 859.  
<https://www.ncbi.nlm.nih.gov/pubmed/23245687>
386. Tiburtius, C., *et al.* Impact of thulium VapoEnucleation of the prostate on erectile function: a prospective analysis of 72 patients at 12-month follow-up. *Urology*, 2014. 83: 175.  
<https://www.ncbi.nlm.nih.gov/pubmed/24103563>
387. Wang, Y., *et al.* Impact of 120-W 2-mum continuous wave laser vapoenucleation of the prostate on sexual function. *Lasers Med Sci*, 2014. 29: 689.  
<https://www.ncbi.nlm.nih.gov/pubmed/23828495>
388. Lusuardi, L., *et al.* Safety and efficacy of Eraser laser enucleation of the prostate: preliminary report. *J Urol*, 2011. 186: 1967.  
<https://www.ncbi.nlm.nih.gov/pubmed/21944122>
389. Zhang, J., *et al.* 1470 nm Diode Laser Enucleation vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia: A Randomized Study. *J Endourol*, 2019. 33: 211.  
<https://www.ncbi.nlm.nih.gov/pubmed/30489151>
390. Zou, Z., *et al.* Dual-centre randomized-controlled trial comparing transurethral endoscopic enucleation of the prostate using diode laser vs. bipolar plasmakinetic for the treatment of LUTS secondary of benign prostate obstruction: 1-year follow-up results. *World J Urol*, 2018.  
<https://www.ncbi.nlm.nih.gov/pubmed/29459994>
391. Xu, A., *et al.* A randomized trial comparing diode laser enucleation of the prostate with plasmakinetic enucleation and resection of the prostate for the treatment of benign prostatic hyperplasia. *J Endourol*, 2013. 27: 1254.  
<https://www.ncbi.nlm.nih.gov/pubmed/23879477>
392. Wu, G., *et al.* A comparative study of diode laser and plasmakinetic in transurethral enucleation of the prostate for treating large volume benign prostatic hyperplasia: a randomized clinical trial with 12-month follow-up. *Lasers Med Sci*, 2016. 31: 599.  
<https://www.ncbi.nlm.nih.gov/pubmed/26822403>
393. Mariano, M.B., *et al.* Laparoscopic prostatectomy with vascular control for benign prostatic hyperplasia. *J Urol*, 2002. 167: 2528.  
<https://www.ncbi.nlm.nih.gov/pubmed/11992078>
394. Sotelo, R., *et al.* Robotic simple prostatectomy. *J Urol*, 2008. 179: 513.  
<https://www.ncbi.nlm.nih.gov/pubmed/18076926>
395. Lucca, I., *et al.* Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. *World J Urol*, 2015. 33: 563.  
<https://www.ncbi.nlm.nih.gov/pubmed/24879405>
396. Autorino, R., *et al.* Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. *Eur Urol*, 2015. 68: 86.  
<https://www.ncbi.nlm.nih.gov/pubmed/25484140>

397. Pokorny, M., *et al.* Robot-assisted Simple Prostatectomy for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Enlargement: Surgical Technique and Outcomes in a High-volume Robotic Centre. *Eur Urol*, 2015. 68: 451.  
<https://www.ncbi.nlm.nih.gov/pubmed/25887786>
398. Sorokin, I., *et al.* Robot-Assisted Versus Open Simple Prostatectomy for Benign Prostatic Hyperplasia in Large Glands: A Propensity Score-Matched Comparison of Perioperative and Short-Term Outcomes. *J Endourol*, 2017. 31: 1164.  
<https://www.ncbi.nlm.nih.gov/pubmed/28854815>
399. Stoddard, M.D., *et al.* Standardization of 532 nm Laser Terminology for Surgery in Benign Prostatic Hyperplasia: A Systematic Review. *J Endourol*, 2020. 34: 121.  
<https://www.ncbi.nlm.nih.gov/pubmed/31880953>
400. Gomez Sancha, F., *et al.* Common trend: move to enucleation-Is there a case for GreenLight enucleation? Development and description of the technique. *World J Urol*, 2015. 33: 539.  
<https://www.ncbi.nlm.nih.gov/pubmed/24929643>
401. Law, K.W., *et al.* Anatomic GreenLight laser vaporization-incision technique for benign prostatic hyperplasia using the XPS LBO-180W system: How I do it. *Can J Urol*, 2019. 26: 9963.  
<https://www.ncbi.nlm.nih.gov/pubmed/31629449>
402. Brunken, C., *et al.* Transurethral GreenLight laser enucleation of the prostate--a feasibility study. *J Endourol*, 2011. 25: 1199.  
<https://www.ncbi.nlm.nih.gov/pubmed/21612434>
403. Elshal, A.M., *et al.* Prospective Assessment of Learning Curve of Holmium Laser Enucleation of the Prostate for Treatment of Benign Prostatic Hyperplasia Using a Multidimensional Approach. *J Urol*, 2017. 197: 1099.  
<https://www.ncbi.nlm.nih.gov/pubmed/27825972>
404. Botto, H., *et al.* Electrovaporization of the prostate with the Gyrus device. *J Endourol*, 2001. 15: 313.  
<https://www.ncbi.nlm.nih.gov/pubmed/11339400>
405. Bucuras, V., *et al.* Bipolar vaporization of the prostate: Is it ready for the primetime? *Ther Adv Urol*, 2011. 3: 257.  
<https://www.ncbi.nlm.nih.gov/pubmed/22164195>
406. Reich, O., *et al.* Plasma Vaporisation of the Prostate: Initial Clinical Results. *Eur Urol*, 2010. 57: 693.  
<https://www.ncbi.nlm.nih.gov/pubmed/19482414>
407. Reich, O., *et al.* In vitro comparison of transurethral vaporization of the prostate (TUVP), resection of the prostate (TURP), and vaporization-resection of the prostate (TUVRP). *Urol Res*, 2002. 30: 15.  
<https://www.ncbi.nlm.nih.gov/pubmed/11942320>
408. Gallucci, M., *et al.* Transurethral electrovaporization of the prostate vs. transurethral resection. Results of a multicentric, randomized clinical study on 150 patients. *Eur Urol*, 1998. 33: 359.  
<https://www.ncbi.nlm.nih.gov/pubmed/9612677>
409. Poulakis, V., *et al.* Transurethral electrovaporization vs transurethral resection for symptomatic prostatic obstruction: a meta-analysis. *BJU Int*, 2004. 94: 89.  
<https://www.ncbi.nlm.nih.gov/pubmed/15217438>
410. Dunsmuir, W.D., *et al.* Gyrus bipolar electrovaporization vs transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up. *Prostate Cancer Prostatic Dis*, 2003. 6: 182.  
<https://www.ncbi.nlm.nih.gov/pubmed/12806380>
411. Fung, B.T., *et al.* Prospective randomized controlled trial comparing plasmakinetic vaporessection and conventional transurethral resection of the prostate. *Asian J Surg*, 2005. 28: 24.  
<https://www.ncbi.nlm.nih.gov/pubmed/15691793>
412. Karaman, M.I., *et al.* Comparison of transurethral vaporization using PlasmaKinetic energy and transurethral resection of prostate: 1-year follow-up. *J Endourol*, 2005. 19: 734.  
<https://www.ncbi.nlm.nih.gov/pubmed/16053367>
413. Hon, N.H., *et al.* A prospective, randomized trial comparing conventional transurethral prostate resection with PlasmaKinetic vaporization of the prostate: physiological changes, early complications and long-term followup. *J Urol*, 2006. 176: 205.  
<https://www.ncbi.nlm.nih.gov/pubmed/16753403>
414. Kaya, C., *et al.* The long-term results of transurethral vaporization of the prostate using plasmakinetic energy. *BJU Int*, 2007. 99: 845.  
<https://www.ncbi.nlm.nih.gov/pubmed/17378844>

415. Geavlete, B., *et al.* Transurethral resection (TUR) in saline plasma vaporization of the prostate vs standard TUR of the prostate: 'the better choice' in benign prostatic hyperplasia? *BJU Int*, 2010. 106: 1695.  
<https://www.ncbi.nlm.nih.gov/pubmed/20518763>
416. Nuhoglu, B., *et al.* The role of bipolar transurethral vaporization in the management of benign prostatic hyperplasia. *Urol Int*, 2011. 87: 400.  
<https://www.ncbi.nlm.nih.gov/pubmed/22086154>
417. Zhang, S.Y., *et al.* Efficacy and safety of bipolar plasma vaporization of the prostate with "button-type" electrode compared with transurethral resection of prostate for benign prostatic hyperplasia. *Chin Med J (Engl)*, 2012. 125: 3811.  
<https://www.ncbi.nlm.nih.gov/pubmed/23106879>
418. Falahatkar, S., *et al.* Bipolar transurethral vaporization: a superior procedure in benign prostatic hyperplasia: a prospective randomized comparison with bipolar TURP. *Int Braz J Urol*, 2014. 40: 346.  
<https://www.ncbi.nlm.nih.gov/pubmed/25010300>
419. Geavlete, B., *et al.* Continuous vs conventional bipolar plasma vaporisation of the prostate and standard monopolar resection: A prospective, randomised comparison of a new technological advance. *BJU Int*, 2014. 113: 288.  
<https://www.ncbi.nlm.nih.gov/pubmed/24053794>
420. Yip, S.K., *et al.* A randomized controlled trial comparing the efficacy of hybrid bipolar transurethral vaporization and resection of the prostate with bipolar transurethral resection of the prostate. *J Endourol*, 2011. 25: 1889.  
<https://www.ncbi.nlm.nih.gov/pubmed/21923418>
421. Elsakka, A.M., *et al.* A prospective randomised controlled study comparing bipolar plasma vaporisation of the prostate to monopolar transurethral resection of the prostate. *Arab J Urol*, 2016. 14: 280.  
<https://www.ncbi.nlm.nih.gov/pubmed/27900218>
422. Lee, S.W., *et al.* Transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement: A quality and meta-analysis. *Int Neurourol J*, 2013. 17: 59.  
<https://www.ncbi.nlm.nih.gov/pubmed/23869269>
423. Wroclawski, M.L., *et al.* 'Button type' bipolar plasma vaporisation of the prostate compared with standard transurethral resection: A systematic review and meta-analysis of short-term outcome studies. *BJU Int*, 2016. 117: 662.  
<https://www.ncbi.nlm.nih.gov/pubmed/26299915>
424. Robert, G., *et al.* Bipolar plasma vaporization of the prostate: ready to replace GreenLight? A systematic review of randomized control trials. *World J Urol*, 2015. 33: 549.  
<https://www.ncbi.nlm.nih.gov/pubmed/25159871>
425. Thangasamy, I.A., *et al.* Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012. *Eur Urol*, 2012. 62: 315.  
<https://www.ncbi.nlm.nih.gov/pubmed/22575913>
426. Bouchier-Hayes, D.M., *et al.* A randomized trial of photoselective vaporization of the prostate using the 80-W potassium-titanyl-phosphate laser vs transurethral prostatectomy, with a 1-year follow-up. *BJU Int*, 2010. 105: 964.  
<https://www.ncbi.nlm.nih.gov/pubmed/19912196>
427. Capitan, C., *et al.* GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up. *Eur Urol*, 2011. 60: 734.  
<https://www.ncbi.nlm.nih.gov/pubmed/21658839>
428. Skolarikos, A., *et al.*, 80W PVP versus TURP: results of a randomized prospective study at 12 months of follow-up., in Abstract presented at: American Urological Association annual meeting. 2008: Orlando, FL, USA.
429. Zhou, Y., *et al.* Greenlight high-performance system (HPS) 120-W laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a meta-analysis of the published results of randomized controlled trials. *Lasers Med Sci*, 2016. 31: 485.  
<https://www.ncbi.nlm.nih.gov/pubmed/26868032>
430. Thomas, J.A., *et al.* A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. *Eur Urol*, 2016. 69: 94.  
<https://www.ncbi.nlm.nih.gov/pubmed/26283011>

431. Al-Ansari, A., *et al.* GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. *Eur Urol*, 2010. 58: 349.  
<https://www.ncbi.nlm.nih.gov/pubmed/20605316>
432. Pereira-Correia, J.A., *et al.* GreenLight HPS 120-W laser vaporization vs transurethral resection of the prostate (<60 mL): a 2-year randomized double-blind prospective urodynamic investigation. *BJU Int*, 2012. 110: 1184.  
<https://www.ncbi.nlm.nih.gov/pubmed/22257240>
433. Kang, D.H., *et al.* A Systematic Review and Meta-Analysis of Functional Outcomes and Complications Following the Photoselective Vaporization of the Prostate and Monopolar Transurethral Resection of the Prostate. *World J Men's Health*, 2016. 34: 110.  
<https://www.ncbi.nlm.nih.gov/pubmed/27574594>
434. Elmansy, H., *et al.* Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60 ml: preliminary results of a prospective, randomized clinical trial. *J Urol*, 2012. 188: 216.  
<https://www.ncbi.nlm.nih.gov/pubmed/22591968>
435. Chung, D.E., *et al.* Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. *J Urol*, 2011. 186: 977.  
<https://www.ncbi.nlm.nih.gov/pubmed/21791350>
436. Reich, O., *et al.* High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. *J Urol*, 2005. 173: 158.  
<https://www.ncbi.nlm.nih.gov/pubmed/15592063>
437. Ruszat, R., *et al.* Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. *Eur Urol*, 2007. 51: 1031.  
<https://www.ncbi.nlm.nih.gov/pubmed/16945475>
438. Sandhu, J.S., *et al.* Photoselective laser vaporization prostatectomy in men receiving anticoagulants. *J Endourol*, 2005. 19: 1196.  
<https://www.ncbi.nlm.nih.gov/pubmed/16359214>
439. Lee, D.J., *et al.* Laser Vaporization of the Prostate With the 180-W XPS-Greenlight Laser in Patients With Ongoing Platelet Aggregation Inhibition and Oral Anticoagulation. *Urology*, 2016. 91: 167.  
<https://www.ncbi.nlm.nih.gov/pubmed/26829717>
440. Jackson, R.E., *et al.* Risk factors for delayed hematuria following photoselective vaporization of the prostate. *J Urol*, 2013. 190: 903.  
<https://www.ncbi.nlm.nih.gov/pubmed/23538242>
441. Knapp, G.L., *et al.* Perioperative adverse events in patients on continued anticoagulation undergoing photoselective vaporisation of the prostate with the 180-W Greenlight lithium triborate laser. *BJU Int*, 2017. 119: 33.  
<https://www.ncbi.nlm.nih.gov/pubmed/28544292>
442. Woo, H., *et al.* Outcome of GreenLight HPS 120-W laser therapy in specific patient populations: those in retention, on anticoagulants, and with large prostates (>80 ml). *Eur Urol Suppl* 2008. 7: 378.  
<https://www.sciencedirect.com/science/article/abs/pii/S1569905608000274>
443. Rajbabu, K., *et al.* Photoselective vaporization of the prostate with the potassium-titanyl-phosphate laser in men with prostates of >100 mL. *BJU Int*, 2007. 100: 593.  
<https://www.ncbi.nlm.nih.gov/pubmed/17511771>
444. Ruszat, R., *et al.* Photoselective vaporization of the prostate: subgroup analysis of men with refractory urinary retention. *Eur Urol*, 2006. 50: 1040.  
<https://www.ncbi.nlm.nih.gov/pubmed/16481099>
445. Horasanli, K., *et al.* Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial. *Urology*, 2008. 71: 247.  
<https://www.ncbi.nlm.nih.gov/pubmed/18308094>
446. Alivizatos, G., *et al.* Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study. *Eur Urol*, 2008. 54: 427.  
<https://www.ncbi.nlm.nih.gov/pubmed/18069117>
447. Bouchier-Hayes, D.M., *et al.* KTP laser versus transurethral resection: early results of a randomized trial. *J Endourol*, 2006. 20: 580.  
<https://www.ncbi.nlm.nih.gov/pubmed/16903819>
448. Bruyere, F., *et al.* Influence of photoselective vaporization of the prostate on sexual function: results of a prospective analysis of 149 patients with long-term follow-up. *Eur Urol*, 2010. 58: 207.  
<https://www.ncbi.nlm.nih.gov/pubmed/20466480>

449. Razzaghi, M.R., *et al.* Diode laser (980 nm) vaporization in comparison with transurethral resection of the prostate for benign prostatic hyperplasia: randomized clinical trial with 2-year follow-up. *Urology*, 2014. 84: 526.  
<https://www.ncbi.nlm.nih.gov/pubmed/25168526>
450. Cetinkaya, M., *et al.* 980-Nm Diode Laser Vaporization versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Randomized Controlled Study. *Urol J*, 2015. 12: 2355.  
<https://www.ncbi.nlm.nih.gov/pubmed/26571321>
451. Chiang, P.H., *et al.* GreenLight HPS laser 120-W versus diode laser 200-W vaporization of the prostate: comparative clinical experience. *Lasers Surg Med*, 2010. 42: 624.  
<https://www.ncbi.nlm.nih.gov/pubmed/20806388>
452. Ruszat, R., *et al.* Prospective single-centre comparison of 120-W diode-pumped solid-state high-intensity system laser vaporization of the prostate and 200-W high-intensive diode-laser ablation of the prostate for treating benign prostatic hyperplasia. *BJU Int*, 2009. 104: 820.  
<https://www.ncbi.nlm.nih.gov/pubmed/19239441>
453. Seitz, M., *et al.* The diode laser: a novel side-firing approach for laser vaporisation of the human prostate--immediate efficacy and 1-year follow-up. *Eur Urol*, 2007. 52: 1717.  
<https://www.ncbi.nlm.nih.gov/pubmed/17628326>
454. Shaker, H.S., *et al.* Quartz head contact laser fiber: a novel fiber for laser ablation of the prostate using the 980 nm high power diode laser. *J Urol*, 2012. 187: 575.  
<https://www.ncbi.nlm.nih.gov/pubmed/22177175>
455. MacRae, C., *et al.* How I do it: Aquablation of the prostate using the AQUABEAM system. *Can J Urol*, 2016. 23: 8590.  
<https://www.ncbi.nlm.nih.gov/pubmed/27995858>
456. Gilling, P., *et al.* WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. *J Urol*, 2018. 199: 1252.  
<https://www.ncbi.nlm.nih.gov/pubmed/29360529>
457. Kasivisvanathan, V., *et al.* Aquablation versus transurethral resection of the prostate: 1 year United States - cohort outcomes. *Can J Urol*, 2018. 25: 9317.  
<https://www.ncbi.nlm.nih.gov/pubmed/29900819>
458. Gilling, P.J., *et al.* Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes. *Urology*, 2019. 125: 169.  
<https://www.ncbi.nlm.nih.gov/pubmed/30552937>
459. Plante, M., *et al.* Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. *BJU Int*, 2019. 123: 651.  
<https://www.ncbi.nlm.nih.gov/pubmed/29862630>
460. Desai, M., *et al.* Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial. *BJU Int*, 2019.  
<https://www.ncbi.nlm.nih.gov/pubmed/30734990>
461. Pimentel, M.A., *et al.* Urodynamic Outcomes After Aquablation. *Urology*, 2019.  
<https://www.ncbi.nlm.nih.gov/pubmed/30721737>
462. Abt, D., *et al.* Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. *BMJ*, 2018. 361: k2338.  
<https://www.ncbi.nlm.nih.gov/pubmed/29921613>
463. Zhang, J.L., *et al.* Effectiveness of Contrast-enhanced MR Angiography for Visualization of the Prostatic Artery prior to Prostatic Arterial Embolization. *Radiology*, 2019: 181524.  
<https://www.ncbi.nlm.nih.gov/pubmed/30806596>
464. Gao, Y.A., *et al.* Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate--a prospective, randomized, and controlled clinical trial. *Radiology*, 2014. 270: 920.  
<https://www.ncbi.nlm.nih.gov/pubmed/24475799>
465. Carnevale, F.C., *et al.* Transurethral Resection of the Prostate (TURP) Versus Original and PERFeCTED Prostate Artery Embolization (PAE) Due to Benign Prostatic Hyperplasia (BPH): Preliminary Results of a Single Center, Prospective, Urodynamic-Controlled Analysis. *Cardiovasc Intervent Radiol*, 2016. 39: 44.  
<https://www.ncbi.nlm.nih.gov/pubmed/26506952>
466. Zumstein, V., *et al.* Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. *Eur Urol Focus*, 2018.  
<https://www.ncbi.nlm.nih.gov/pubmed/30292422>



467. Shim, S.R., *et al.* Efficacy and Safety of Prostatic Arterial Embolization: Systematic Review with Meta-Analysis and Meta-Regression. *J Urol*, 2017. 197: 465.  
<https://www.ncbi.nlm.nih.gov/pubmed/27592008>
468. Jiang, Y.L., *et al.* Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: A meta-analysis. *BMC Urol*, 2019. 19: 11.  
<https://www.ncbi.nlm.nih.gov/pubmed/30691478>
469. Moreira, A.M., *et al.* A Review of Adverse Events Related to Prostatic Artery Embolization for Treatment of Bladder Outlet Obstruction Due to BPH. *Cardiovasc Intervent Radiol*, 2017. 40: 1490.  
<https://www.ncbi.nlm.nih.gov/pubmed/28795212>
470. Ray, A.F., *et al.* Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). *BJU Int*, 2018. 122: 270.  
<https://www.ncbi.nlm.nih.gov/pubmed/29645352>
471. National Institute for Health and Care Excellence. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE GUidelines, 2018.  
<https://www.nice.org.uk/guidance/ipg611>
472. McVary, K.T., *et al.* Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study. *J Sex Med*, 2016. 13: 924.  
<https://www.ncbi.nlm.nih.gov/pubmed/27129767>
473. Roehrborn, C.G., *et al.* Convective Thermal Therapy: Durable 2-Year Results of Randomized Controlled and Prospective Crossover Studies for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. *J Urol*, 2017. 197: 1507.  
<https://www.ncbi.nlm.nih.gov/pubmed/27993667>
474. McVary, K.T., *et al.* Rezum Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study. *Urology*, 2019. 126: 171.  
<https://www.ncbi.nlm.nih.gov/pubmed/30677455>
475. Chin, P.T., *et al.* Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urology*, 2012. 79: 5.  
<https://www.ncbi.nlm.nih.gov/pubmed/22202539>
476. McNicholas, T.A., *et al.* Minimally invasive prostatic urethral lift: surgical technique and multinational experience. *Eur Urol*, 2013. 64: 292.  
<https://www.ncbi.nlm.nih.gov/pubmed/23357348>
477. Roehrborn, C.G., *et al.* The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. *J Urol*, 2013. 190: 2161.  
<https://www.ncbi.nlm.nih.gov/pubmed/23764081>
478. Woo, H.H., *et al.* Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). *BJU Int*, 2011. 108: 82.  
<https://www.ncbi.nlm.nih.gov/pubmed/21554526>
479. Woo, H.H., *et al.* Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Sex Med*, 2012. 9: 568.  
<https://www.ncbi.nlm.nih.gov/pubmed/22172161>
480. Perera, M., *et al.* Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. *Eur Urol*, 2015. 67: 704.  
<https://www.ncbi.nlm.nih.gov/pubmed/25466940>
481. Roehrborn, C.G., *et al.* Three year results of the prostatic urethral L.I.F.T. study. *Can J Urol*, 2015. 22: 7772.  
<https://www.ncbi.nlm.nih.gov/pubmed/26068624>
482. Roehrborn, C.G., *et al.* Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol*, 2017. 24: 8802.  
<https://www.ncbi.nlm.nih.gov/pubmed/28646935>
483. Sonksen, J., *et al.* Prospective, Randomized, Multinational Study of Prostatic Urethral Lift Versus Transurethral Resection of the Prostate: 12-month Results from the BPH6 Study. *Eur Urol*, 2015. 68: 643.  
<https://www.ncbi.nlm.nih.gov/pubmed/25937539>

484. Gratzke, C., *et al.* Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. *BJU Int*, 2017. 119: 767.  
<https://www.ncbi.nlm.nih.gov/pubmed/27862831>
485. Rukstalis, D., *et al.* Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. *Prostate Cancer Prostatic Dis*, 2019. 22: 411.  
<https://www.ncbi.nlm.nih.gov/pubmed/30542055>
486. Magistro, G., *et al.* New intraprostatic injectables and prostatic urethral lift for male LUTS. *Nat Rev Urol*, 2015. 12: 461.  
<https://www.ncbi.nlm.nih.gov/pubmed/26195444>
487. Marberger, M., *et al.* A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. *Eur Urol*, 2013. 63: 496.  
<https://www.ncbi.nlm.nih.gov/pubmed/23098762>
488. McVary, K.T., *et al.* A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. *J Urol*, 2014. 192: 150.  
<https://www.ncbi.nlm.nih.gov/pubmed/24508634>
489. Shim, S.R., *et al.* Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis. *Int Urol Nephrol*, 2016. 48: 19.  
<https://www.ncbi.nlm.nih.gov/pubmed/26560471>
490. Elhilali, M.M., *et al.* Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. *J Urol*, 2013. 189: 1421.  
<https://www.ncbi.nlm.nih.gov/pubmed/23142202>
491. Denmeade, S.R., *et al.* Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Eur Urol*, 2011. 59: 747.  
<https://www.ncbi.nlm.nih.gov/pubmed/21129846>
492. Shore, N., *et al.* Fexapotide trifluate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. *World J Urol*, 2018. 36: 801.  
<https://www.ncbi.nlm.nih.gov/pubmed/29380128>
493. Porpiglia, F., *et al.* Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. *BJU Int*, 2015. 116: 278.  
<https://www.ncbi.nlm.nih.gov/pubmed/25382816>
494. Porpiglia, F., *et al.* 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. *BJU Int*, 2018. 122: 106.  
<https://www.ncbi.nlm.nih.gov/pubmed/29359881>
495. Sakalis, V.I., *et al.* Medical Treatment of Nocturia in Men with Lower Urinary Tract Symptoms: Systematic Review by the European Association of Urology Guidelines Panel for Male Lower Urinary Tract Symptoms. *Eur Urol*, 2017. 72: 757.  
<https://www.ncbi.nlm.nih.gov/pubmed/28666669>
496. Marshall, S.D., *et al.* Nocturia: Current Levels of Evidence and Recommendations From the International Consultation on Male Lower Urinary Tract Symptoms. *Urology*, 2015.  
<https://www.ncbi.nlm.nih.gov/pubmed/25881866>
497. Cannon, A., *et al.* Desmopressin in the treatment of nocturnal polyuria in the male. *BJU Int*, 1999. 84: 20.  
<https://www.ncbi.nlm.nih.gov/pubmed/10444118>
498. Han, J., *et al.* Desmopressin for treating nocturia in men. *Cochrane Database Syst Rev*, 2017. 10: CD012059.  
<https://www.ncbi.nlm.nih.gov/pubmed/29055129>
499. Weiss, J.P., *et al.* Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. *J Urol*, 2013. 190: 965.  
<https://www.ncbi.nlm.nih.gov/pubmed/23454402>
500. Sand, P.K., *et al.* Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. *J Urol*, 2013. 190: 958.  
<https://www.ncbi.nlm.nih.gov/pubmed/23454404>

501. Juul, K.V., *et al.* Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia. *BJU Int*, 2017. 119: 776.  
<https://www.ncbi.nlm.nih.gov/pubmed/27862898>
502. Cohn, J.A., *et al.* Desmopressin acetate nasal spray for adults with nocturia. *Expert Rev Clin Pharmacol*, 2017. 10: 1281.  
<https://www.ncbi.nlm.nih.gov/pubmed/29048257>
503. Djavan, B., *et al.* The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: Preliminary results of a pilot study. *Eur Urol Suppl*, 2005. 4: 1119.  
[https://www.eu-openscience.europeanurology.com/article/S1569-9056\(04\)00127-7/fulltext](https://www.eu-openscience.europeanurology.com/article/S1569-9056(04)00127-7/fulltext)
504. Yokoyama, O., *et al.* Efficacy of fesoterodine on nocturia and quality of sleep in Asian patients with overactive bladder. *Urology*, 2014. 83: 750.  
<https://www.ncbi.nlm.nih.gov/pubmed/24518285>
505. Yokoyama, O., *et al.* Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. *J Urol*, 2011. 186: 170.  
<https://www.ncbi.nlm.nih.gov/pubmed/21575976>
506. Johnson, T.M., 2nd, *et al.* The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. *J Urol*, 2007. 178: 2045.  
<https://www.ncbi.nlm.nih.gov/pubmed/17869295>
507. Oelke, M., *et al.* Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies. *World J Urol*, 2014. 32: 1141.  
<https://www.ncbi.nlm.nih.gov/pubmed/24903347>
508. Oelke, M., *et al.* Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies. *World J Urol*, 2014. 32: 1127.  
<https://www.ncbi.nlm.nih.gov/pubmed/24504761>
509. Drake, M.J., *et al.* Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. *J Urol*, 2004. 171: 1199.  
<https://www.ncbi.nlm.nih.gov/pubmed/14767300>
510. Reynard, J.M., *et al.* A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. *Br J Urol*, 1998. 81: 215.  
<https://www.ncbi.nlm.nih.gov/pubmed/9488061>
511. Falahatkar, S., *et al.* Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. *Urology*, 2008. 72: 813.  
<https://www.ncbi.nlm.nih.gov/pubmed/18692876>
512. Sigurdsson, S., *et al.* A parallel, randomized, double-blind, placebo-controlled study to investigate the effect of SagaPro on nocturia in men. *Scand J Urol*, 2013. 47: 26.  
<https://www.ncbi.nlm.nih.gov/pubmed/23323790>

## 8. CONFLICT OF INTEREST

All members of the EAU Non-neurogenic Male LUTS Guidelines Panel have provided disclosure statements on all relationships that they have that might be perceived to be a potential source of a conflict of interest. This information is publically accessible through the EAU website: <http://www.uroweb.org/guidelines/>. These Guidelines were developed with the financial support of the EAU. No external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

## 9. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

*EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4.*

If a publisher and/or location is required, include:

*EAU Guidelines Office, Arnhem, the Netherlands. <http://uroweb.org/guidelines/compilations-of-all-guidelines/>*

References to individual guidelines should be structured in the following way:

*Contributors' names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.*